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ABSTRACT 
 Synthetic manipulation of chromatin dynamics has applications for medicine, 
agriculture, and biotechnology. However, progress in this area requires the identification 
of design rules for engineering chromatin systems. In this thesis, I discuss research that 
has elucidated the intrinsic properties of histone binding proteins (HBP), and apply this 
knowledge to engineer novel chromatin binding effectors. Results from the experiments 
described herein demonstrate that the histone binding domain from chromobox protein 
homolog 8 (CBX8) is portable and can be customized to alter its endogenous function. 
First, I developed an assay to identify engineered fusion proteins that bind histone post 
translational modifications (PTMs) in vitro and regulate genes near the same histone 
PTMs in living cells. This assay will be useful for assaying the function of synthetic 
histone PTM-binding actuators and probes. Next, I investigated the activity of a novel, 
dual histone PTM binding domain regulator called Pc2TF. I characterized Pc2TF in vitro 
and in cells and show it has enhanced binding and transcriptional activation compared to 
a single binding domain fusion called Polycomb Transcription Factor (PcTF). These 
results indicate that valency can be used to tune the activity of synthetic histone-binding 
transcriptional regulators. Then, I report the delivery of PcTF fused to a cell penetrating 
peptide (CPP) TAT, called CP-PcTF. I treated 2D U-2 OS bone cancer cells with CP-
PcTF, followed by RNA sequencing to identify genes regulated by CP-PcTF. I also 
showed that 3D spheroids treated with CP-PcTF show delayed growth. This preliminary 
work demonstrated that an epigenetic effector fused to a CPP can enable entry and 
regulation of genes in U-2 OS cells through DNA independent interactions. Finally, I 
described and validated a new screening method that combines the versatility of in vitro 
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transcription and translation (IVTT) expressed protein coupled with the histone tail 
microarrays. Using Pc2TF as an example, I demonstrated that this assay is capable of 
determining binding and specificity of a synthetic HBP. I conclude by outlining future 
work toward engineering HBPs using techniques such as directed evolution and rational 
design. In conclusion, this work outlines a foundation to engineer and deliver synthetic 
chromatin effectors. 
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CHAPTER 1 
MOLECULAR STRUCTURES GUIDE THE ENGINEERING OF CHROMATIN 
Chromatin Engineering: An Important and Challenging Undertaking 
Chromatin is a dynamic nuclear structure that has a central role in eukaryotic 
development. The mechanics of this ancient, highly conserved system (1-2) are primarily 
driven by the physical structure and interactions of its components, proteins and nucleic 
acids. Electrostatic bonds and hydrophobic interactions determine the composition of 
multipart subunits such as nucleosomes, transcription initiation complexes, and 
repressive complexes. Because of its impact on tissue development, chromatin has great 
potential for engineering cell populations. Chromatin proteins exert strong and flexible 
control over cohorts of genes that determine cell fate and tissue organization. Chromatin 
states, i.e. actively transcribed and silenced, can switch from one to the other. At the same 
time chromatin-mediated regulation can be very stable, persisting over many cycles of 
DNA replication and mitosis. The latter property is a mode of epigenetic inheritance, 
where cellular information that is not encoded in the DNA sequence is passed from 
mother to daughter cells. The stability of chromatin states allows specific epigenetic 
programs to scale with tissue development in multicellular organisms. 
Early biochemical and protein structure studies of the nucleosome (3) have 
generated a high resolution model that has persisted over time. A single nucleosome 
includes a complex of eight histone proteins arranged in a spiral-like disc. Each histone 
contains a C-terminal globular region composed of helix-turn-helix motifs called the 
histone fold domain, and an unfolded N-terminal tail (4) (Figure 1.1A). Within each 
nucleosome, a tetramer of histones H3 and H4 is stacked between two dimers of histones 
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H2A and H2B (Figure 1.1B). The stacking model can be viewed as a data guided 3D 
animation, created by D. Berry (5). Roughly 200 bp of DNA is wrapped twice around the 
histone complex. HistonesH1/H5 interact with the ‘linker’ DNA at the entry and exit site 
of the wrapped DNA (6, 7). Nucleosome structures appear repeatedly along each linear 
chromosome in eukaryotic cells and support higher-order packaging of the entire genome 
(Figure 1.1B).  
In natural systems, the histone octamer is modular and dynamic. There are four 
natural variants of H2A and H3 with distinct amino acid sequences (reviewed in 8, 9), 
while histones H4 and H2B are largely invariant (10). Substitutions of H2A and H3 with 
variants in the octamer complex play critical roles in gene regulation, DNA replication, 
and chromosome structure (4). Kinetic studies of fluorescently labelled histones have 
shown that H3 and H4 turnover is very slow. In contrast, exchange of the H2A/H2B 
dimer occurs within a few minutes to two hours (11). Exchange of histone H1 occurs in 
under two minutes (12). Addition and erasure of post-translational modifications (PTMs) 
is another highly dynamic feature of nucleosomes. Histone-modifying enzymes 
covalently link or remove small molecules at the side chains of specific amino acids 
within each histone. These modifications take place mostly in the unfolded tails, while a 
few occur in the globular domain. Over 15 known modifications include lysine 
acetylation (Kac), lysine methylation (Kme), serine phosphorylation (Sp), sumoylation 
(su), ubiquitination (ub) and crotonylation (cr) (13) (Figure 1.2). In total, over 50 
different amino acid positions are known to be modified. Certain types of PTMs result in 
transcriptional silencing of a nearby gene, while others enable activation.  
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Collectively, PTMs make up a rich set of biological information in which single 
or combinations of molecular tags recruit histone-binding effectors to target genes. By 
the year 2000, dozens of PTMs had been documented, relationships between histone 
modifications and gene regulation states began to materialize, and the term ‘histone code’ 
was coined by Brian Strahl and David Allis (14–17). Since the first report of the structure 
of the histone-binding domain from P/CAFin 1999 (18) a plethora of other 3D structures 
have become available to the scientific community. Investigations of binding pocket 
specificity support the idea that peptide motifs can distinguish one PTM from another 
(19–21). These protein structure and interaction data can be used by synthetic biologists 
to design artificial epigenetic systems and to further confirm or correct aspects of the 
histone code model. Taverna et al. provide an excellent detailed review of lessons learned 
from the molecular structures of PTM-binding domains (19). 
In spite of its potential usefulness, chromatin is often perceived by biological 
engineers as an impediment rather than as an enabling tool. Cells are typically engineered 
by integrating exogenous, recombinant DNA into the chromosomes of the host cell. 
These transgenes include regulatory components that are carefully designed to operate 
with predetermined kinetics. However, the transgene often becomes subjected to the 
surrounding chromatin environment and is mis-regulated (silenced or hyper-activated). 
The molecular complexity of chromatin may give scientists the impression that 
chromatin-mediated expression states are impossible to control. Chromatin complexes are 
often composed of multiple subunits, which have several paralogs in a single organism. 
For instance, Polycomb Repressive Complex 1 (PRC1) appears as six sub-types that 
occupy different genomic regions (22). Each of the PRC1 subunits may be one of several 
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distinct paralogs. Furthermore, the core subunit of chromatin known as the nucleosome 
contains two copies of four types of histones (H2A, H2B, H3, H4) (4), two of which have 
multiple variants. Histones H3 and H2A have eight and five known variants, respectively. 
The variants differ in primary sequence, genome distribution, and expression in different 
tissues and phases of the cell cycle (23, 24). Compared to simpler biological principles 
such as Watson–Crick base-pairing, the complex interactions that govern the behavior of 
chromatin may seem less amenable to bioengineering. Is it worthwhile to attempt to 
engineer multi-layered systems like chromatin within a complex cellular milieu? 
Synthetic biologists have demonstrated so far that such work produces valuable new 
knowledge as well as useful innovations (25, 26).We believe that the current wealth of 
information produced by decades of research in chromatin epigenetics provides a 
sufficient platform to support engineering efforts. In this review, we discuss how proteins 
and nucleic acids that guide epigenetic regulation in nature have been harnessed for 
custom-built systems. Specifically, we focus on the molecular structures of chromatin 
proteins and how our understanding of molecular interactions can be leveraged for 
chromatin engineering. We discuss best practices for chromatin engineering endeavors 
and present a flexible, standard workflow for efficient, high-throughput engineering of 
chromatin-derived proteins. 
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Figure 1.1. The nucleosome, the core subunit of chromatin, is a modular protein 
complex. (A) 3D model based on K. Luger's 1997 X-ray crystallography data, PDB ID: 
1AOI (3). (B) The cartoon abstraction shows the general shape of each histone: the Z-
shape is the globular region and the thinner line is the unfolded N-terminal tail. A H3/H4 
tetramer (green and blue) and two H2A/H2B dimers (orange and pink) bind across ∼120 
bp DNA and become stacked to form a solenoid, DNA-wrapped structure (for a data-
based animation, see (5)). The lower-right cartoon depicts higher-order packaging of 
nucleosomes into a metaphase chromosome. 
Engineering Nucleosomes, the Core Subunits of Chromatin 
 Early efforts to engineer nucleosomes used chemical reactions 
to modify purified histones in vitro. Chemical ligation (Figure 1.2B) has been used to 
attach synthetic, pre-modified peptides into recombinant histone proteins. A detailed 
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discussion of specific chemical methods is available in (27). Chemical ligation has been 
used to generate histones bearing acetylation at H3K4, 9, 14, 18, 23, H4K5, 
8, 12, 16, tri-methylation at H3K9, and phosphorylation at H3S10 (28–30). Soon after, 
methylation intermediates (one, two or three methyl groups) were produced on analogs of 
H3K9, 36, 79 and H4K20 (31). Chemical ligation, and subsequently split inteins,were 
used to produce ubiquitinated H2B (32,33). Semi-synthetic histones have enabled 
scientists to build custom nucleosomes and nucleosome arrays to investigate how isolated 
proteins engage with diverse chromatin templates (27). 
Recent advances have allowed scientists to build modified histones via translation 
of mRNA (Figure 1.2B). Engineered synthetases have been used to charge amber stop 
codon-binding tRNAswith pre-modified amino acids. During translation, the modified 
amino acid is incorporated at any position where a codon has been replaced with UAG in 
a customized (recoded) mRNA sequence. Acetylation at H2AK9, H2BK5 and K20, 
H3K56, K23 and K27, and H4K16 were all recombinantly expressed in bacteria with 
this method (34, 35). Kim et al. demonstrated successful incorporation of a crotonyl 
group at position K11 in histone H2B (36). Recently developed synthetases that charge 
tRNAs with propionyl-lysine, butyryl-lysine (37) and ε-N-2- hydroxyisobutyryl-lysine 
(38) further broaden the spectrum of expressed custom histones. In a landmark 
mammalian cell study, Elsasser et al. used a genetically-integrated recoded mRNA 
translation system to produce pre-modified histones in E14 mouse embryonic stem cells. 
Six lysine codons in the genes for histones H3.2 and H3.3 were replaced with amber stop 
codons. Incorporation of acetyllysines at H3.3 positions 9, 23, 27, 37, 56 and 64 resulted 
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in the upregulation of 16 genes, including the locus for the noncoding RNA Xist, 
compared to a wild type H3.3 parental line (39). This technology provides a powerful 
platform to explore the impact of a variety of histone modifications, natural or novel, in 
the context of live cells. 
Fusion proteins have been used to generate and erase PTMs on endogenous 
histones, and to enhance or repress transcription at genomic sites in live cells. Histone 
modifying enzymes can be fused in-frame with a DNA binding domain (i.e. 
dCas9/gRNA, Gal4, LexA, TALE, TetR and Zinc Finger) to generate silencing- or 
activationassociated PTMs at a gene or non-coding locus (Figure 1.2B). Fusion enzymes 
have been used to repress gene expression through methylation of histones: H3K27 via 
Enhancer of Zeste homologue 2 (EZH2) (40, 41), EED (42) and Nuclear Effector (NUE) 
(43), methylation of H3K9 via Suppressor of Variegation 3–9 homologue 1 (SUV39H1), 
G9A (44), Kryptonite (KYP) (43), DNA methyltransferase via DMNT3B (42), lysine 
methyltransferase 1D (EHMT1) (45); and methylation of H4K20 via TgSET8 (43). Gene 
repression has also been controlled by removal of methyl groups from H3K4 via lysine 
demethylase 1A (LSD1, KDM1A) (46, 47), and removal of acetyl groups from histones 
via histone deacetylase 4 (HDAC4) (37), HDAC8, RPD3, silent information regulator 2 
(Sir2a), and Sin3a (43). Examples of gene-activating PTMs generated by fusion proteins 
include acetylation of lysines via the catalytic domain of p300 (48, 49) and P/CAF 
(KAT2B) (48). In a creative application of light-regulated peptides, Konermann et al. 
controlled histone PTMs H3K9me1, H4K20me3, H3K27me3, H3K9ac and H4K8ac with 
a TALE-cryptochrome 2 fusion and its light-induced conjugating binding partner CIB1 
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fused with a variety of catalytic domains (43). Fusion protein-mediated histone 
modification has been reviewed in detail in other excellent reviews (26, 50). 
Fusion proteins have demonstrated great utility for testing simple assumptions about the 
impact of histone PTMs on gene expression. Further progress in the use of histone 
modifying fusion proteins to regulate genes requires careful consideration of important 
contextual aspects: cross signaling between PTMs and interactions of specific PTM 
modifying enzymes with other enzymes. Cross-signaling between PTMs occurs when 
one modification leads to the generation or erasure of another modification (51). This 
event is mediated by enzymes that bind pre-existing histone modifications and then 
catalyze new PTMs (reviewed in 52– 54). A classic example is H3K9 methylation by the 
HP1 SUV39H1 complex. H3K9me3 is recognized by HP1, which recruits SUV39H1, an 
enzyme that methylates K9 at neighboring H3 histones (55). Other examples of crosstalk 
occur between distinct types of modifications. Phosphorylation of H3S10 induces Gcn5 
to acetylate H3K14 in yeast (56). H2B ubiquitination stimulates methylation of H3K4 
and K79 via hDot1L (57). Complexes that contain SGF29, NuA or HBO bind H3K4me3 
and acetylate histones H3 andH4 (54). In the case ofRpd3S, cross-signaling promotes the 
conversion of one gene expression state into another. H3K27me3, which is associated 
with active transcriptional elongation, is targeted by Rpd3S which removes acetyl groups 
from histones H3 and H4 to promote silencing (58). Cross-signaling can also be 
inhibitory, where the presence of one PTM blocks the function of another. The activation 
associated mark H3K4me3 blocks interaction of the PRC2 complex withH3, prevents 
methylation of H3K27, and prevents gene silencing (59). H3S10p disrupts binding of 
Dido3 with H3K4me3 (60) and enables progression through mitosis. The second 
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contextual aspect we discuss here is the corecruitment of PTM-modifying enzymes. 
KRAB is a strong repressor that has been widely used in early and recent work to silence 
gene targets (e.g. see (41, 42, 61–64)). The consequences of KRAB fusion-mediated 
regulation are complicated by interactions with H3K9 methylases (via HP1) as well as 
histone deacetylases (65). Unintended recruitment of endogenous enzymes can be 
avoided in some cases by using only the core catalytic domain of the histone modifier 
(e.g. p300 (48, 49)). In summary, the wealth of information from mechanistic studies 
such as those cited here should be leveraged to design effective chromatin engineering 
strategies. Pre-existing PTMs at target loci should be determined so that scientists can 
predict whether fusion enzyme activity will be blocked or enhanced. Recruitment of 
PTM-modifying binding partners should either be taken into account or avoided in 
experiments that aim to investigate mechanisms associated with individual PTMs. 
 
Figure 1.2 Graphical survey of known histone posttranslational modifications and 
techniques for generating histone PTMs. (A) PTMs that have been artificially generated 
are shown in red (28–38, 40, 43–46, 49, 63, 150). Positions of methylation, acetylation, 
phosphorylation and other PTMs are shown for each canonical histone. Other 
modifications (stars) include citrullination/deimination, ADP-ribosylation, 
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propionylation, butyrylation, formylation, proline isomerization, hydroxylation, 
malonylation, glutathionylation, crotonylation and succinylation (166). Globular, folded 
histone regions are shaded. (B) Illustration of three general methods for generating 
histone PTMs. Chemical ligation adds pre-modified peptides to recombinant histone 
proteins. The products are assembled with other histones and DNA to generate 
nucleosomes in vitro. Translation of mRNA using engineered tRNA synthetases 
incorporate modified amino acid residues into genetically encoded amber stop codons 
(UAG) in the open reading frame of a custom sequence/histone. Fusion enzymes are 
produced in cells by expressing a DNA-binding domain (DBD) in-frame with a histone-
modifying enzyme (HME) or catalytic domain. The fusion protein binds a DNA target 
and generates or erases PTMs at native nucleosomes. 
Engineering Proteins to Recognize Histone Tags 
 PTM-binding proteins can be used to integrate information from histone marks 
into engineered systems by physically interacting with histone PTMs. In natural systems, 
PTM binding proteins act as effectors that regulate gene expression at sites that are 
enriched for the target histone modification. Here, we highlight four PTM-binding motifs 
that have been used for chromatin engineering: the chromodomain (CD), bromodomain 
(BRD), baculovirus inhibitor of apoptosis repeat (BIR) domain, and PHD finger. Several 
studies have demonstrated that these PTM-binding motifs retain their intrinsic function as 
isolated peptides, and in some cases after they are incorporated into a fusion protein 
(Table 1.1). For a detailed discussion of other well-characterized PTM-binding domains, 
see Park et al. (26). 
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The chromodomain (CD) motif interacts with methylated histone lysine residues. 
3D structure analyses and binding assays have demonstrated that the HP1 chromodomain 
(66–68) and Polycomb chromodomain paralogs (68–70) show preferential binding to 
their cognate PTM targets in vitro. The CD consists of three β strands packed against a 
C-terminal α-helix, and a hydrophobic pocket that interacts with methyl-lysine (Figure 
1.3A) (66,68,69,71,72). Various CD-containing proteins interact with histone H3 (K4, 
K9, K27, K36 and K79) and histone H4 (K20) methylated once, twice or three times 
(me1, me2, me3) (73). Structural studies determined how heterochromatin protein 1 
chromodomain (HP1 CD) specifically recognizes trimethylated (me3) histone H3K9. 
K9me3 is buried in a binding pocket comprised of three aromatic residues, while four 
amino acids preceding K9 interact with the chromodomain (67). Mutational analysis of a 
Drosophila HP1 CD showed that the hydrophobic binding cage is necessary for HP1 CD 
ligand affinity (66). Side chain interactions between the H3 tail and residues from HP1 
form a zipper-like β-sheet, underscoring the contribution of K9-adjacent histone residues 
to HP1 CD binding. The Polycomb chromodomain (PCD) is a different type of CD that 
preferentially binds H3K27me3 and has been shown to cross react with H3K9me3 in 
vitro (71). Although they share high levels of sequence similarity, five mammalian PCDs 
(CBX2, 4, 6, 7, 8) show significant differences in binding preferences (70). Negatively 
charged and hydrophobic surfaces distinguish two classes of mammalian PCDs that have 
high and low affinity, respectively, for their histone ligands (74). Like HP1 CD, the CBX 
PCDs have a conserved binding motif where a β-strand from the histone tail forms a β 
sheet with the CD. PCDs share a unique binding site for A25, which fits into a 
hydrophobic pocket that will not tolerate any other amino acids. In summary, the 
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structural studies of chromodomains suggest two general requirements for CD binding: a 
hydrophobic pocket and a CD-histone beta sheet (Figure 1.3). Studies in live cells have 
demonstrated that CD peptides retain intrinsic PTM-recognition activity within fusion 
proteins. In Drosophila, fusion proteins containing beta-galactosidase and either the HP1 
CD (75) or the Polycomb CD (76) show binding distributions on chromosomes that are 
similar to the corresponding natural proteins. The Polycomb CD from CBX8 has been 
used to build a synthetic activator that stimulates gene expression at H3K27me3-enriched 
genes in human cells (77, 78), potentially counteracting oncogenic, repressed chromatin 
states. 
Bromodomains (BRDs) bind acetylated histones tails. These motifs are typically 
110 residues in length and appear in histone acetyltransferases and nucleosome 
remodeling complexes (79–81). Isolated BRD domains from tail peptides in 3D structure 
studies and in affinity assays (79, 80, 82, 83). Although there is a high degree of sequence 
variation among the 61 known human BRD proteins, they share a conserved tertiary 
structure consisting of a lefthanded bundle of four α helices linked by variable length 
loops that surround the histone binding site (Figure 1.3B). For instance, the BRD region 
of BRD2 contains a deep hydrophobic pocket contributes to the affinity for acetylated 
lysines (82, 83). Specificity is determined by the primary sequences of the variable loops 
(80) and by a hydrogen bond between the oxygen of the acetyl carbonyl on the peptide 
and the amide nitrogen of a conserved asparagine residue (Asn407) (79). In some cases, 
BRDs recognize PTMs other than acetylation (80). Natural bromodomains from BRD9, 
CECR2 and TAF1 have been shown to bind to butyryland crotonyllysine (84). Flynn et 
al. discovered a gain-offunction mutation in BRD1 that conferred affinity for butyryl, 
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with no loss of the intrinsic acetyl binding (84). Studies of a BRD fusion suggests that 
BRD can be used to engineer proteins that bind acetyl-histones. BRD domains confer 
histone-binding activity to the NUT protein in cells where an oncogenic chromosome 
rearrangement fuses the N-terminal BRD domains of BRD4 to NUT (85). A potential use 
for BRD domains is a fusion that binds acetyl marks and represses target genes. Aberrant 
histone acetyltransferase activity has recently become the focus of novel anti-
inflammatory therapeutics (reviewed in (86)). 
Table 1.1 PTM-binding motifs that retain their intrinsic histone specificity in isolation or 
as a sub-domain within a synthetic or oncogenic fusion protein 
Motif Protein 
(length, 
a.a.) 
Species Target 
PTM(s) 
Experiments with 
isolated peptides 
in vitro 
Peptide  
(a.a.) 
Synthetic 
(S) and 
oncogenic 
(O) fusions 
studied in 
cells 
Peptide  
(a.a) 
CD HP1 
(206) 
D. mel H3K9me2, 
3 
X-ray 
crystallography 
(47, 51) FP (70) 
17-76 (S) CD-
beta-gal 
(72) 
1-95 
CD Pc (390) D. mel H3K27me3 X-ray 
crystallography 
(70-71), FP* (70) 
15-77, 
23-77, 
1-98*  
(S) CD-
beta-gal 
(73) 
1-117 
CD CBX8 
(389) 
H. sap 
M. 
musc* 
H3K27me3 FP* (52) 1-62 (S) CD-
VP64 (7, 
74) 
1-62 
BRD BRD4 
(1362) 
H. sap H3Kac, 
H4Kac 
X-ray 
crystallography, 
SPOT array (55) 
44-168, 
333-460 
(O) BRD4-
NUT (75) 
1-719 
BRD BPTF 
(3046) 
H. sap H4K12ac,  
H4K16ac, 
H4K20ac 
X-ray 
crystallography, 
SPOT array, 
peptide pulldown, 
FP, ITC (76) 
2781-
2890 
(S) FLAG-
PHD-BRD 
(76) 
2722-
2890 
BIR BIRC5 
(142) 
H. sap H3T3p NMR (62) 1-120 n/r 
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PHD BPTF 
(3046) 
H. sap H3K4me3 X-ray 
crystallography, 
SPOT array, 
peptide pulldown, 
FP, ITC (76) 
2722-
2781 
(S) FLAG-
PHD-BRD 
(76) 
2722-
2890 
PHD Dido3 
(2256) 
Dido1* 
(614) 
M. 
musc  
H3K4me3 NMR, X-Ray 
crystallography, 
fluorescence 
microscopy, 
peptide pulldown, 
microarray, 
tryptophan 
fluorescence,  
(68) 
266-325  (S) HA-
DIDO (68) 
1-528* 
 
 
 
  
Representative examples from published reports are included in the table. CD = 
chromodomain, BRD = bromodomain, FP = fluorescence polarization assay, ITC = 
isothermal titration calorimetry, n/r = none reported. Lengths of proteins are from 
Uniprot. 
The baculovirus inhibitor of apoptosis repeat (BIR) domain is an approximately 
70 amino acid domain containing a zinc coordinated by histidine and cysteine residues, 
and recognizes phosphorylated histones (87) (reviewed in 88). BIR domain binding has 
been determined by X-ray crystallography of full-length BIRC5 bound to H3T3p (87, 89, 
90). The BIRC5 (Survivin) protein contains a BIR domain that binds to phosphorylated 
histone H3 threonine 3 (H3T3p) by surrounding the first four residues of the peptide with 
10 negatively charged residues. The residues from BIRC5 that make direct contact with 
the H3 tail are conserved across vertebrates (89, 91). Structural analysis shows that the 
BIR domain contains an accessible, preformed binding site for H3T3p recognition, which 
suggests a rigid scaffold for binding. This BIR-H3 interaction pattern is highly conserved 
in other regulatory proteins that contain BIR domains (87, 90). Studies revealed a 
consensus binding motif that includes an N-terminal phosphorylated A-X-S/T-R/K (90) 
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(Figure 1.3C). Mutational analysis targeting the histone-interacting residues of BIR 
resulted in reduced binding and reduced centromere localization or poor microtubule 
depolymerase (MCAK) recruitment in cells (87). Kelley et al. showed that BIR interacts 
with its cognate histone PTM in the absence of other subunits from the chromosomal 
passenger complex (89). This observation suggests an intrinsic histone recognition 
activity that might enable a BIR fusion protein to bind H3T3p. No BIR fusion proteins 
have been reported, so this is yet to be determined. 
Plant homeodomain fingers (PHD) are a class of diverse motifs consisting of two 
50–80 amino acid domains that contain a zinc binding site. PHDs generally interact with 
histone H3 trimethylated at lysine 4 (92, 93). Isolated PHD fingers from several proteins, 
such as Yng1 (94), ING2 (95), TAF3 (96), NURF(97, 98), ING3 (99), JARID1A (100) 
and DIDO (Death Inducer Obliterator) (60) have shown similar interactions with 
H3K4me3 in different crystal structure studies. The PHD finger of L3MBTL1 recognizes 
its target via cavity insertion (101). The PHD domain of DIDO (Figure 1.3D), binds 
H3K4me3 with a noncanonical aromatic cage that contains a histidine residue. When 
aligned against other PHD fingers known to bind to H3K4me3, all proteins shared a 
conserved tryptophan residue (W291 in full length Dido3) in the aromatic cage, as well 
as other residues known to coordinate zinc ions (60). Using structural information from 
methyllysine binding, Li et al. engineered a plant homeodomain (PHD) finger, which 
normally binds trimethylated lysines (H3K4me3), to preferentially bind me2 and me1. A 
single mutation (Y > E) in the aromatic cage responsible for substrate recognition 
changed the mode of interaction from cavity insertion to surface groove recognition. 
PHD motifs can also recognize acetyllysines, as observed for the protein DPF3b which 
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interacts with H3K14ac (102). PHD motifs retain their intrinsic activity in fusion 
proteins. The oncogenic fusion of nucleoporin 98 (NUC98) with the PHD domain from 
JARID1A shows broad colocalization with H3K4me3 and accumulates at the H3K4me3-
enriched HOXA9 gene in human cells (100). In a study using mouse cells, an HA-tagged 
N terminal peptide containing the PHD domain from Dido1 (528 aa) was sufficient to 
rescue the epigenetic activity of the full length Dido3 isoform (2256 aa) (K. van Wely, 
personal communication) and (60)). A mouse model has been generated to express a 
DIDO PHD-RFP fusion (60,103), but neither the subcellular localization nor histone 
interaction of this fusion protein have been reported yet. 
Allosteric regulation of PTM-binding proteins by small molecules suggests that 
chromatin proteins can be designed to switch between binding and nonbinding states at 
will. Tightly-regulated chromatin systems enable insights into epigenetic dynamics, as 
seen in other work where a small molecule (doxycycline) was used to control docking of 
TetR fusions at reporter genes (42,64). Gelato et al. described a H3 binding protein, 
UHRF1 that is allosterically regulated to allow or to block binding to modified histones. 
UHRF1 has two binding states that target either unmodifiedH3 tails via a homeodomain 
or H3K3me3 via a tandem tudor domain (TTD). In the apo state, a polybasic region on 
the C terminus sterically occupies a binding groove in the TTD, disrupts interaction with 
H3K9me3, and allows the homeodomain to bind to unmodified H3 tails. When UHRF1 is 
bound by phosphatidylinositol phosphate at the polybasic region, a global conformational 
change is induced, allowing the tudor domain to bind to H3K9me3. This mechanism 
demonstrates basic allosteric modulation of a histone reader (104). In summary, 
mechanistic studies of PTM binding protein folds have provided a useful, relatively 
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untapped resource for fusion protein design. The recognition of specific histone marks 
could enable broad co-regulation of sets of genes (Figure 1.3E). Alternatively, DNA and 
histone recognition could be coupled to conditionally control a single gene target based 
upon the epigenetic state of the locus or allele (Figure 1.3F). 
 
Figure 1.3 Structural features of representative histone binding domains and their 
applications in synthetic systems. (A) The Chromodomain of CBX7 (116), (B) 
bromodomain of GCN5 (79), (C) BIRC5 (Survivin) subunit of the Chromosomal 
Passenger Complex bound to H3T3p (90) and (D) the PHD finger of Dido3 (60). Green = 
histone sidechain and PTM, blue sphere = coordinating metal ion. Cartoons below each 
structure depict the binding domain–PTM interaction in the context of a whole 
nucleosome. (E, F) Cartoons illustrate uses of histone-binding domains to design 
synthetic transcriptional regulators. Hypothetical applications have italic captions. (E) 
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Synthetic effectors co-regulate all genes (gene 1, 2, ..., n) near a target PTM. This 
application could be used to convert silencing PTMs into gene activation and activating 
PTMs into gene repression. The CD from CBX8 has been used to build a synthetic reader 
that targets the H3K27me3 gene-silencing mark and stimulates gene expression through a 
C-terminal VP64 domain (77, 78). (F) Synthetic regulators could be designed to integrate 
DNA sequence and PTM information at a specific target gene or allele. (top) Assembly 
of a split transcriptional activator requires the binding of two fusions. (bottom) Stable 
binding of weak DNA binding domain (WDB) requires the presence of a specific PTM. 
AD = transcriptional activator domain, RD = transcriptional repressor domain. 
Multivalent Histone-Binding Domains Integrate Multiple PTM Signals 
 
Natural multivalent PTM-binding proteins and complexes can interpretmultiple 
epigenetic marks at once and increase binding affinity for a target histone (26). Structures 
of these multivalent proteins have provided insights into how multivalency can be 
exploited for synthetic systems. Recognition of combinatorial PTMs could provide 
greater specificity. For instance, Su et al. reported a Kd of 45 nM for the dual spin/Ssty 
repeat domains of Spindlin1 for histone H3 trimethylated at K4 and dimethylated at R8 
(H3K4me3- R8me2) (105). The Kd was lower (139 nM) for an off-target peptide 
H3K4me3R8me1. Multivalent binding might compensate for the intrinsic low affinity of 
interactions between single PTM-binding proteins and single targets. In the same 
investigation, Su et al. observed reduced binding affinity (22 µM) of Spindlin for 
H3R8me2 alone (105). The HP1 protein achieves enhanced affinity through self 
dimerization. In a study of HP1 in vitro, mutations that disrupted HP1 self-dimerization 
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showed reduced affinity for H3K9me3 (106). The dimerization motif is also required for 
HP1 activity in cells (107,108). 
Research of natural and synthetic multivalent domains suggests principles for 
designing proteins that recognize more than one PTM. Spacing and orientation of the 
PTM binding motifs within the protein appears to be critical for optimal function. The 
double bromodomain module from TAFII250 recognizes H4K5acK12ac (Kd of 1.4 µM). 
Interestingly, the distance between the tandem bromodomains matches the distance 
between the acetylated residues (109). In a study of the tandem PHD finger and 
bromodomain of BPTF, Ruthenburg et al. observed that the insertion of two amino acids 
(QS) into the rigid alpha helical linker region to rotate the domains 200° out of phase 
disrupted binding to a doubly-modified nucleosome (94). Mutations in the linker that 
added flexibility also impaired bivalent binding, underscoring the importance of domain 
orientation in multivalent interactions. 
The arrangement of nucleosomes and histone PTMs at genomic target regions 
influences the function of multivalent PTM-binding proteins. The combined contribution 
of the PHD finger domain in Rco1 and the chromodomain in Eaf3 direct the histone 
deacetylase complex Rpd3S to active loci that are enriched H3K36me (58, 110). Hu et al. 
proposed that di-nucleosome recognition reinforces Rpd3S binding, thus allowing Rpd3S 
to tolerate fluctuations in H3K36me levels (111). Optimal binding was achieved in vitro 
when the adjacent nucleosomes were 30–40 bp apart (112). BPTF is another example of a 
protein that shows a preference for specific PTM placement. In experiments with 
reconstituted, customized nucleosomes, the divalent PHD bromodomain from BPTF 
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showed greater interaction with histones when the target PTMs were placed on a single 
nucleosome, compared to PTMs that were distributed across two nucleosomes (94). 
Disrupting Chromatin: Synthetic Antagonists of Chromatin Complexes 
 Chromatin complexes are stabilized by several intramolecular interactions 
between proteins and histone tails as well as between subunits within the complex. 
Molecular antagonists have been designed to disrupt chromatin complexes and alter gene 
expression states by targeting a core subunit that recruits other binding partners to the 
gene target. Polycomb Repressive Complex 1 types 2 and 4 (PRC1.2, PRC1.4) generally 
include a histone PTM-binding chromobox (CBX) paralog, RING1A/B, RING1 and 
YY1- binding protein (RYBP), and polycomb group ring finger 2 (PCGF2, Mel-18) or 
polycomb group ring finger 4 (PCGF4, BMI1) (22) (Figure 1.4A). Histone deacetylases 
(HDACs) support PRC function by removing acetyl groups from H3K27 to allow 
methylation, which is recognized by CBX. These proteins work in concert to support 
chromatin compaction and gene silencing, often at tumor suppressors in cancer cells. To 
perturb CBX7 activity, inhibitors have been designed to bind H3K27me (113) or CBX7 
(114–116). Informed by the solved structure of CBX7 in complex with a native peptide 
or a synthetic inhibitor, Ren et al. performed an in vitro screen of a library of compounds 
to identify CBX7 inhibitors. These compounds (see Figure 1.4B for an example) led to 
de-repression (transcriptional activation) of CBX7 target genes in human prostate cancer 
cell lines (72). An in silico screen identified a structurally unique compound that 
demonstrated improved cellular activity. When tested in mouse ES cells, highly specific 
de-repression of CBX7 target genes was observed, compared to almost no impact on non-
target genes (72). Simhadri et al. started with trimethyl-lysine peptides and structural data 
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to eventually develop a peptide to directly bind the CBX7 CD and inhibit its function 
(114) (Figure 1.4C). In later work, Stuckey et al. used a molecular dynamics platform to 
develop a compound that mimics natural peptide binding to CBX7 (115). Structure-
guided work has also led to the discovery of inhibitors of the paralog CBX6 (117). 
Lastly, molecular structures have enabled the discovery of inhibitors of PTM-modifying 
enzymes. Whitehead et al. identified class 1 HDAC inhibitors that are selective for the 
HDAC8 isoform (118) (Figure 1.4D). This work demonstrates that enzyme inhibitors can 
be highly specific while maintaining biologically-relevant affinities. 
BRD2 interacts with acetylated histones, as well as several non-histone proteins 
including glioma tumor suppressor candidate region gene 1 (GLTSCR1), the histone 
arginine demethylase JMJD6, and histone methyltransferase NSD3to stimulate gene 
expression (119) (Figure 1.4E). BRD containing proteins stimulate MYC oncogene 
expression and promote the growth of cancer cells (119). Therefore, BRD is an important 
therapeutic target (81). Bromodomain inhibitors such as JQ1 (120) and I-BET (121) have 
been identified in high throughput screens to identify small compounds that fit the 
histone recognition pocket of BRD2 (1- 473), BRD3 (1-434) and BRD4 (1-477) (121). 
A noteworthy example of structure-guided design come from James et al., who 
developed strong inhibitors that bind within the methyl-lysine recognition cavity in 
malignant brain tumor (MBT) repeat domains (122), and others who developed inhibitors 
of the H3K27 methyltransferase EZH2 (123, 124). Horton et al. determined the structures 
of a diverse set of demethylase inhibitors to elucidate the molecular mechanism of 
binding. Their work provides a general platform for designing epigenetic inhibitors. 
Structures of the demethylase complexed with various small molecules indicated the 
22 
 
potential diversity of inhibitors. The complexes showed a similar binding interfaces but 
differed in atomic interactions, such as metal coordinating ligands (125). 
Since the first reports of the role of Polycomb proteins in oncogenesis and 
metastasis, a multitude of inhibitors have been developed as epigenetic drugs. Inhibitors 
of PTM-generating enzymes and their impact on drug discovery is discussed in several 
excellent reviews (126–131). Structure-focused work has illuminated the molecular 
interactions between inhibitors and PTM-binding proteins or histone deacetylase 
enzymes (HDACs). Stuckey et al. demonstrated that a PRC1 inhibitor could be designed 
to inhibit human prostate cancer cell (PC3) proliferation (115). The structure of the 
inhibitor is similar to the natural ligand H3K27me3 and is highly specific for two 
chromodomains, CBX4 and CBX7. Inhibitors that bind and interfere with bromodomains 
(BRDs) have been used to control gene expression in disease-relevant cell culture model 
systems. Small molecule-mediated inhibition of BRD was used to down-regulate MYC 
transcription in leukemia and myeloma cells (132,133) and to suppress inflammation in 
bone marrow-derived macrophages (121). Recently, in vivo work has shown that a new 
BRD-specific inhibitor, MS402, preferentially binds to the first bromodomain motif 
within BET proteins and is therefore more specific than the broadacting inhibitor JQ1 
(Figure 1.4F). Cheung et al. demonstrated the therapeutic potential of MS402 by 
preventing and reducing T-cell transfer-induced colitis in mice (134). These studies 
underscore the clinical potential for synthetic, epigenetic regulation of genes that have 
therapeutic properties. 
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Figure 1.4 Artificial disruption of multi-protein chromatin complexes. Cartoons depict 
the context in which inhibitors interact with specific subunits. Shapes are scaled to reflect 
relative protein sizes (kiloDaltons). Histone PTM symbols are the same as in Figure 1.2. 
Arcs = protein interactions (referenced in the text), dashed arrows = histone modifying 
activity, red lines = inhibitor-mediated disruption. (A) The PRC1.2/1.4 type silencing 
complex can be disrupted by inhibiting the binding of CBX7 CD to H3K27me3 or by 
inhibiting the removal of acetyl groups from H3K27 by HDAC8. Examples of CBX7 CD 
inhibitors include MS351 (116) (B) and a synthetic peptide (114) (C). (D) The inhibitor 
Ligand 4 (118) disrupts HDAC8 activity. (E) BRD2 recruits several proteins, including 
histone modifiers, to stimulate gene activation. Inhibitors such as JQ1 (120) (F) have 
been designed to disrupt the central histone-binding activity. (B–D, F) Boxes show sites 
within chromatin proteins where low molecular weight inhibitors (green) interact with 
specific residues (red). 
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Building Chromatin: Scaffolding Chromatin Complexes with RNA and DNA 
In natural systems, histone-modifying proteins and other chromatin components 
are spatially arranged along DNA strands. Several studies have demonstrated that specific 
arrangements of these proteins are non-random, highly regulated, and play a role in 
epigenetic regulation of gene expression. Chromosome looping, sub-nuclear 
compartmentalization and gene expression can be altered by manipulating non-coding 
DNA elements such as the locus control region (LCR), CTCF-bound insulators, and 
lamina-associated domains (LADs) (reviewed in Park et al. (26). Here, we discuss the 
two classes of epigenetic scaffold elements that have been rigorously analysed within 
synthetic systems: Polycomb Response Elements and long non-coding RNA. 
Polycomb Response Elements (PREs) are cis-regulatory DNA sequences that 
recruit chromatin complexes to clusters of genes. Robust epigenetic control through PRE 
activity is required to stabilize distinct transcription profiles within subpopulations of 
cells (135). Drosophila PREs contain clusters of short motifs that interact with several 
chromatin proteins including Pleiohomeotic (PHO), Zeste protein, GAGA factor (GAF), 
Dsp1 and others (135). A remarkable characteristic of PREs is ‘epigenetic memory’, the 
ability to confer a stable silenced or active state at nearbygenes after removal of the 
inducer of either state. Earlywork in Drosophila demonstrated that a PRE called Fab-7 
could be used to switch the expression state at an adjacent reporter gene from active to 
silenced and vice versa (136–138). These artificially-induced expression states persisted 
over several rounds of mitosis andmeiosis.While Drosophila PREs have been well 
documented (139), discovery of human PREs has been elusive (140) until recently. In 
2010, Woo et al. identified a noncoding PRE-like DNA element from the human HOXD 
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gene region (141). When this element, D11.12, was placed upstream of a luciferase 
reporter, the transgene became enriched for repressive histone PTMs and silencing 
associated proteins and luciferase expression was reduced to <5% of the active state. 
Since this discovery, other human PREs have been identified (142). Experiments have 
shown that PRE function can be ported fromone metazoan species into another, 
demonstrating that epigenetic memory is an inherent property of PRE DNA fragments. 
For instance, mammalian PRE candidates have been validated based on their activity in 
Drosophila. PREs that were identified in studies of human T cells (143) or the mouse 
genome (144, 145) showed Polycomb protein binding and repression of a reporter gene in 
transgenic flies. 
Investigations of PREs provide some guidance on how these elements can be used 
to control synthetic genetic systems. In Drosophila, artificially-induced states mediated 
by PREs can persist over timescales of metazoan tissue development, a characteristic that 
is critical for the practical use of synthetic gene circuits in multicellular organisms. An 
important outstanding question for PRE-based genetic engineering is to what extent the 
behavior of a PRE can be customized to generate distinct gene expression patterns. 
Mounting evidence from studies in Drosophila show that PREs respond to inducers either 
early or late in development, and are sensitive or insensitive to their genomic location 
(reviewed in (140)). Multiple short motifs of varying copy number and order can be 
found in PREs from Drosophila (146, 147) and mammalian genomes (135, 141, 142) 
(Figure 1.5A). Therefore, it is tempting to surmise an underlying protein-scaffolding 
code. However, current models for PRE function are incomplete. For instance, no human 
orthologs have been identified for two key Drosophila PRE-recognition proteins, GAF 
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and Zeste (Figure 1.5A). The Drosophila protein Dsp1 and the human ortholog HMGB2 
(hHMG2) have been linked to PRE activity, but there is conflicting evidence for the 
DNA sequence motif that is recognized by the proteins (135). Finally, although the 
number of motifs can be identified within a PRE, the stoichiometry of proteins per PRE is 
not precisely defined. If a deterministic code is eventually identified, artificial PREs 
could be designed to control the magnitude and dynamics of epigenetic expression in 
synthetic genetic constructs. 
Reminiscent of PREs, synthetic DNA constructs can be designed to include 
combinations of shortDNAmotifs that are recognized by transcriptional regulators. 
Artificial operators have been constructed de novo from protein-binding motifs found in 
well-studied bacterial operons (e.g. Tet, lac, trp) (148) as well as eukaryotic loci (e.g. 
yeast Gal4 UAS, Zinc finger recognition sites) (149). These motifs can be arrayed within 
a synthetic DNA fragment and placed upstream of a target gene. Chromatin fusion 
proteins that recognize the motifs assemble at the scaffold based on the number and 
arrangement of motifs. Keung et al. used two orthogonal Zinc finger (ZF) adapters to co-
recruit pairs of gene-regulating proteins to a single promoter (150) (Figure 1.5A). 
Although this study was limited to observing synergy or antagonism between single 
chromatin proteins and the ZF-VP16 activator, the synthetic ZF platform has potential for 
more general use, i.e. to control spatial arrangements of pairs or larger combinations of 
chromatin proteins. 
Long noncoding RNAs (lncRNAs) also act as modular scaffolds for multi-protein 
complexes. The underlying design principles of these elements are just beginning to 
emerge. Engreitz et al. provide a superb review of lncRNA structure and function in the 
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context of chromatin and epigenetics (151). Here, we highlight examples of well defined 
modular lncRNAs may eventually inform synthetic RNA scaffold design. The lncRNA 
known as HOTAIR (HOX transcript antisense RNA) has two modules with secondary 
structures that each interact with distinct histone modifying complexes to maintain 
transcriptional repression (152). The 5’ domain of HOTAIR binds the PRC2 complex 
that generates H3K27me3, while the 3’ domain binds the LSD1/CoREST/REST complex 
that stimulates H3K4 demethylation (153). The 5’ domain is a distinct module with 
intrinsic PRC2 binding activity. Structural dissection of HOTAIR revealed that 
nucleotides 1–300 are sufficient for interaction with PRC2 (153) and that a core motif of 
89 nucleotides is required for binding (154). However, recent work has shown that the 
role of PRC2 is dispensable for HOTAIR-mediated silencing (155). The lncRNA Firre 
(functional intergenic repeating RNA element) con- tains twelve tandem repeats of an 
RNA motif that binds the nuclear matrix protein HNRNPU, also known as SAFA 
(scaffold attachment factor A) (156). The structure of Firre demonstrates that tandem 
replicate RNA modules can operate as independent units, allowing several proteins to 
cooccupy a single RNA scaffold. Xist is an example of a lncRNA that interacts with a 
with a DNA-binding protein as well as other chromatin proteins. SAFA acts as a 
DNA-binding module that tethers the Xist RNA–protein complex to DNA sequences 
(Figure 1.5B). The RNA-binding arginine–glycine–glycine (RGG) domain of SAFA is 
required for interaction with Xist (157). Chromatin proteins may recognize a variety of 
RNA sequences and secondary structure conformations. Mounting evidence is beginning 
to shed light on the mechanistic details of protein-lncRNA binding, but there is not 
sufficient information to engineer lncRNA-derived systems (158). 
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Scientists must first identify core RNA subunits with intrinsic, portable activity 
beforewe can use lncRNAs for synthetic systems. For an immediate solution, researchers 
have turned to protein-RNA modules from well-understood viral systems to design 
lncRNA-inspired gene regulators. Zalatan et al. used the viral RNA stem-loop hairpins 
MS2, PP7 and com to build a scaffold that was recognized by the proteins MCP, PCP and 
Com respectively (Figure 1.5B). They targeted the scaffold to a specific gene by using a 
CRISPR/dCas system where the DNA-binding guide RNA (gRNA) included a long RNA 
extension with different combinations of the viral hairpins. The group demonstrated 
epigenetic repression of a target gene by recruiting KRABCom fusion to a com RNA 
hairpin (159). The RNA hairpin adapters are also functional in tandem (Figure 1.5B), 
which suggests that this system could be used to recruit combinations of chromatin 
proteins to a single locus. 
 
Figure 1.5 Scaffolding of chromatin proteins on DNA or RNA. (A) Natural Polycomb 
response elements (top) include combinations of short motifs that are recognized by non-
histone chromatin proteins. Known PRE-binding proteins and DNA core motifs are 
shown for Drosophila and mammals. Crystal structure data (168) (top right) shows that 
YY1 (human PHO homologue) interacts with DNA via a zinc finger motif. A synthetic 
operator (bottom) designed by Keung et al. is shown as an example of a synthetic DNA 
29 
 
chromatin scaffold. Nucleotides are named according to the IUPAC code. CP = 
chromatin protein, ZF = zinc finger. (B) HOTAIR (top) is an example of a natural RNA 
chromatin scaffold. Its 3’ and 5’ regions act as modules for PRC2 and 
LSD1/CoREST/REST recruitment. The role of PRC2 (dashed circle) may be dispensable 
for HOTAIR function (154). LSD1 residues 171–317, 571–654 and 769–836 and RNA 
(UUAGG) are shown from the crystal structure model (169). Two CRISPR/dCas9-based 
RNA scaffolds (bottom) are shown as examples of synthetic RNA scaffold systems 
(158). AD = activation domain. 
Conclusions and Future Outlook: Best Practices for Chromatin Engineering 
 We have described recent advances in synthetic, chromatin derived systems and 
the fundamental research discoveries that have preceded and enabled the development of 
these technologies. In this section, we will discuss important next steps and opportunities 
for continued advancement of chromatin engineering. 
Deeper understanding of the consequences of artificial post-translational 
modifications (PTMs) on chromatin is critical to advance synthetic PTM technology. 
Exploratory studies should determine the impact of customizable parameters such as the 
relative position of the PTM nucleation site to the target gene, rate of PTM production, 
and the interactions between PTMs and regulators at single target sites. Recent studies 
have demonstrated the value of systematically adjusting design parameters. For instance, 
Hilton et al. placed the active core domain of the p300 acetyltransferase at different 
distances from the target gene and observed significant activation of genes at distal 
enhancers and regulatory regions up to 46 kb from the transcriptional start site (49). Bintu 
et al. determined the kinetics of four distinct silencing regulators (EED, KRAB, HDAC4, 
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DMNT3B) in single CHO-K1 cells to identify conditions that generally enable silencing 
of a predetermined degree and duration (42). Amabile et al. recruited combinations 
fusion proteins to a single gene to compare silencing induced by one, two or three 
repressors (KRAB, DMNT3a, DNMT3L). Two or three repressors generated long-term 
silencing at endogenous genes in human HEK293T, K562 and B-lymphoblastoid cells, 
human primary T lymphocytes, and mouse NIH-3T3 cells (64). In a study of KRAB and 
Sss1 co-recruitment, synergy was dampened by competition of each effector for shared 
cofactors (41). This work revealed an important caveat in using components from 
overlapping pathways. Keung et al. recently reported an impressive study in which 223 
PTM-generating fusion proteins enhanced, antagonized, or did not affect the function of a 
VP16 activator at a target reporter gene in yeast (150). Pioneering efforts such as the 
studies highlighted here provide a glimpse of the exciting work yet to be done. In 
addition to customizable parameters, uncontrollable events such as cross-talk between 
PTMs, enzyme co-recruitment and the impact of these processes on gene expression 
states (discussed previously in this review) must also be considered and measured to 
maximize the value of the results from synthetic studies. 
Customization of non-enzymatic chromatin proteins represents an expansive 
design space that has barely been explored. In order to accelerate the pace of discovery, 
scientists should develop and share workflows to efficiently parse large libraries of 
synthetic protein candidates. As an example, we present a workflow that is under 
development in our lab. We begin with a large library of fusion protein variants and carry 
out protein–histone peptide interaction tests in vitro (ELISA) to identify functional 
candidates (Figure 1.6). Candidates that show preference for the target histone PTM in 
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the first-pass test are used to build synthetic gene regulators. We then expose a PTM-
bearing reporter gene to the synthetic regulator to validate its function in live cells. This 
workflow allows us to identify modular, reusable PTM binding domains to aid in the 
design, construction, and application of synthetic, chromatin-derived proteins. In 
addition, we use peptide arrays to determine cross-reactions with various histone PTMs 
and to calculate affinities for each target. So far, our workflow has demonstrated the 
interaction of a Polycomb Chromodomain fusion (PCDmCherry) with H3K27me3 in 
vitro (not published), which corroborates previous studies of this fusion protein in live 
cells (77, 78). We expect ongoing work to identify new variants with interesting 
properties, such as enhanced affinity for H3K27me3. 
A challenge for practical and reliable use of PTM-binding domains in living cells 
(e.g. as illustrated in Figure 1.3E and F) is the broad and varying distribution of histone 
modifications throughout the genome over time and at different stages of cell 
development. Therefore, it is important to carefully consider the histone PTM target from 
a systems viewpoint rather than as a single gene, as is the case for DNA-binding 
regulators. For instance H3K27me3, the target of the PCD motif, appears at thousands of 
genes and many non-coding regions in human cells. The real utility of regulating a cohort 
of this size may not be immediately obvious. However, a single PTM might not be 
sufficient to support artificial regulation of the entire set of genes. We have observed that 
a regulator fused to the PCD from CBX8 affects only a subset of all H3K27me3-positive 
genes (77, 78) and that many of these genes are near bivalent H3K27me3/H3K4me3-
marked promoters (78). The key lesson from this example is that simple assumptions 
about epigenetic targets should be tested by using integrated transcriptomic and 
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epigenomic analyses. The identification of predictive epigenetic signatures at target genes 
will enable practical use of PTM-binding proteins for synthetic systems. 
Eventually, new chromatin engineering tools may become available for human 
and animal health applications. The safety and efficacy of these tools will need to be 
determined in the context of a complex epigenome. Therefore, it is critical to determine 
the global impact of the synthetic component on genome-wide expression levels in order 
to identify off-target or broad effects. Evidence from HDAC inhibition experiments in 
pancreas cells (160–164) suggest that generating activation-associated PTMs at key genes 
could transdifferentiate alpha cells into beta cells, boost insulin production in pancreatic 
tissue, and cure diabetes. The RNAseq data from Bramswig et al. show that dozens of 
genes that are not involved in the insulin production pathway are also affected (162). 
Nyer et al. used RNA-seq and ChIPseq to determine that a broad-acting H3K27me3-
binding synthetic regulator reactivated silenced tumor suppressors as well as hundreds of 
other genes (78). The data from the pancreas and cancer cell studies should be further 
explored to determine the long-term impact of broad changes in gene expression on cell 
phenotype. Even in cases where the synthetic chromatin protein binds a single unique 
DNA target, chromatin modifications nucleated at one site can spread into neighboring 
loci (discussed in (49)). To verify target specificity of a Cas9-p300 histone 
acetyltransferase fusion protein, Hilton et al. performed RNA-seq to identify cases where 
only the target gene was activated and no other genes were affected (49). It is imperative 
that synthetic biologists and chromatin engineers include genome-wide analysis, 
bioinformatics, and gene network analysis in their arsenal of research techniques. 
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Synthetic epigenetic research is still in its infancy. The plethora of structural and 
biochemical data that describe histone-modifying enzymes, histone PTM-binding 
proteins, and modular nucleic acid scaffolds present an opportunity to expand the 
bioengineering toolbox. Histone PTMs represent a rich set of biological information that 
can be exploited for gene targeting and cellular regulation. Genomic profiling can be 
coupled with chromatin protein engineering to identify and manipulate epigenetically-
regulated target sites. While some epigenetic fusion constructs have been successfully 
used to activate or repress target genes, the number of utilized domains represents a small 
fraction of well-characterized PTM binding and modifying proteins (80,149). So far, 
most of the reported synthetic epigenetic systems are limited to specific regulation of a 
single genetic locus using PTM modifying enzymes that are fused to DNA-binding 
domains. Histone PTM-binding proteins fused with effector domains, which have been 
explored less, could enable co-regulation of many genes at once. The efforts summarized 
in this review represent important, initial advances into a vast exploration space of 
potential chromatin protein designs and applications. Chromatin is a central mechanism 
for precise and reliable control of genes that drive multicellular development. Maturation 
of the synthetic epigenetics field will produce new technologies and discoveries that will 
have significant impacts on genetic research, agricultural science and biomedical 
engineering. 
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Figure 1.6. Workflow to discover modular, reusable chromatin-derived peptides that 
bind histone PTM's. FP = fluorescent protein, HRP = horseradish peroxidase-conjugated 
antibody, Mam. vector = mammalian expression vector, ED = effector domain. 
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CHAPTER 2 
DESIGN, CONSTRUCTION, AND VALIDATION OF HISTONE-BINDING 
EFFECTORS IN VITRO AND IN CELLS 
 
Figure 2.0 Abstract Figure. 
Introduction 
 Chromatin engineering is a burgeoning field with applications in disease 
treatment (1), tissue engineering (2), and development of cell lines for industrial 
production of biologicals (3). Recently, proteins that bind specific histone 
posttranslational modifications (PTMs) have been used as probes for histone PTM states 
in cells and to target gene regulators to sites based on histone PTM status (4, 5). Protein 
motifs that interact with specific acetylated and methylated residues on histone H3 have 
been used to design fusion fluorescent proteins to label genomic regions that contain high 
levels of H3K14ac (6), H3K9me3 (7), and H3K4me3 and H3K27me3 (8). The wealth of 
basic research that has supported the design and application of recombinant, chromatin-
based proteins is discussed in detail in reviews from our group (9) and others (10).  
Here, we describe a workflow to measure binding of recombinant histone-binding 
proteins in vitro and to validate their activity in live cells using techniques that do not 
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require highly specialized equipment or high-yield protein preparations. Current 
approaches to validate the function of histone PTM binding domains (HBDs) include 
fluorescence polarization (FP) (11) isothermal calorimetry (ITC) (12), surface plasmon 
resonance (SPR) (13), and peptide arrays (14). The primary limitation of these 
approaches is the need for high yields of purified protein, which limits the number and 
variety of proteins that can be assayed efficiently. Recently, we demonstrated the rapid 
prototyping of novel multivalent histone-binding transcriptional activators built from a 
human orthologue called CBX8 (14). The results showed that small volumes (<12 μL) of 
cell-free transcription−translation lysates (TXTL) can be used to produce sufficient RFP-
tagged histone binding fusion proteins to generate significant binding signal over 
background in an enzyme-linked immunosorbent assay (ELISA). Here as a proof of 
concept, we screened a small library of additional TXTL-expressed variants for 
H3K27me3 avidity. Open reading frames that encoded histone-binding candidates were 
then cloned into a mammalian expression vector and tested for gene-regulating activity in 
HEK293 cells. The cells used here include an ectopic heterochromatic site where the 
target histone PTM is located near the promoter of a reporter transgene (luciferase). Our 
report includes guidance for identifying other useful target PTMs and genomic loci.  
Materials and Methods 
Constructs for Histone-Binding Protein Fusions. BioBrick assembly (15) was 
used to build open reading frames that encoded full-length fusion proteins in the general 
purpose vector V0120. Full-length, annotated sequences are available at the Haynes lab 
Benchling Web site (https://benchling.com/ hayneslab/f_/rmSYkAAU-synthetic-
chromatin-actuators-2-0/). 
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DNA Constructs for Cell-Free Transcription−Translation (TXTL) Expression. 
Constructs were assembled via directional cloning of PCR-amplified and digested fusion 
coding regions (from vector V0120) into pET28 as previously described (14) with the 
following modifications: EcoRI and HindIII restriction sites were used instead of BamHI 
and XhoI sites. All histone PTM-binding domains (HBDs) were separated by a [GGGGS] 
x4 linker. Human (Pcα) = CBX8 (amino acids 1−62). Fish (Pcβ) = CBX2 or pc1 (amino 
acids 2−63). Fly (Pcγ) = Pc (amino acids 16−77) (5). Plasmids were cloned in compatible 
strains: pET28 fusion-expressing constructs in Escherichia coli BL21 and σ70-T7 RNA 
polymerase plasmid in E. coli KL740. 
Enzyme-Linked Immunosorbent Assays (ELISAs). Capture antibodies included 
mouse anti-6-histidine (Abcam 18184) and chicken anti-mCherry (Novus biologicals 
NBP2- 25158). Biotinylated peptides were H3K27me3 (21−44) (Anaspec AS-64367-
025) and H3 (21−44) (Anaspec AS- 64440-025). Primary antibodies were chicken anti-
mCherry (Novus biologicals NBP2-25158) and mouse anti-6-histidine (Abcam 18184). 
Secondary antibodies were rabbit anti-chicken HRP (Gentel, 0.5 mg/mL, RCYHRP) and 
goat anti-mouse HRP (KPL 074-1806). Data shown in this report were generated using a 
Synergy H1 Hybrid Reader with the following key settings: standard 96-well plate 
option; detection, absorbance; read type, end point; read speed, normal. We have 
obtained very similar A450 values [absorbance units (a.u.)] using two different plate 
reader models (Synergy H1 Hybrid Reader and PerkinElmer EnVision 2104 Multilabel 
Reader). For each Pc fusion, the A450 value for each H3K27me3 well (four replicates) 
was divided by the mean A450 value of four H3 (unmodified histone) control wells. 
“Histone peptide capture: relative binding” is the mean of the four normalized values. 
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Nonspecific binding was assessed by using a fusion protein that contained no HBD 
(PcΔ(14)). We used two methods to determine histone peptide capture as percent fusion 
protein input, where either the mean six-His capture A450 value or the TXTL RFP end 
point signal (533−610, a.u.) was used to represent input. 
DNA Constructs for Mammalian Cell Expression. Constructs were assembled via 
nondirectional cloning of fusion-coding regions (from V0120) into vector MV10 as 
previously described (14). Colony PCR was used to screen for forward inserts: 1× GoTaq 
green master mix (Promega M7122), 0.4 μM forward primer 5′-caccatcgtggaacagtacg, 
and 0.4 μM reverse primer 5′-gcaactagaaggcacagtcg in a final volume of 25 μL. PCR was 
performed as follows: 95 °C for 2 min; 25 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 
°C for 1 min; 72 °C for 5 min; and held at 4 °C. Candidate clones were grown in 3 mL of 
liquid LB and 100 μg/mL ampicillin. Restriction digestion followed by electrophoresis 
(1% agarose in TAE) was used to analyze purified plasmid DNA (Sigma PLN350-1KT): 
500−1000 ng of plasmid DNA, 1 μL each of FastDigest enzymes XbaI and PstI, and 1× 
FastDigest buffer (Thermo Fisher FD0684, FD0614, and B72). 
Cell Culture and Transfection. HEK293 Gal4-EED/luc cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% tetracycline-free 
fetal bovine serum and 1% penicillin and streptomycin (pen/strep) at 37 °C in a 
humidified CO2 incubator. Silencing of the reporter gene (Tk-luciferase) was induced by 
supplementing the medium with 1 μg/mL dox for 96 h. For wash-out of doxycycline (to 
allow depletion of Gal4-EED), growth medium was removed and replaced with dox-
minus medium. Prior to transfection, doxtreated cells were plated in 12-well culture 
dishes at 40% confluency (∼1.0 × 105 cells/well) in 2 mL of pen/strep-free growth 
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medium. Transient transfections were performed by adding 300 μL of 
DNA/Lipofectamine complexes to each well: 1 μg of plasmid DNA or ddH2O for mock 
transfections (10 μL), 5 μL of Lipofectamine LTX (Invitrogen 15338100), or 285 μL of 
OptiMEM (Gibco 31985062). Plates were spun at 100 g for 5 min to increase the 
transfection efficiency and then incubated at 37 °C in a humidified CO2 incubator. 
RFP, Hoechst, and Luciferase Plate Reader Assay Data Analysis. For each 
channel, luciferase (chemiluminescence), RFP, and Hoechst 33342, the average signal 
from the 1× PBS wells was subtracted from the value for every sample well. Next, the 
average background-subtracted luciferase value for untransfected (UT) cells was 
subtracted from each experimental luciferase value. UT-subtracted luciferase values were 
scaled by multiplying each value by [(mean UT Hoechst)/(sample Hoechst)] and then by 
[(mean Pcαα RFP)/(sample RFP)]. 
Statistical Analyses. Reported p values were determined by a Student’s paired t 
test, with a two-tailed distribution. 
Overview of Histone PTM-Binding and Gene Regulation Assays 
 Binding of TXTL-expressed, fluorescently tagged fusion proteins with target 
histone peptides is assessed by a user-friendly ELISA. Previous work has shown that 
bacterially expressed, eukaryotic histone PTM-binding domains (HBDs) have specific 
avidity for their ligands (reviewed in ref 9). Therefore, TXTL in bacterial lysates is 
suitable for producing ligand-binding HBDs and allows researchers to circumvent cell 
transformation or transfection. Ligands (modified histone tail peptides conjugated with 
biotin) are immobilized in neutravidin-coated microwells, and TXTLexpressed fusions 
are incubated in the wells to allow binding. Next, candidate regulators are transferred into 
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mammalian expression vectors to determine gene regulation activity in live cells, where 
the fusion proteins are expected to interact with whole nucleosomes. Excellent work 
reported by others has utilized single nucleosomes and nucleosome arrays as templates to 
study histone PTM-binding proteins (16−19). Because our workflow aims to identify 
proteins that interact with histone PTMs and activate the transcription of target genes, we 
use chromatin in cellulo rather than reconstituted nucleosomes or nucleosome arrays. 
However, we encourage researchers to perform experiments using whole nucleosomes to, 
for instance, determine the impact of PTM spacing over the nucleosome on the kinetics 
of binding. 
Design and Construction of Histone PTM-Binding Fusion-Expressing Plasmids 
 In this report, we focus on PTMs within the unfolded N-terminal tail domain of 
histone H3. These PTMs represent some of the most well- characterized modifications in 
regard to the proteins that recognize these marks and their impact on gene regulation (9) 
Our group is interested in designing and optimizing histone binding transcriptional 
activators that recognize elevated levels of H3K27me3 in cancer cell epigenomes and 
induce activation of repressed anticancer loci. The procedure described herein uses a 
library of fusion proteins built for this purpose as an example (Figure 2.1A). The fusions 
contain conserved, H3K27me3-binding polycomb chromodomains (PCD) from human 
(CBX8), fish (Danio rerio CBX2, pc1), and/or fly (Drosophila melanogaster CBX2, pc1) 
orthologues. These PCD orthologues contain 62 amino acids, including three conserved 
residues that make up an aromatic pocket that binds H3K27me3 (20-21). The 59 
remaining residues show a lower level of conservation; reports suggest that some of these 
residues may contribute to stabilizing the interaction of PCD with the histone tail (20-21). 
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In our previous work, we directly compared the human, fly, and fish PCD orthologues by 
testing each as a histone-binding module in a fusion activator protein (5). The fusion 
protein that contained a single human CBX8 PCD activated target genes more effectively 
than the fish or fly homologues. Unknown differences in protein processing, such as 
folding and degradation, prevented a full understanding of the differences in fusion 
protein activity. In our current work, we investigated the three PCD orthologues to 
determine H3K27me3 binding under controlled conditions in vitro and to compare the 
results with gene regulation in live cells. 
Generally, we recommend keeping the N- or C-terminal position of the histone 
PTM-binding domain (HBD) in the fusion protein consistent with its native context (e.g., 
the H3K27me3-binding PCD is an N-terminal motif) (Figure 2.1A). In our hands, a linker 
peptide is apparently unnecessary at the HBD−fluorophore junction in fusion proteins 
that show histone-binding activity. However, we do recommend the inclusion of linker 
peptides between tandem HBDs. Recent work has shown that combinatorial PTM-
binding motifs increase the overall avidity of the fusion for its target (14, 22-23), or allow 
for specific co-recognition of two distinct histone PTMs within a single nucleosome (8). 
Pairs of H3 as well as H4 nucleosome tails are expected to be oriented in cis so that they 
protrude away from the nucleosome in the same general direction (see Protein Data Bank 
entry 1AOI (24)). These histone tails are flexible enough to come into the proximity of 
each other. Therefore, a flexible (GS repeat) or rigid (α helix) peptide of 20 amino acids 
is a good starting point for HBD− HBD linker design. A three-dimensional (3D) structure 
based model of this format can be found in our previous work (14). It is critical to include 
in the fusion protein a fluorophore with efficient folding properties, such as the 
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monomeric Cherry (mCherry) we have used in our work. The tag enables protein 
detection after expression in TXTL or in cultured mammalian cells. The transcription-
regulating domain (activator or repressor) should be included at the in vitro testing stage 
so that any effects of whole protein folding on binding with the target ligand can be 
observed. A standard directional cloning approach (e.g., BioBrick assembly (15)) or 
scarless assembly (e.g., Golden Gate (25)) is suitable for construction of the fusion 
protein-expressing plasmid DNA (Figure 2.1B). Two plasmids, one encoding a fusion 
protein and one expressing T7 RNA polymerase under the control of a constitutive σ70 
promoter, are added to the TXTL reagent for the expression reaction. 
 
Figure 2.1 Constructs, plasmids, and a schematic for TXTL expression. (A) We 
constructed a library of nine fusion histone-binding protein open reading frames (ORFs) 
with tandem N-terminal HBDs separated by a 20-amino acid flexible linker (4x[GGGGS]). 
The 3D structure for CBX7 bound to H3K27me3 (Protein Data Bank entry 4X3K) is shown 
to represent CBX8/H3K27me3. (B) Plasmid maps, drawn to scale, used for expression in 
TXTL. Fusion protein ORFs were cloned into the EcoRI, HindIII site of pET28. A T7 RNA 
polymerase-expressing plasmid was included in the TXTL reactions to supply T7 
polymerase, which is not present in the lysate mix. Legend: 6H, six-histidine; Term., 
transcription terminator sequence. 
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Real Time Detection of Cell-Free Transcription-Translation (TXTL) 
TXTL is a flexible system that enables expression of recombinant, ready-to-use 
proteins without the need for cell lysis and purification. In reaction mixtures containing 
∼100 ng of fusion-encoding plasmid, an increase in the intensity of the RFP signal began 
at just >2 h and continued to increase linearly up to 19 h (Figure 2.2). Our previous work 
with similar fusion proteins, including the Pcαα variant used here, showed a sigmoidal 
trend for RFP signal over time in TXTL reactions and began to plateau at 12−16 h.14 The 
slower, varying linear increases we observed in the current experiments could be due to 
incomplete translation, degradation, or misfolding of the fusion proteins. A Western blot 
with an antibody against mCherry (Figure 2.S1) showed that the full-length proteins were 
the predominant product in a representative set of TXTL reactions. Another possible 
cause of variability is inefficient production of fusion proteins due to batch-to-batch 
differences in components of the TXTL reagent (e.g., ribosomes, ATP, nucleases, 
proteases, etc.) or variable plasmid quality (i.e., supercoiled or nicked DNA). In the 
Western blot, anti-mCherry signal intensities generally agreed with end point RFP signal 
values. We conclude that RFP signal variation is likely due to differences in production. 
The general procedure used for TXTL is as follows. (1) Set up a TXTL reaction 
by combining 9 μL of Sigma 70 Master Mix (myTXTL, Arbor Biosciences), 1 μL of 5 
nM P70a-T7 RNA pol vector (Arbor Biosciences), and 2 μL of 50 ng/μL T7 promoter-
driven template vector (pET28) in a total volume of 12 μL in one well of a white, 96-well 
plate (Roche 04729692001). (2) Seal the plate with a clear film (Roche 04729757001) 
and run a Roche 480 LightCycler II program (or machine of your choice) as follows: 29 
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°C for 10 min and 30 °C for 1 s, scan at 533−610 nm twice, and repeat 96 times (total of 
16 h). 
 
Figure 2.2 Real time detection of RFP-tagged fusion protein expression in TXTL. 
Graphs show the RFP signal captured every 10 min over ∼16 h at a temperature of 29 °C, 
detected by a Roche Light Cycler 480 real time thermal cycler. The negative control (T7) 
contains the polymerase vector without the fusion-expressing pET28 vector. The grid 
shows the mean end point RFP signal values (bold) and standard deviations. 
ELISA Capture for Quantification of Protein Generated by TXTL 
Prior to histone PTM-binding experiments, total input (TXTL-generated fusion 
protein) should be determined with a reliable assay. In this report, we consider two 
parameters to represent input: end point fluorescent signal from the TXTL reaction 
(Figure 2.2) and signal values from control ELISA wells where antibodies are used to 
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capture the TXTL products. The TXTL RFP signal value is readily available and does not 
require additional experiments. However, this value may not correspond precisely with 
total full-length, histone-binding protein if incomplete folding of mCherry has occurred. 
Control ELISA wells using high-affinity antibodies against the fusion proteins 
circumvent the problem of misleading RFP signal values. 
To determine the best epitopes for capture and detection, we compared different 
capture antibodies (Figure 2.3A): one against the fluorophore within the fusion (mCherry 
RFP) and the other against the six-histidine motif that appears at both the Nand C-termini 
of the fusion proteins. The ELISA HRP signals generated from the six-histidine capture 
were stronger than those from the anti-RFP capture. This is perhaps due to the higher 
ratio of six-histidine epitopes: two per fusion protein molecule, compared to the single 
mCherry tag (Figure 2.1B). The six-histidine capture data and the end point RFP signal 
values from real time detection of RFP in TXTL reactions show a modest correlation [R2 
= 0.61 with the Pcγα outlier removed (Figure 2.S2B)]. Therefore, the RFP signal may be 
used to roughly approximate the amount of fusion protein. However, epitope capture 
(e.g., via anti-six-histidine) should be used as a control to more accurately determine 
fusion protein input.  
The general procedure for the ELISA control experiment is as follows. On the day 
the TXTL reaction is being set up and run (1 day before the ELISA experiment), prepare 
ELISA plates. (1) Add 50 μL of 2 μg/mL capture antibody in 200 mM carbonate buffer 
(pH 9.6) to each well. (2) Seal well with sealing foil (Cryostuff FS100) and incubate at 4 
°C overnight. All subsequent incubations take place at 800 rpm at room temperature 
unless otherwise noted. (3) On the day of the ELISA, remove foil, shake out the coating 
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solution, and tap the inverted plate on paper towels to remove excess liquid. (4) Rinse the 
plate with 200 μL of 0.2% PBST (10 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, 137 
mM NaCl, and 0.2% Tween 20) three times for 3 min each. (5) Block the plate with 
200μL of 5% BSA (Cell Signaling Technologies 9998S) in 0.2% PBST for 30 min. (6) 
Rinse the plate with 200 μL of 0.2% PBST three times for 3 min each. (7) Dilute the 
TXTL reaction mixture (∼11 μL after evaporation) into 400 μL of 5% skim milk in 0.2% 
PBST. (8) Add 50 μL of the TXTL/skim milk solution to each well and incubate for 1 h. 
(9) Rinse the plate with 200 μL of 5% skim milk in 0.2% PBST three times for 3 min 
each. (10) Add 100 μL of the 1:3000 primary antibody diluted in 5% skim milk in 0.2% 
PBST to each well and incubate for 1 h. (11) Rinse the plate with 200 μL of 5% skim 
milk in 0.2% PBST three times for 3 min each. (12) Add 100 μL of the 1:3000 secondary, 
HRP-conjugated antibody diluted in 5% skim milk in 0.2% PBST to each well and 
incubate for 30 min. (13) Wash the plates five times with 200 μL of 0.2% PBST for 3 
min each. (14) Remove buffer and add 100 μL of the one-step Ultra TMB-ELISA 
solution (Thermo 34029) to each well, protect from light, and incubate for 15 min. (15) 
Stop the reaction with 100 μL of 2.0 M sulfuric acid and incubate for 2 min. Measure 
A450 using a plate reader of choice (see details in Materials and Methods). See Figure 
2.3A for an illustration of immunocapture and detection. 
Initial First-Pass Screening for Histone PTM Binding 
An enzyme-linked immunosorbent assay (ELISA) is used to assess histone PTM 
binding by measuring the amount of fusion protein that remains bound to an immobilized 
target ligand (histone peptide) after washing away unbound and nonspecifically bound 
proteins. 
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The procedure for measuring histone peptide capture includes the steps from 
“ELISA Capture for Quantification of Protein Generated by TXTL” with the following 
modifications. (1) Coat a 96-well plate (Greiner Bio-one 655101) with 20 ng/ μL 
neutravidin (Invitrogen 31000) in PBS [10 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, 
and 137 mM NaCl (pH 8.0)] and add 50 μL to each well. (2) Follow steps 2−6 and then 
dilute biotinylated peptides to 1 μM in 0.2% PBST. Add 50 μL of the appropriate peptide 
solution to each well and incubate the plate at 800 rpm for 1 h. Following the peptide 
incubation, rinse the plate with 200 μL of 0.2% PBST three times for 3 min each. Block 
the plate with 200 μL of 5% skim milk (Apex 20- 241) in 0.2% PBST for 30 min. After 
this step, continue the protocol starting at step 7. See Figure 2.3B for an illustration of 
capture via immobilized histone peptides and detection. 
We used the ELISA-based histone peptide capture procedure to generate data for 
the library of fusion proteins described in Figure 2.1. Normalized HRP signal values from 
the H3K27me3 capture showed that tandem human orthologues of the PCD motif 
(variant Pcαα) conferred the strongest binding (Figure 2.3B). ELISA trials using 
additional replicate TXTL products agreed with this general observation (Figure 2.S3). 
For the other variants, we observed relative binding values that were significantly higher 
(p < 0.029) than PcΔ, but at no more than half the level of Pcαα. Overall, these data 
suggest that Pcαα has the strongest preference for H3K27me3 versus unmodified H3 and 
that this activity is reduced when the second PCD is changed to the fly for fish 
orthologue. These results also provide the first in vitro evidence to suggest that low level 
of relative binding of the fly and fish HDBs with H3K27me3 may contribute to the 
weaker activity of the fusion gene regulators in human cells, as previously reported (5). 
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Next, we investigated histone peptide-binding activity by determining the 
proportion of input protein that remained bound in the H3K27me3 and H3 histone 
peptide capture wells (Figure 2.3C). When six-histidine capture was used to represent 
input, the values for all variants with the fish (β) or fly (γ) orthologue in position 1 were 
at least half of or slightly higher than Pcαα (Figure 2.3C, top chart). These variants also 
showed H3 peptide capture values significantly higher than Pcαα (p < 0.017), suggesting 
higher levels of nonspecific binding. When the data were calculated using the TXTL end 
point RFP signal to represent input, relatively high or low RFP values changed the 
relationships between values; e.g., the values for Pcβγ and Pcγα become higher and 
lower, respectively, than Pcαα (Figure 2.3C, bottom chart). Discrepancies between the 
six-histidine epitope capture values and RFP signal lead to different interpretations of the 
data and underscore the importance of using a reliable internal control to determine input 
protein levels in the ELISA-based experiments. 
 
Figure 2.3 Relative protein levels and H3K27me3 binding of TXTL-expressed fusions 
determined by an ELISA. (A) To determine relative protein levels, three replicate TXTL 
reaction mixtures per fusion protein (from Figure 2.2) were combined and 1.4 μL of the 
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total TXTL reaction mixture was brought to 50 μL with 5% skim milk in 0.2% PBST and 
applied to each well containing immobilized anti-six-histidine (anti-his) or anti-mCherry 
(anti-RFP). Primary and secondary antibodies used in the detection step are shown in the 
table above each graphic. The grid shows mean values (bold) and standard deviations (±). 
(B) Interaction of each Pc fusion with the target ligand was assessed by histone peptide 
capture using H3K27me3 (green/blue) or unmodified H3K27 (negative control, not 
shown) anchored to immobilized neutravidin (orange). “Histone peptide capture: relative 
binding” is the mean A450 value from four replicate H3K27me3 wells, each normalized 
to the mean A450 for H3K27. (C) The top chart shows relative H3K27me3 capture 
scaled to six-His capture (A, bottom left). The bottom chart shows relative H3K27me3 
capture scaled to mean RFP (from Figure 2.2). Legend: error bars, standard deviation; 
HRP, horseradish peroxidase; FP, fluorescent protein; ED, effector domain for gene 
regulation. 
Determination of Target Specificity and Apparent Kd 
After first-pass screening for fusions that preferentially bind the histone PTM of 
interest, ELISA and microspot arrays can be used to determine apparent dissociation 
constants (Kdapp) (14) as well as target histone PTM selectivity. Both histone peptide 
capture techniques detect the amount of protein that remains bound after washing away 
nonspecifically bound proteins. Therefore, the calculated Kdapp will be biased toward the 
off kinetics. Previously, we used E. coli-expressed, purified fusion proteins and an HRP 
ELISA to assess binding as a function of histone PTM concentration in mixtures of 
immobilized ontarget PTMs (H3K27me3) with unmodified peptides (H3). We used direct 
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visualization of mCherry (RFP) on microspot arrays to assess binding as a function of 
fusion protein concentrations. 
TXTL potentially produces a suitable amount of protein for quantitative analysis. 
For our previously reported HRP ELISA binding curves (14) 100 nM (50 μL) E. coli-
expressed, purified Pcαα showed a ratio of ∼5:1 for signal (binding to 100% H3K27me3) 
to background (100% H3K27), as well as significant signal for 20−90% H3K27me3. In 
the current study, we observed that 1.4 μL of TXTL-expressed Pcαα produced a HRP 
ELISA signal:background ratio of ∼6:1 (Figure 2.3). Therefore, we would expect to 
detect a range of binding values (above background) if TXTL-produced Pcαα protein 
were exposed to an H3K27me3 dilution series (as previously described (14)). This should 
hold true for other Pc fusion variants with similar HRP ELISA values. 
An important feature of histone PTM-binding domains (HBDs) is their ability to 
discriminate between distinct histonetags within a cellular chromatin landscape that is 
decorated with a wide variety of modifications. Therefore, it is important to perform 
histone peptide capture using a variety of potential “off-target” PTMs, e.g., H3K27me3 
versus K4me3, K9me3, and K36me3, or different degrees of methylation (me1−me3). In 
our previous work, ELISA experiments showed that Pcα fusions had no interaction with 
K4me3 or K9me3 that was significantly stronger than that of unmodified H3 (14). 
Microspot binding assays have a substantial advantage over an ELISA in that the former 
supports miniaturization, which allows a variety of histone PTMs at several 
concentrations to be tested in a single application of soluble protein. One challenge for 
this approach is that it does not allow signal amplification (i.e., via HRP) prior to 
detection and thus requires a sufficient amount of protein to visualize linked tags (e.g., 
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mCherry used here) or immunostaining of the histone-peptide-bound fusion proteins. In 
our previous work, purified Pcαα (14) produced a detectable signal (∼2000 fluorescence 
units) on H3K27me3 microspots (1 mm each) with no background signal from 
unmodified H3 peptides when 0.5 mL of 100 nM fusion protein was applied over an area 
of 187 cm2. Theoretically, if 1.4 μL of TXTL is equivalent to 50 μL of 100 nM purified 
protein (as suggested by the HRP ELISAs that used purified proteins), we could expect to 
require at least ∼35 μL of TXTL to produce a detectable signal on a microspot array. 
Because the reaction volume used here is 11 μL, a few reactions may need to be 
combined for a sufficient yield. We encourage researchers to review the work of Tekel 
etal (14) and Filippakopoulos et al (26) for examples of glass slide- and cellulose 
membrane-based histone peptide capture experiments, respectively. 
Construction of Plasmids for Mammalian Cell Expression 
We have constructed a vector called MV10 (14) for the overexpression of fusion 
proteins in frame with a nuclear localization sequence and six-histidine tag. A single 
XbaI cloning site is included to accept BioBrick RFC23 standard inserts flanked by XbaI 
and SpeI overhangs (Figure 2.4). Nondirectional cloning theoretically yields equal 
proportions of forward (desired) and reverse insertions. We recommend the following 
colony PCR protocol to quickly screen for forward insertions. (1) Assemble constructs 
via nondirectional cloning of fusion-coding regions into vector MV10 using restriction 
digests and ligations as previously described (14). (2) Prepare colony PCR mixes as 
follows: 1× GoTaq green master mix (Promega M7122), 0.4 μM forward primer 5′-
caccatcgtggaacagtacg, and 0.4 μM reverse primer 5′-gcaactagaaggcacagtcg in a final 
volume of 25 μL in each 0.5 mL tube. (3) Pick colonies grown from ligation-transformed 
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E. coli with a sterile, disposable micropipette tip, streak onto a small area (1 cm2) on a 
gridded and labeled LB agar, 100 μg/mL ampicillin plate, swirl the same tip in each PCR 
mix, and discard the tip. Incubate the streak plate overnight at 37 °C. (4) Perform PCR as 
follows: 95 °C for 2 min; 25 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min; 
72 °C for 5 min; and held at 4 °C. (5) Analyze 20−50% of each reaction mixture via gel 
electrophoresis. (6) Inoculate 5 mL of liquid LB, 100 μg/mL ampicillin cultures with 
candidate clones from the streak plate; grow for 18 h at 37 °C with shaking, and miniprep 
the plasmid DNA (Sigma PLN350-1KT). (7) Perform restriction digests as follows: 
500−1000 ng of plasmid DNA, 1 μL of each of FastDigest enzymes XbaI and PstI, and 
1× FastDigest buffer (Thermo Fisher FD0684, FD0614, and B72). Analyze the products 
using standard agarose gel electrophoresis with TAE buffer. 
 
Figure 2.4 Vector for mammalian cell expression and scheme for verifying constructs. 
The MV10 vector is designed to accept XbaI–SpeI donor fragments at a XbaI site so that 
the open reading frame (red) is cloned in frame with the translation start site within the 
yeast-derived Kozak (K) sequence and the downstream nuclear localization sequence, 
six-histidine tag, and stop codon. The downstream SpeI/XbaI junction is a mixed site (5′-
actaga) that cannot be recut. Concurrence of both results shown for the validation assays 
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is unique for a single forward insert for any construct that includes the C-terminal 
mCherry-VP64 sequence used here. 
Determination of Transcriptional Regulation in Mammalian Cells: Microwell Assay 
for Luciferase 
Standard transfection techniques (polyplex or electroporation) can be used to 
deliver fusion-expressing plasmids into cells. In our hands, transiently transfected cells 
(nonhomogeneous) for which the transfection efficiency is ≥50% (determined by 
fluorescence microscopy and flow cytometry) is sufficient for quick validation of large 
sets of plasmids. For more rigorous quantitative analyses of histone PTM-binding 
candidate fusion transgenic line in Limitations. 
We have used an H3K27me3-enriched locus as a target to test the function of 
PCD fusion regulators (Figure 2.5A). In this system, accumulation of H3K27me3 near 
the promoter of a luciferase target gene in HEK293 cells is controlled by adding 
doxycycline to the growth medium (as described in Cell Culture and Transfection). Other 
mammalian ectopic chromatin systems have been developed for H3K27me3 (27), 
H3K9me3 (27, 28), and acetylation of H3 and H4 (29). These systems provide a powerful 
platform for comparing the activity of libraries of histone PTM-binding regulators but 
represent a very limited set of PTMs; we discuss endogenous loci as an alternative option 
in the next section. 
Regulation of a reporter gene at ectopic chromatin is performed as follows. (1) 
Transfect cells and grow for 3 days to allow fusion protein expression and regulation of 
the target. (2) Collect semiadherent cells with 1× PBS washes, pellet (200 g, room 
temperature, 5 min), and resuspended in 1.5 mL of 1× PBS. (3) Transfer cells to Black 
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Costar Clear Bottom 96-Well Plates (Corning 3631). To test each sample in triplicate, 
load three wells with a 200 μL cell suspension for RFP detection, three wells with a 100 
μL cell suspension and 100 μL of 2× Hoechst 33342 stain (2 μg/mL, Invitrogen H3570), 
and three wells with 100 μL of cells and 100 μL of prepared Luciferase Assay Buffer 
with D-luciferin substrate (Biotium 30085). Add 200 μL of 1× PBS to one or more 
columns of wells to determine background noise. Allow the plate to incubate at room 
temperature protected from light for 10 min, allowing cells to settle for optimal 
fluorescence reads. (4) Scan the plate in a Biotek Synergy H1 microplate reader with the 
following parameters: read, fluorescence at 580−610 nm (RFP), gain set to 100; read 
fluorescence, 360−460 nm (Hoechst 33342), gain set to 75; orbital shake, 5 min; read 
chemiluminescence (luciferase activity). (5) Determine fluorescence signal detection 
limits of the plate reader with a set of standard samples as described in Figure 2.S4. (6) 
Analyze the data from each channel separately. Subtract the average background (1× PBS 
wells) from each value. See Figure 2.5B for an illustration of a microwell plate 
configuration. 
Results from the in vitro histone peptide capture assays suggest that Pcα confers 
H3K27me3-selective binding to HDB fusion proteins (Figure 2.3B). The other 
orthologues might enhance general, nonspecific interaction with unmodified histone H3, 
as indicated by relatively high input-normalized values (Figure 2.3C). To investigate the 
significance of the observed histone peptide-binding activities for gene regulation 
activity, we tested five fusion protein variants in the mammalian cell assay: two that 
showed high and moderate levels of relative binding with H3K27me3 and low levels of 
H3 binding (Pcαα and Pcββ), one that showed moderate levels of relative binding and 
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high levels of H3 binding (Pcγα), other variants that showed low levels of relative 
binding and contained at least one human PCD orthologue (Pcαβ, Pcαγ, or Pcβα), and the 
truncated PcΔ protein (negative control). Cells expressing Pcαα showed the highest levels 
of luciferase reactivation (luciferase enzyme activity), and the only mean value that was 
higher (p = 0.058) than PcΔ after scaling by the RFP signal (Figure 2.5C). This result 
suggests that a high relative binding level of a fusion protein with H3K27me3 from the 
ELISA-based assay may predict effective transcriptional activation at a silenced 
chromatin site in cells. Overall, our results demonstrate that an ELISA using TXTL-
expressed proteins is an effective method for identifying histone PTM-binding regulators 
that can activate target genes in live cells. 
 
Figure 2.5 Microwell plate reader assay for assessing fusion protein expression and 
regulation of a target reporter gene. (A) Gal4-EED/luc cells were treated with dox to 
induce ectopic recruitment of polycomb repressive complex 1 (PRC1) and accumulation 
of H3K27me3 and PRC2 at a luciferase reporter. (B) After luciferase silencing, cells 
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were transfected with each fusion-expressing plasmid, harvested, and aliquoted into a 96-
well plate. In this procedure, RFP is used to assess fusion protein expression, the signal 
from the Hoechst 33342 DNA stain is a proxy for cell loading, and luciferase activity 
indicates gene expression induced by each Pc activator fusion. (C) Bar charts show mean 
background-subtracted values from triplicate wells, normalized and scaled as described in 
Materials and Methods. Legend: error bars, standard deviation; UT, untransfected cells. 
Determination of Gene Regulation in Mammalian Cells: RT-qPCR Assay for 
Endogenous Genes 
If the Gal4-EED/luc system or other similar reporters are not available or relevant 
for one’s own project, we recommend an expression assay based on an endogenous target 
locus (or several loci) with a well-characterized epigenetic state. These genes can be 
identified as those reported to show changes in expression when histone-modifying 
enzymes are disrupted by inhibitors or RNAi-mediated knockdown. For instance, our 
group identified a set of 14 genes for which polycomb-mediated silencing was supported 
by genetic and pharmacologic disruption studies in human cancers and stem cells (4). 
Epigenetic regulation can be confirmed by investigating genomic chromatin feature 
maps. Table 2.1 presents publicly available data from whole-genome chromatin profiling 
experiments (chromatin immunoprecipitation followed by deep sequencing, ChIP-seq) to 
assist in the identification of target loci in widely used model cell lines. 
Reverse transcription followed by quantitative PCR (RTqPCR) (30) is a standard, 
flexible method for determining changes in gene transcription. For each experiment, a 
minimum of three transcripts must be measured: a housekeeping gene (e.g., GAPDH), the 
fusion regulator, and the regulated target gene. We have successfully used RT-qPCR to 
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measure changes in luciferase expression in the Gal4-EED/luc reporter cell line to 
validate luciferase assay results (14) and to measure the expression of several endogenous 
genes in the presence of an H3K27me3- binding fusion activator called PcTF (4-5). In 
our hands, it is not necessary to sort for fusion protein-positive cells prior to RTqPCR 
because the gene expression values can be scaled by RFP signal (flow cytometry) or 
fusion mRNA levels as needed. (1) Transfect ∼1.0 × 105 cells per well as described in 
Materials and Methods. Include a mock-transfection control: empty vector or water 
instead of fusion protein-expressing DNA. Grow for 2−3 days in an appropriate cell 
culture medium. (2) Prepare total RNA from ∼1.0 × 106 cells using a method similar to 
that previously described by our group (2-3). We recommend direct lysis of pelleted cells 
with 500 μL of TRIzol (Thermo Fisher 15596026) followed by spin column purification 
of RNA from the aqueous phase of chloroformextracted samples (Qiagen RNeasy Mini 
kit 74104). (3) Generate cDNA libraries by using 2 μg of total RNA and the SuperScript 
III first-strand synthesis system (Invitrogen 18080051). (4) Perform qPCR (15 μL each) 
using 2 μL of a 1:10 cDNA dilution for the endogenous gene(s) of interest or a 1:1000 
dilution for the highly expressed genes (i.e., reference gene GAPDH, ACTB, etc., or the 
overexpressed fusion transgene). Follow the manufacturer’s recommendations for other 
reagents (primers, probes, polymerase, dNTPs, and buffer). (5) Calculate the mean 
quantification cycle (Cq, also described as Ct and Cp) for three replicate wells per unique 
reaction. Calculate the expression level with the equation ΔCq = 2mean Cq reference−mean Cq 
target. Calculate the log 2-fold change in gene expression as log 2(ΔCq transfected cells/ΔCq 
mock). 
Table 2.1 Recommended Human Cell Lines For Identifying Endogenous Target Sites 
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Histone 
H3 PTM 
Correspondi
ng HBD 
Cells lines and ChIP-seq data sources 
  
HEK293 
(kidney) 
MCF7 (breast) K562 (blood) H1-hESC 
(stem) 
H3K4me
3 
PHD8 ENCSR000D
TU 
ENCSR000D
WJ 
ENCSR668L
DD 
ENCSR000A
MG 
H3K9me
3 
CD7 ENCSR000F
CJ 
ENCSR000E
WQ 
ENCSR000AP
E 
ENCSR000AP
Z 
H3K14ac BRD6 N/A N/A N/A ENCSR057BT
G 
H3K27m
e3 
PCD5,8,14 N/A ENCSR000E
WP 
ENCSR000E
WB 
ENCSR000AL
U 
H3K27ac
* 
YEATS33 ENCSR000F
CH 
ENCSR000E
WR 
ENCSR000A
KP 
ENCSR880SU
Y 
aDetailed information for HBDs tested in vitro and in cells is available in the cited 
references and in our recent review (9). Data ID numbers from the ENCODE project 
online database at https://www.encodeproject.org/experiments are listed. These can be 
used to access and download BAM files. To view ChIP enrichments, we recommend 
loading the BAM file into the Integrated Genome Viewer from the Broad Institute (free 
download, http://software.broadinstitute.org/software/igv/). bAbbreviations: PHD, plant 
homeodomain; PCD, polycomb chromodomain; CD, chromodomain; BRD, 
bromodomain; YEATS, “Yaf9, ENL, AF9, Taf14, Sas5” domain. cNot available in 
ENCODE. dAlso expected to interact with H3K9ac and H3K18ac. 
Chromatin Immunoprecipitation to Determine Fusion Protein Binding at Target 
Loci 
A critical step in validating the behavior of fusion proteins that interact with 
histone PTMs is to detect the interaction of the fusion protein with target loci in cells. For 
fusion transcriptional regulators, it is important to identify instances in which the histone 
PTM binding fusion interacts with chromatin sites but does not influence gene 
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expression. Furthermore, several HDB fusion proteins have been used to label histone 
PTM-enriched regions and are not intended to artificially regulate genes (6, 8, 31). 
Crosslinked chromatin immunoprecipitation (X-ChIP), first reported in 1988 (33) has 
become a gold standard method for measuring the accumulation of proteins at specific 
genomic loci. In brief, cells are treated with formaldehyde to cross-link chromatin 
proteins with target DNA, the chromatin is sheared (sonicated or enzymatically digested) 
into soluble particles, particles containing the protein of interest (e.g., the fusion protein) 
are immunoprecipitated, and the co-immunoprecipitated DNA is purified and analyzed 
by quantitative PCR of specific sites (ChIP−qPCR) or by next-generation sequencing and 
computational alignment of all DNA fragments in the sample (ChIPseq). Fusion proteins 
expressed from transgenes are highly amenable to ChIP because they can be designed to 
include a reliable epitope tag, and uniform expression across all cells can be achieved in a 
stable transgenic cell line. In our previous work, we used ChIP-seq to profile the genome 
wide distribution of a Pcα fusion (called PcTF) and its target histone PTM H3K27me3 in 
a transgenic U2OS cell line (4). As an alternative to the resource-intensive ChIP-seq 
assay, we have used ChIP− qPCR to measure changes in Pc fusion and histone PTM 
levels over time near a specific PcTF-responsive gene (4). In cases in which the HBD 
fusion shows strong, specific localization within nuclei, immunofluorescence cytology 
with antibodies against specific histone PTMs can be used to assess the co-localization of 
HBD fusion proteins and their targets (34). 
Limitations 
TXTL May Not Be Sufficient for Single-HBD Fusion Proteins. In previous trials, 
we observed very little HRP signal over background for a TXTL-expressed Pc fusion 
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called PcTF, which carried a single copy of Pcα (unpublished). However, using 
overexpressed and purified protein from transformed E. coli, we demonstrated specific 
binding of PcTF to H3K27me3 (vs H3Kme3 and H3K9me3) in an ELISA. We also 
observed H3K27me3 binding of PcTF at levels higher than that of the negative control 
(mCherry-VP64) using a histone peptide microspot array. These assays showed a weaker 
Kdapp value (∼0.5-fold) for PcTF than for the double- HBD variant Pc2TF [identical to 
Pcαα (Figure 2.1)]. Thus, the lower-affinity fusion PcTF functions in vitro, but the TXTL 
reaction as described here may not produce a sufficiently high yield for a detectable HRP 
signal after binding and washing during the ELISA. 
Fusion Protein Dose and Cell Heterogeneity Are Difficult To Measure and 
Control in Transiently Transfected Cells. The transiently transfected HEK293 cells that 
we generated for this study produced RFP signal levels that varied between expression 
plasmids and were near the lower end of the detection limits for the microwell plate 
reader that we used (Figure 2.S4). Therefore, we recommend transient transfections only 
for preliminary assessment of expression levels and fusion regulator activity in a model 
system. For follow-up studies that require precise measurements of gene expression in 
response to the dose (expression level) of the fusion regulator or require a homogeneous 
population of transgenic cells for optimal results (e.g., ChIP-seq), we recommend 
generating stable cell lines. Inducible transgene expression systems prevent premature 
expression of the fusion, which may broadly regulate genes in the host cells prior to 
treatment and analysis. There are many available options that do not require viral 
transduction. For instance, we have used the popular T-REx system (Invitrogen) to 
express PcTF in U-2 OS cells (4-5). We have also successfully used an all-in-one 
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doxycycline-inducible expression cassette based on the sleeping beauty transposon-based 
system pSBtet- GP (35) to express PcTF in MCF7 cells. 
Associated Content 
 
Figure 2.S1 Western blot analysis of TXTL-expressed fusion proteins. TXTL reactions 
containing each fusion construct (“Variant”) plus T7 RNA polymerase vector, or T7 
RNA polymerase alone (negative control) were run as described in Materials and 
Methods. Samples were subjected to PAGE, blotted onto nitrocellulose, and 
immunostained with anti-mCherry and an HRP-conjugated secondary antibody. The 
procedure is described in detail in Supporting Methods. Predicted molecular weights 
(expected size, kDa) were calculated using the protein report tool within the CLC Main 
Workbench program (Qiagen). The positions of the TXTL-expressed fusion protein 
bands relative to the protein standard (lane 1) and to each other are consistent with our 
previously published Western blots for mammalian cell-expressed proteins (1). The 
protein standard shown here (Thermo Fisher #10748010) may not be an accurate 
indicator of protein size. 
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Figure 2.S2 Comparison of TXTL RFP signal with total protein determined by RFP- or 
6-his capture ELISA. (A) To determine reproducibility of expression via TXTL, we ran 
two additional TXTL reactions (TXTL 4 and 5) per fusion construct using the same 
plasmid DNA preparations are TXTL 1-3. “TXTL 1-3” represents the samples and values 
from Figure 2.2. Each value shown for TXTL 4 and 5 is from a single reaction. (B) 
Samples TXTL 1-3 were combined and used for ELISA experiments with different 
capture antibodies, anti-RFP or anti-6-histidine. Left dot plot: comparison of the endpoint 
TXTL RFP signal values (TXTL 1-3 in panel A) with the mean HRP signal values from 
the ELISA data (Fig. 3A). Right dot plot: comparison of the mean HRP signal values for 
6 his versus RFP-capture. R squared values are shown for comparisons of all data (i) or 
with the Pcγα outlier excluded (ii). 
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Figure 2.S3 ELISA assays for additional replicate TXTL samples. To determine 
reproducibility of histone capture for TXTL-expressed fusion proteins we carried out 
ELISA for two additional TXTL reactions (4 and 5). Endpoint RFP signal values for 
these samples are shown in Fig. S2A. Error bars, standard deviation. 
 
 
Figure 2.S4 Determination of plate reader detection limits for Hoechst and RFP 
(mCherry). Samples of varying signal intensity were used to determine the linear range of 
signal detection for the Biotek Synergy H1 plate reader using the settings described in our 
report. (A) To prepare samples for the Hoechst channel (360-460 nm), HEK293 cells 
were grown to 90% confluency in a 12-well plate, collected, stained with varying 
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concentrations of dye. Dots show mean values from triplicate cell samples (bars, standard 
deviation). The maximum and minimum Hoechst signal values from the plate reader data 
from Figure 2.5 are marked with dotted lines. (B) Samples for the RFP channel contained 
5.0 to 62.0 μM 6-histidine-tagged recombinant PcΔ protein diluted in 1X PBS (200 μl per 
well). PcΔ was over-expressed in E. coli cultures and purified on a nickel-column as 
described in detail in Tekel et al. Dots show mean values from triplicate protein samples 
(error bars, standard deviation). 
 
Western blot and immunostaining of TXTL-expressed fusion proteins. Samples for 
denaturing polyacrylamide gel electrophoresis (PAGE) were prepared by heating 1 μL of 
TXTL reaction plus 4 μl NuPAGE LDS Sample Buffer 4x (Thermo Fisher #NP0007) and 
1 μl 1 M Dithiothreitol (DTT, Millipore Sigma #D0632-1G) at 95°C for 5 min in a total 
volume of 20 μL. Samples (cooled to room temperature) and a pre-stained protein 
standard (10 μl, Thermo Fisher #10748010) were electrophoresed at 200 V for 45 
minutes in a 4-12% Bis-Tris gel (Thermo Fisher #NP0322BOX) with MOPS-SDS buffer 
[(50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7) diluted 1:20] in an 
XCell SureLock vertical chamber (Invitrogen #EI0001). 0.5 mL antioxidant solution 
(Invitrogen #NP0005) was added to the inner (cathode) chamber prior to electrophoresis. 
PAGEseparated proteins were transferred onto a nitrocellulose membrane (Bio-Rad 
#1704158) via semidry transfer in a Trans-Blot Turbo system (Bio Rad #1704150). 
Complete transfer was verified by S6 staining the membrane with 1x Ponceau-S (G-
Biosciences #786-576). Immunostaining was carried out with the following: blocking 
buffer, 5% nonfat dry milk in 1x PBST (1x PBS, 0.2% Tween-20); primary, chicken 
polyclonal anti-mCherry 1:1000 (Novus Biologicals #NBP2-25158); secondary, HRP-
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conjugated rabbit anti-chicken 1:5000 (Millipore Sigma #AP162P). Immunostaining was 
performed at 4°C overnight (primary) or at room temperature for 1 hour (secondary) with 
rotation in a Parafilm pouch. Immunostained blots were washed 4x, 10 min each in 1x 
PBST, with orbital shaking at room temperature. HRP signal was detected using the 
SuperSignal West Femto substrate kit (Thermo Fisher #34095) and a PXi4 imager 
(Syngene) with GeneSys software. 
Abbreviations 
PTM, post-translational modification; HBD, histone PTM binding domain; PCD, 
polycomb domain; PHD, plant homeodomain; HRP, horseradish peroxidase; EED, 
embryonic ectoderm development; VP64, viral protein 64; BSA, bovine serum albumin; 
RFP, red fluorescent protein; ELISA, enzyme linked immunosorbent assay; Pc, 
polycomb; TXTL, E. coli based in vitro transcription and translation system; mCh, 
mCherry; BRD, bromodomain; CD, chromodomain; PCR, polymerase chain reaction. 
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CHAPTER 3 
TANDEM HISTONE-BINDING DOMAINS ENHANCE THE ACTIVITY OF A 
SYNTHETIC CHROMATIN EFFECTOR 
 
Figure 3.0 Abstract Figure. 
Introduction 
The discovery of histone post-translational modifications (PTMs) and the peptides 
that specifically interact with these marks has enabled scientists and cell engineers to 
manipulate chromatin, the DNA−protein structure that regulates gene expression states in 
eukaryotic cells. Structure-based models have informed targeted knockdown of 
chromatin subunits and the rational design of low molecular weight inhibitor compounds 
(reviewed in ref 1). DNA-binding domains fused with structural chromatin proteins and 
histone-modifying enzymes have been used to generate ectopic chromatin conformations 
at specific loci (2-3). Until recently, scientists had not yet leveraged PTM-binding 
peptides from natural effector proteins to “read” the rich biological information encoded 
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in histone marks in living cells. Peptides that recognize specific histone PTM signals are 
essential for synthetic systems that integrate epigenetic regulatory signals. In order to use 
PTM binding peptides in synthetic fusion proteins, the peptides must be portable, that is, 
maintain their intrinsic function within a new protein sequence. Early studies established 
important foundational knowledge by demonstrating that the interaction of the 
chromodomain motif (CD) with trimethylated histone H3 lysine 27 (H3K27me3) is an 
intrinsic activity that is maintained by the CD in the context of recombinant, fusion 
proteins (4-5). Other protein folds including the bromodomain (BRD) and plant 
homeodomain finger (PHD) function as isolated peptides (6−8) and within fusion 
proteins (7, 9) to specifically interact with acetylated histone lysines (BRD) and 
H3K4me3 (PHD). 
We constructed the polycomb-based transcription factor (PcTF) using a histone 
PTM-binding motif from the natural protein CBX8 (10). The CBX8 effector protein 
binds to histone H3 trimethylated at lysine 27 (H3K27me3) through its Nterminal 
polycomb chromodomain (PCD) and establishes a silenced transcriptional state. 
Expression of PcTF, an artificial transcriptional activator with an N-terminal PCD, 
mCherry tag, and C-terminal VP64 activation domain, led to increased expression of 
H3K27me3-enriched genes in three different cancer-derived cell lines (11) These results 
show promise for designing transcription factors that can read chromatin marks to rewire 
aberrant epigenetic programming. However, binding affinities observed in vitro for 
isolated PCDs is poor, reported as 5 to >500 μM (12-13) compared to DNA-binding 
domains with target affinities in the pico- to nanomolar range such as transcription 
activator-like effectors (TALEs, ∼3−220 nM) (14), zinc fingers (∼0.01−16 nM) (15, 16), 
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and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR 
associated domains (Cas) (∼0.5 nM) (17). In other work, we observed stronger gene 
upregulation when mCherry-VP64 was targeted to a promoter via a Gal4 DNA binding 
domain compared to the PCD histone-binding domain (10) PcTF mediated gene 
activation is dose dependent (11) and high PcTF expression levels are required for 
optimal activity. This limits the usefulness of PcTF for therapeutic applications where 
barriers to delivery severely limit the number of proteins that ultimately reach the nuclei 
of target cells. Although pharmacokinetic barriers to DNA and protein delivery in vivo 
are not trivial, increasing the effective dose of PcTF could significantly advance this 
technology toward clinical use. 
The appearance of tandem histone binding domains within natural proteins 
suggests that the performance of histonebinding regulators can be customized and tuned 
through multivalency, defined as contact with more than one histone PTM via multiple 
domains (reviewed in refs 3, 18, and 19). Multivalent chromatin proteins can engage 
adjacent PTMs within a single histone tail, such as K4me3 and R8me2 on histone H3 
bound by Spindlin1 (20) or K5ac and K12ac on histone H4 bound by TAFII250 (21). 
PTM targets can also reside on two distinct histone tails, such as H4K16ac and H3K4me3 
bound by BPTF (7). Dual recognition of histone PTMs is accomplished by tandem 
protein motifs within the histonebinding protein. Comparisons of natural mono- and 
divalent proteins (22) as well as histone peptide on- and off-target binding studies (20, 
23) have produced compelling evidence that tandem motifs contribute to avidity and 
specificity. The idea that combinatorial avidity allows proteins to read a “histone code” 
has been the topic of some controversy. Until recently, multivalency had not been 
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demonstrated using a rationally designed composition of binding domains. Tandem 
histone binding domains have been used to design protein probes to fluorescently label 
regions that are enriched for specific histone modifications (24-25) To date, multivalency 
has not been used to design a transcriptional regulator and tandem PCDs have not been 
reported. In order to compensate for the modest affinity of the CBX8 PCD (12) for its 
target, we added a second copy of H3K27me3-binding PCD to the N-terminus of PcTF to 
build Pc2TF. Here, we demonstrate that Pc2TF shows stronger avidity for H3K27me3 in 
vitro. This activity corresponds with enhanced activation of an H3K27me3-repressed 
gene in cultured cells. Our results have important implications for building and tuning 
fusion proteins that target sites of polycomb-mediated silencing, which plays a central 
role in cancer and stem cell plasticity. 
 
Figure 3.1 Three-dimensional model layout to show the plausibility of Pc2TF binding to 
adjacent H3K27me3 marks. (A) PCD (CBX8) in complex with trimethyl lysine (PDB 
3I91) (37). Three residues form a hydrophobic cage and surround the Kme3 moiety 
(inset). (B) H3K27me3 recognition by synthetic fusion proteins that carry a single or 
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tandem PCD domains (PcTF and Pc2TF, respectively). The 3D rendering was composed 
in the PyMOL Molecular Graphics System, version 1.3, Schrödinger, LLC 
(https://www.pymol.org), using data for CBX8/H3K9me3 (PDB 4X3K) (51) and a whole 
nucleosome assembly (PDB 5AV8) (51-52) from the Protein Data Bank. 
Design of a Bivalent Synthetic Chromatin-Based Transcriptional Regulator 
 We designed the Pc2TF protein to simultaneously recognize two copies of the 
histone posttranslational modification H3K27me3. The polycomb chromodomain motif 
(PCD) consists of three β strands packed against a C-terminal α helix and a hydrophobic 
pocket formed by three aromatic residues that interact with a methyl-lysine side chain 
(13, 26) (Figure 3.1A). The arrangement of histones within the nucleosome octamer 
suggests that Pc2TF might bind adjacent trimethylated H3K27 residues. A single 
nucleosome includes eight individual histone proteins. The central tetramer contains two 
copies of histone H3 and H4. The H3 proteins are oriented in cis so that the unfolded N-
terminal tails protrude away from the nucleosome in the same direction (27) (Figure 
3.1B). One or both H3 tails (28) can become trimethylated at lysine 27 by the enzyme 
enhancer of zeste (EZH) (29). Therefore, tandem PCDs in the multivalent protein Pc2TF 
might interact with two histone post translational modifications (PTMs) in a single 
nucleosome (Figure 3.1B) or single PTMs on adjacent nucleosomes. 
To quickly and efficiently identify a linker that would allow contact of each PCD 
with an H3K27me3 ligand, we used an in vitro expression and ELISA procedure to test 
four Pc2TF variants. Different lengths and physical characteristics were explored by using 
flexible glycine−serine linkers (30) and rigid α- helical (31-32) linkers. Glycine and 
serine, amino acids with small side chains, have been used in a wide range protein 
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engineering applications to build linker peptides that have minimal interference with the 
function of tethered proteins. However, as was demonstrated by mutagenesis of a rigid 
linker in the bivalent protein BPTF, added flexibility can destabilize protein−histone 
interactions (7). Rigid linkers might perform better by stabilizing the distance between 
PCDs to support interactions with neighboring K27me3 moieties (33-34). The Pc2TF 
constructs included two tandem copies of the PCD separated by one of four linkers: 
flexible (GGGGS)4, long flexible (GGGGS)16, rigid (EAAAR)4, and long rigid 
(EAAAR)16. Based on a simplified layout of the interacting components (PCDs and a 
nucleosome carrying two H3K27me3 modifications; Figure 3.1B), we predicted that 20 
amino acids would provide sufficient length for adjacent PCDs to bind simultaneously. 
The 80-amino-acid linkers were used to determine the impact of increased spacing 
between PCDs. 
To expedite the prototyping stage, we used a cell-free expression system (35). 
Pc2TF variants and a control protein with no binding domain (PcΔTF) were expressed 
from a pET28 vector (Figure 3.2A) in TXTL solution. Real-time detection of mCherry 
fluorescence in a Roche thermal cycler confirmed expression of recombinant proteins. 
For ELISAs, biotinylated histone peptides were immobilized on a neutravidin-coated 96 
well plate. HRP-conjugated anti-mCherry was used for immunodetection of bound fusion 
proteins. Significantly higher HRP signal was detected compared to background 
(unmodified K27 and K27ac) for variants that contained the flexible (GGGGS)4, long 
flexible (GGGGS)16, and long rigid (EAAAR)16 linkers (Figure 3.2C). The implications 
of these results are discussed in depth in the Conclusions. Assuming that HRP signal is 
proportional to Pc-fusion molecules bound, the flexible (GGGGS)4 linker conferred the 
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strongest avidity in this assay. Therefore, we used this variant in subsequent experiments 
to determine the impact of bivalency on the activity of synthetic, histone-binding 
effectors. 
 
Figure 3.2 Comparison of Pc2TF variants that were expressed in a bacterial cell-free 
expression system. (A) Map of the expression vector and open reading frames (ORFs). 
Fusion-encoding ORFs were cloned in the pET28 vector at BamHI and XhoI. (B) Real-
time detection of mCherry fluorescence was used to determine expression of recombinant 
protein in TXTL in a 96-well PCR plate in a Roche thermal cycler. Each replicate is an 
independent TXTL reaction in a single well (1 replicate for PcΔTF and TXTL without 
DNA, 3 replicates for others). Replicates were pooled for ELISAs in panel C. Solid line = 
mean, shaded regions = SDM. (C) The bar chart shows mean signal from anti-mCherry-
HRP signal at an absorbance of 450 nm (3 ELISA wells) from TXTL-expressed fusion 
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proteins or plasmid-free “blank” TXTL captured by tethered trimethyl-K27 (K27me3), 
unmodified (K27), or modified nontarget (K27ac) histone H3 peptides. For each TXTL 
product, individual values are normalized to the unmodified H3 mean value within the set 
(error bars = SDM). 
Bivalency Strengthens the Avidity of the Pc-Fusion for H3K27me3 
 To compare known concentrations of Pc fusion proteins in subsequent 
experiments, we overexpressed and purified recombinant proteins from E. coli. 
Denaturing polyacrylamide electrophoresis (PAGE) of lysates from isopropyl β-D-1-
thiogalactopyranoside (IPTG)-treated and untreated E. coli confirmed inducible 
production of the proteins at roughly the expected sizes: 37, 44, and 52 kDa for PcΔTF, 
PcTF, and Pc2TF, respectively (Figure 3.3A). Nickel-NTA column-purified proteins were 
soluble in 1× phosphate buffered saline (PBS). The visible red hue under white light, 
which is typical of the mCherry protein (36), indicated proper protein folding (Figure 
3.3A). 
To determine impact of the additional PCD domain on PcTF avidity, we exposed 
tethered histone peptides to varying concentrations of soluble PcTF and Pc2TF. Liquid 
phase ligand (H3K27me3 peptide) binding assays (fluorescence polarization, FP) 
reported by other groups have determined affinities of N-terminal PCD motifs from the 
Drosophila Pc protein (residues 1−90, Kd = 5.0 ± 1 μM (13)) and mammalian CBX8 
protein (mouse residues 1−62, Kd = 165 ± 20 μM (12), human residues 8−61, Kd > 500 
μM (37)). The amino acid sequence of the PCD in our fusion proteins (human CBX8 
residues 1−62) is identical to the mouse ortholog. To acquire data that is relevant to the 
full-length fusion proteins (295 to 445 residues) that we had previously tested as gene 
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regulators in cancer cell lines (11), we used a histone peptide microspot array. We used a 
mathematical model to predict relative RFP signal levels after Pc-fusion binding and 
subsequent washing of the microarray. PcTF has a higher mCherry/PCD ratio than Pc2TF 
(1:1 versus 1:2). Therefore, PcTF should show higher relative RFP signal when all targets 
(H3K27me3 peptides) within a microspot are saturated by PCD binding (Figure 3.S1). 
Assuming that bivalency supports an additive increase in avidity, a higher fraction of 
Pc2TF molecules should remain bound at the microspot during washing, resulting in 
higher total RFP signal. Results from a test array were consistent with this prediction 
(Figure 3.3B). We tested concentrations of the recombinant proteins over 2 orders of 
magnitude (0.2−20 μM) to determine the apparent dissociation constant (Kdapp) of each 
protein for 10, 20, and 50 μM tethered H3K27me3 ligand (Figure 3.S2). We detected 
no interaction with unmodified histone H3 peptides and very little signal above 
background for the PcΔTF negative control. The Kd app of monovalent PcTF was 
5.14−8.95 μM for four independent trials (Figure 3.3C and 3.S2). The micromolar Kd app 
values are comparable to Kd values from the aforementioned FP experiments, although 
the wash steps in microspot assay may bias Kd app toward the off kinetics of the binding 
process. We conclude that PCD retains its intrinsic affinity for H3K27me3 as an N-
terminal motif within a fusion protein. 
Overall, analysis of the microspot array data suggest that at 10 and 20 μM of 
H3K27me3 the Kdapp of Pc2TF is roughly 2- fold smaller than PcTF (Figure 3.S2). 
Assuming that the second PCD fold (PCD2) maintains its intrinsic affinity, PCD2 should 
approximately double the overall association rate for Pc2TF since there is twice the 
chance of a PCD−H3K27me3 collision. Avidity is related to the inverse of the 
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equilibrium constant, and the equilibrium constant is proportional to the ratio of 
association rate over dissociation rate. Thus, the effect we observed is most likely due to 
increasing the association rate or decreasing the dissociation rate, which would decrease 
the Kdapp value (compared to PcTF) roughly 2-fold. 
 
Figure 3.3 A bivalent PCD fusion peptide shows enhanced avidity for H3K27me3 in 
microspot array experiments. (A) For high-yield expression, E. coli was transformed with 
pET28 plasmids encoding PcΔTF (negative control), PcTF (single PCD), and the Pc2TF 
containing the flexible linker (GGGGS)4. Native polyacrylamide gel electrophoresis 
(PAGE) of overexpressed proteins purified from E. coli. (B) Test slides were spotted with 
histone H3 peptides (K27me3 or unmodified K27) as indicated in the grid for qualitative 
analysis. Pseudocolored images show mCherry signal after an application of 1.0 μM 
fusion protein to individual arrays. (C) New arrays were spotted with 10, 20, and 50 μM 
H3K27me3 for quantitative analysis. Fluorescence signal versus the concentration of 
fusion protein applied to the array was used to calculate the apparent dissociation 
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constant (Kdapp, not applicable for PcΔTF). Each point in the graph is the mean signal 
from four spots in one application (error bars = SDM). The data displayed in the graph 
are from representative applications (out of four total) for 20 μM immobilized 
H3K27me3. 
Bivalent Pc2TF Shows Cooperative, On-Target Binding with Solid Phase Target 
Ligands 
 Next, we investigated the binding properties of the mono- and bivalent PCD 
proteins over a range of target ligand densities to approximate dynamic distributions of 
H3K27me3 that may occur in chromatin. We assumed that random distribution within 
each mixture would decrease the spacing between H3K27me3 targets as their 
concentration was increased. We applied dilutions of the target ligand (0−100% 
H3K27me3 mixed with unmodified H3K27, 1000 nM final concentration) to ELISA 
wells and exposed the immobilized ligands to the highest concentration of fusion proteins 
that produced minimal background signal in preliminary ELISA trials (0.1 μM). At 
0−15% H3K27me3, HRP signal for PcTF or Pc2TF was not significantly greater than the 
negative control fusion protein (PcΔTF). In this range, the number of fixed H3K27me3 
ligands may not have captured enough fusion proteins to yield detectable signal after 
washing. At 20−30% and higher, the HRP signal from the PcTF and Pc2TF wells 
increased with H3K27me3 concentration. 
A Hill slope of 2.75 from the nonlinear regression (R2 = 0.90) for Pc2TF (Figure 
3.4B) indicates that binding scales nonlinearly with the concentration of its ligand. It is 
difficult to fit a Hill curve to the data for PcTF (R2 = 0.64) because the increase in HRP 
signal is interrupted by a plateau at 30−80% H3K27me3. The cause of the plateau is 
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unclear; however it is possible that the increase observed above 80% is due to the binding 
avidity between PcTF and H3K27me3 being exceeded at these concentrations. Overall, 
we can conclude from the ELISA data that Pc2TF binding is cooperative. 
To investigate ligand selectivity, 50 nM purified PcTF, Pc2TF, or PcΔTF was 
tested for interaction with histone peptides that were trimethylated at different lysine 
residues. PcTF and Pc2TF showed significant binding with H3K27me3 peptides 
compared to the control protein PcΔTF (Figure 3.4C). HRP signal from the H3K27me3 
wells was significantly higher than what appears to be nonspecific binding with 
unmodified H3. This was not the case for off-target ligands H3K4me3 and H3K9me3, 
suggesting that the Pc-fusions can discriminate between the different methyl marks. No 
significant increase in HRP signal in the off-target wells was observed for Pc2TF, 
suggesting that target preference was not lost as avidity was enhanced. One might expect 
cross-reactivity with H3K9me3 since this PTM appears within a similar motif (ARKS) as 
H3K27me3 (13, 37). Others have reported that in vitro, chromodomain peptides from 
different orthologues (CBX1−8) have varying preferences for the two histone 
modifications (12, 37-38) CBX8, the PCD used for PcTF in our work, has shown weak 
affinity for H3K27me3 and none for H3K9me3 (12, 37), which is consistent with our 
results. 
The results from the assays with purified proteins led us to ask; what is the 
biological consequence of increased binding in living cells where the physical 
distribution of H3K27me3 is much different? In the cellular chromatin environment, 
H3K27me3 can occur in cis on the radial surface of a single nucleosome (Figure 3.1B), in 
trans where DNA bending brings the H3 tails of neighboring nucleosomes close together, 
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or sparsely distributed across many nucleosomes. Furthermore, H3K27me3 marks in 
living cells are dynamic. The enzyme EZH1/2 adds methyl groups to H3K27, and the 
enzymes KDM6A (UTX) and KDM6B (JMJD3) removes these marks (39). We set out to 
compare Pc2TF to PcTF in a cellular milieu. 
 
Figure 3.4 Bivalent Pc2TF shows cooperative and on-target binding with H3K27me3 
ligands. (A) The scatter plot shows mean HRP signal at an absorbance of 450 nm (one 
ELISA trial, means of four technical replicate wells, error bars = SDM) from wells in 
which 0.1 μM purified protein (Pc2TF, PcTF, or PcΔTF) was allowed to bind with 
different proportions of H3K27me3 biotinylated peptides (0–100%) mixed with 
unmodified H3 and tethered to neutravidin-coated surfaces. (B) Hill curves were fit to 
data for three ELISA trials (dots = technical replicate wells from all trials). (C) ELISA 
was used to detect interaction of 0.05 μM purified proteins with immobilized histone H3 
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peptides that were trimethylated at lysine 27, 4, or 9 or unmodified. The bar chart shows 
mean signal values from anti-mCherry-HRP at an absorbance of 450 nm (4 technical 
replicates, bars = SDM). 
Bivalent Pc2TF Activates a Target Gene in a Partially Silenced State 
 Previously, we demonstrated that PcTF activated a reporter gene near ectopic 
H3K27me3 in HEK293 cells (10). Here, we determined the biological significance of 
PCD bivalency by comparing the gene-regulation activities of Pc2TF and PcTF at the 
same reporter. Doxycycline (dox)-mediated induction of Gal4-EED in HEK293 Gal4-
EED/ luc cells leads to accumulation of H3K27me3 at and silencing of a chromosomally 
integrated Tk-luciferase transgene (Figure 3.5A) (40-41) Tk-luciferase repression reaches 
steady state at 96 h (40), and repression is maintained by epigenetic inheritance after loss 
of Gal4-EED (41). 
We transfected dox-treated cells (96 h) with the PcΔTF negative control, PcTF, or 
Pc2TF cloned into a mammalian expression vector (Figure 3.5B). Fluorescence 
microscopy and Western blots confirmed nuclear localization and expression of full 
length proteins. Using reverse transcription followed by quantitative PCR (RT-qPCR), 
we detected higher luciferase transcript levels in Pc2TF and PcTF-expressing cells 
compared to PcΔTF (Figure 3.5C). These results indicate that bivalent Pc2TF is a stronger 
activator than PcTF. Luciferase (luc) activity levels detected by an enzymatic assay 
(Figure 3.5D) and normalized to RFP signal-to-noise ratios from flow cytometry 
corroborated the RT-qPCR results; Pc2TF stimulated greater luc expression than PcTF. 
We did not detect significantly higher luc activity for PcTF-expressing cells versus the 
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negative control in this trial (Figure 3.5D), but did so in additional experiments (Figure 
3.5E). 
Expression of fusion regulators in cells that were treated with dox for 0, 48, and 
96 h showed that Pc2TF had roughly twice the activity as PcTF (96 h) and that Pc2TF 
activated Tk-luciferase without prior dox-induced silencing (Figure 3.5E). The latter 
result can be explained by an intermediate, partially silenced level of Tk-luciferase 
expression (40) compared to fully active Tk-luciferase in a “Luc14” parental cell line that 
lacks the Gal4-EED gene, as previously observed (40). H3K27me3 was detected via 
chromatin immunoprecipitation (ChIP) coupled with qPCR (ChIP-qPCR) near the 
luciferase promoter (Tk) in uninduced Gal4-EED/luc cells at significantly higher levels 
than in Luc14 cells. Dox treatment resulted in a further decrease in Tk-luciferase 
expression and a significant increase in H3K27me3 accumulation. In the experiments 
reported here, basal Tk-luciferase expression (Figure 3.5A) agrees with independent 
experiments from our prior study (0.02−0.07 luciferase activity per cell, au) (40). The 
uninduced state may have low levels of H3K27me3 at nucleosomes near the reporter 
gene in all cells or high levels of H3K27me3 at the reporter gene in a small proportion of 
cells in the population. In contrast to Pc2TF, monovalent PcTF only activated Tk-
luciferase after silenced chromatin had been induced for 96 h. These results suggest that 
Pc2TF is more tolerant of low levels of H3K27me3 in cellular chromatin. 
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Figure 3.5 Pc2TF stimulates expression at a polycomb-silenced reporter gene. (A) An 
engineered HEK293 cell line, Gal4-EED/luc, was used for doxycycline-mediated control 
of H3K27me3 and PRC-mediated silencing at a Tk-luciferase reporter. Expression is 
partially silenced prior to dox treatment, as demonstrated previously (40) and becomes 
fully repressed at 96 h. (B) Fusion constructs were cloned into the MV10 vector at XbaI. 
Fluorescence microscopy confirmed nuclear localization of the fusion proteins in 
transfected cells. The same samples were used for Western blots to confirm cellular 
expression of full length proteins, RT-qPCR to measure mRNA levels (C), and flow 
cytometry to measure RFP signal (D). Changes in the expression states of Tk-luciferase 
in 96-h dox-treated cells were determined by RT-qPCR (C) and luc activity assays (D) 
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(circles = replicates, described in Methods). (E) Fusion proteins were expressed in cells 
treated with dox for 0, 48, or 96 h to determine the activity of the fusion activators at 
intermediate repressed states (bars = mean values for 3 luciferase assays from one 
transfected sample, each scaled to mean PcΔTF luc/cell; error bars = SDM). 
Conclusions 
 This report presents the first demonstration of modular, synthetic multivalency of 
a chromatin-derived histone-binding protein with gene-regulating activity. In our 
previous work, we have demonstrated the use of a monovalent synthetic effector to 
activate chromatin-silenced genes in live cells. Natural bivalent chromatin proteins that 
recognize two histone posttranslational modifications at once suggest a broader design 
space for synthetic chromatin effectors. Our application of bivalency to design a synthetic 
fusion protein produced two important advances for engineering synthetic chromatin 
effectors. First, we determined that synthetic linkers allow tethered histone PTM-binding 
peptides to function within the context of a fusion protein in vitro and in live cells. 
Second, we have established that doubling the valency with tandem PCDs strengthens 
avidity and increases gene regulation activity by at least 2-fold. 
Here, we demonstrated that different synthetic linkers allow tethered histone 
PTM-binding peptides to bind in vitro to varying degrees. We observed weaker binding 
for the longer flexible linker (80 amino acids) compared to the shorter linker in our 
ELISA experiment. This result is likely due to lower production of the long flexible 
linker variant in TXTL. Given that both variants showed binding above background, 
GGGGS repeat number may not significantly affect bivalent PCD engagement with 
H3K27me3 in vitro. For the rigid linker tethered PCDs, only the longer length (80 amino 
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acids) appeared to support binding. Assuming that this variant protein was properly 
folded, lack of binding over background for the shorter EAAAR-repeat variant could be 
caused by suboptimal rotation, that is, in trans instead of in cis, of the second PCD away 
from the 2-D binding surface in the ELISA well. This mechanism was demonstrated with 
mutated α-helical linkers in bivalent BPTF7 and with tandem zinc finger DNA binding 
domains (32). In the context of cellular chromatin where looping and folding occurs, 
H3K27me3 would not necessarily be constrained to one face of the Pc2TF protein. 
Valuable insights and perhaps greater Pc2TF performance might be acquired by exploring 
additional linker variants in cells as well as in vitro. Such work is beyond the scope of the 
studies reported here, which accomplished a major step by identifying a functional 
bivalent synthetic effector protein that specifically interacts with its target H3K27me3. 
We have established that tandem PCDs strengthen avidity for H3K27me3 in a 
cooperative manner in vitro and increase gene regulation activity in live cells by at least 
2-fold compared to a monovalent PCD. The wide distribution of multivalency within 
bromodomain family (6) and other effector proteins (7) suggests that multivalent 
engagement has an important, evolutionarily conserved biological role. Multivalency 
appears to largely be represented by cell-cycle and gene-activating effectors. Relatively 
few multivalent proteins that recognize silencing marks have been studied in biophysical 
detail. Examples include the chromodomains of the Arabidopsis protein CMT342 and the 
mammalian protein HP1β (43) as bivalent homodimers, these proteins show enhanced 
interaction with their respective ligands H3K9meK27me and H3K9me3. Pc2TF is novel 
in its composition of histone-binding motifs: adjacent, identical polycomb 
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chromodomains within a single peptide. Therefore, its activity in vitro and in cells 
provides new insights into the recognition of histone marks by effector proteins. 
In the context of cellular chromatin, Pc2TF appears to be active at the target gene 
prior to full repression (Figure 3.5E, 0 h dox), whereas detectable activity of monovalent 
PcTF required a prolonged period of induced repression at the target (Figure 3.5E, 96 h 
dox). Our previous ChIP mapping data (40) confirm that compared to the fully active and 
fully silenced states, intermediate levels of H3K27me3 appear at Tk-luciferase (on 
average) without the addition of doxycycline. It is likely that in the pretreated state, leaky 
Gal4-EED expression causes a few cells in the population have one or two H3K27me3 
marks at a nucleosome near the Tk promoter. Stronger avidity, supported by the 
additional PCD module, may increase the likelihood of an activation event at the target in 
this small population of cells. This idea is consistent with the behavior of synthetic zinc 
finger-based DNA-binding regulators, where stronger affinity of the regulator for its 
DNA target is associated with stronger gene activation (44). Similar behavior can also be 
observed for multivalent receptor-binding peptides, which bind with high avidity and 
specificity to a small number of receptor-positive cells (45). 
Further engineering efforts to achieve greater nonlinear enhancement of 
PcTF/Pc2TF may require changes within the PCD binding motif. The hydrophobic 
interaction between the methylammonium cage and the methyl-lysine moiety (Figure 
3.1A) depends upon proper positioning of PCD residues that appear discontinuously in 
the primary sequence; this positioning requires specific intramolecular contacts of peptide 
residues within the PCD fold. Reverse engineering and de novo design of a new binding 
pocket through randomization of sequences would likely yield many nonfunctional 
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proteins. K27-adjacent interactions that contribute to interactions with the histone tail 
(13) could be leveraged to enhance affinity. However, increasing the stability by 
introducing additional hydrogen bonding could overwhelm the hydrophobic, K27me3-
specific interaction and allow PCD to recognize unmodified tails or off target 
modifications. Trade-offs between affinity and specificity pose formidable challenges to 
enhancing PCD affinity. Therefore, the most practical strategy for identifying alternative 
PCDs is to leverage H3K27me3-specific orthologues and paralogues from various 
species (46). It will be important to determine cross-reactivity with different histone 
modifications since certain CBX PCD peptides have been shown to bind H3K9me3 (12). 
Multivalent engagement of combinatorial histone marks has recently become a 
key line of evidence to support the controversial histone code hypothesis. Rationally 
designed synthetic multivalency will advance this important area of research by exploring 
functions beyond the limits of preexisting natural multivalent proteins. Furthermore, 
engineered chromatin effectors provide a practical tool to support artificial regulation of 
gene expression states through direct engagement with highly conserved components of 
chromatin, that is, histone tails and their modifications. Therapeutic synthetic gene 
regulators that leverage this mechanism could help circumvent the shortcomings of 
epigenetic inhibitors, which target chromatin enzymes that can gain drug-resistant 
mutations (47-48). In conclusion, our findings demonstrate that synthetic biology is a 
powerful tool for fundamental investigations of chromatin biology and epigenetic 
engineering. 
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Methods 
 Plasmid Constructs for TXTL and Bacterial Expression. Constructs (Figure 3.2A, 
Figure 3.3A) were assembled as BioBrick compatible fragments in vector V0120 (49). 
Fragments were PCR amplified with Phusion polymerase using primers 1−6 (Table 3.S1) 
and a protocol adapted from New England Biolabs Phusion High Fidelity DNA 
Polymerase (98 °C 0:45, [98 °C 0:10, 67 °C 0:20, 72 °C 0:45] × 25, final extension of 
5:00), column purified (Qiagen PCR Cleanup Kit), and double-digested with BamHI and 
XhoI (New England BioLabs). BamHI/XhoIdigested inserts and 50−75 ng of 
BamHI/XhoI linearized pET28(+) vector were ligated at a 3:1 molar ratio in a 20 μL 
reaction as described in the New England BioLabs (NEB) protocol for T4 ligase 
(M0202). Five microliters of each ligation was incubated with 50 μL of Turbo competent 
DH5- alpha E. coli (NEB) on ice for 5 min, transferred to 42 °C for 45 s, then to ice for 5 
min, and allowed to recover in 350 μL of SOC medium at 37 °C with shaking for 30 min. 
Pelleted cells were resuspended in 50 μL of SOC, plated on LB agar (50 ug/ mL 
kanamycin), and grown at 37 °C overnight. Colony PCR was performed to identify 
positive ligation results using primers 6 and 7 (Table 3.S1) and the GoTaq Promega 
protocol. Plasmids were cloned, extracted (Sigma GeneElute Plasmid Miniprep Kit), and 
Sanger sequenced for verification prior to protein expression in cell-free TXTL or in E. 
coli. Annotated sequences for all pET28 constructs are available online at Benchling-
Haynes lab: Synthetic Chromatin Actuators 2.0 (https:// 
benchling.com/hayneslab/f_/rmSYkAAU-synthetic-chromatinactuators- 2-0). 
 TXTL: Cell-free Expression. TXTL reactions were set up with the following 
conditions as previously described (35). 9 μL of lysate, 10 nM final template vector, 0.5 
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nM σ70-T7 RNA pol vector to a total of 12 μL. A Roche Lightcycler 480 was used to 
detect mCherry fluorescence with the following protocol: 29 °C for 10 min, bring to 30 
°C for 1 s, scan 533−610 nm, repeat 96 times (total 16 h). 
 E. coli Expression and Purification of Proteins. All selection media contained 50 
μg/mL kanamycin. PcΔTF, PcTF, and Pc2TF in pET28 were transformed into Rosetta 
2pLys DE3 cells and plated on LB agar and grown at 37 °C overnight. The next day, a 
single colony from each was used to inoculate 50 mL of LB and grown overnight at 37 
°C at 300 rpm. The next day, 1 L of LB in a baffled Erlenmeyer flask was inoculated to 
an OD600 of 0.1. The cultures were grown to an OD600 = 0.6, induced with IPTG (1 mM 
final concentration), and allowed to express PcΔTF and PcTF at 37 °C for 5 h with 
shaking (220 rpm). Pc2TF expression was carried out overnight at room temperature with 
shaking (220 rpm) to aid solubility of the protein. Cell disruption and protein purification 
are described in detail in Supporting Information and Methods. Purification of 
recombinant protein from E. coli is described in Supporting Information (Methods). 
 Enzyme-Linked Immunosorbent Assays (ELISAs). All steps were carried out at 
room temperature except specifically noted, and all incubations and washes were agitated 
at 800 rpm on an Eppendorf Thermomixer R. Clear bottom plates (Greiner bio-one 
#655101) were coated in 50 μL of 20 ng/ μL neutravidin in PBS pH 8.0 overnight at 4 
°C. The plates were washed the next day 3× with 200 μL of 0.2% PBS-Tween (PBST) 
with 5 min of shaking at 800 rpm between washes. The plate was blocked for 30 min at 
800 rpm at room temperature with 200 μL of 5% BSA in 0.2% PBST followed by 3× 
washes of 200 μL of 0.2% PBST for 5 min each at 800 rpm. Fifty microliters of 1 μM 
biotinylated peptides (Anaspec, H3 (21− 44), H3K4me3 (1−21), H3K9me3 (1−21), 
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H3K27me3 (21− 44), or H3K27Ac (21−43)) in 0.2% PBST) were incubated at room 
temperature for 1 h at 800 rpm, followed by 3× washes of 200 μL of 0.2% PBST for 5 
min at 800 rpm. The plate was blocked with 200 μL of 5% skim milk in 0.2% PBST 
(room temperature, 800 rpm, 30 min). TxTL, 1.5 μL (Figure 2), or 50 μL of 0.1 μM 
(Figure 3.3A) or 0.05 nM (Figure 3.3C) purified proteins in 50 μL of 5% skim milk in 
PBST were incubated in each well for 1 h (room temperature, 800 rpm). The wells were 
washed 3× with 200 μL of 5% skim milk in PBST with 5 min of 800 rpm shaking. After 
adding 100 μL of 1:3000 chicken polyclonal anti-mCherry (Novus Biologicals 
#NBP2−25158) in 5% nonfat milk in 0.2% PBST, wells were incubated for 1 h, followed 
by 3× of 200 μL of 5% skim milk in 0.2% PBST for 5 min each (room temperature, 800 
rpm). After addition of 100 μL of 1:3000 rabbit anti-chicken−HRP (RCYHRP Genetel 
0.5 mg/mL) in 5% skim milk in 0.2% PBST wells were incubated for 30 min (room 
temperature, 800 rpm). The plate was washed 5× with 200 μL of 0.2% PBST for 3 min 
each at 800 rpm. The plate was incubated with 100 μL of 1-step Ultra TMB-ELISA 
(Thermo-Fisher #34029) for 15 min while protected from light. Reactions were stopped 
with 100 μL of 2.0 M sulfuric acid, incubated for 2 min, and read at 450 nm. Each plate 
contained four technical replicates per H3K27me3 concentration per fusion protein. Two 
ELISA plates (trials) were run for each of two purified protein samples per construct. 
One trial failed to show significant signal over background (for all recombinant proteins) 
and was omitted from the final analysis. In Figure 3.4 “anti-mCherry-HRP (A450)” = 
HRP signal − mean HRP signal for 0% H3K27me3. The Microsoft Excel Solver tool was 
used to fit the Hill equation, 1 / ((Kdapp/ [L])n + 1) to the data by minimizing the sum of 
the squared errors between the equation and data (varying Kdapp and n). R2 was calculated 
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as 1 − (SSreg/SStot), where total sum of squares SStot = Σi(yi − y̅)2 and regression sum of 
squares SSreg = Σi(fi − y̅)2. 
Peptide Microspot Arrays. APTES functionalized glass slides were coated with 
200 μL of 1:1 (v/v) 40 mg/mL BS3 cross-linking solution and 1 mg/mL neutravidin with 
a cover slide (Thermo Scientific, #651-2-5251) and incubated overnight at 4 °C. The next 
day, the cover slide was removed, and the slide was rinsed 3× with 0.2% PBST for 5 min 
each. Slides were deactivated by incubation with Na2CO3/NaHCO3 buffer, pH 9.4, for 30 
min. The slides were quickly rinsed with ddH2O and centrifuged to dry at 1200 rpm for 2 
min. Slides were printed with biotinylated peptides (Anaspec) at concentrations of 10, 20, 
or 50 μM in 20% glycerol and PBS with a pin-printer (spot to spot distance = 600 μm) 
and incubated at room temperature for 1 h. The slide was rinsed with ddH2O as described 
above and blocked with superblock for 1 h at room temperature. Proteins were diluted in 
superblock and incubated on the slide for 1 h at room temperature. The slides were rinsed 
with 0.2% PBST for 3 min each followed by quick rinsing with ddH2O 3× and 
centrifuged dry (as described). Red fluorescent protein (mCherry) signal was detected at 
50% gain and 50% intensity on a PowerScanner at 635 and 535 nm, 10 μm resolution. 
Slides were also scanned at 75%−75% and 100%− 100% to obtain a suitable signal-to-
noise ratio. Arraypro software was used to quantify the median intensity values for each 
spot and background levels. Graphpad Prism software was used to fit the binding 
saturation nonlinear regression equation y = (Bmax* X) / (Kdapp + X) to the data, where 
Bmax is the highest binding value, and X is the concentration of protein. 
Plasmid Constructs for Mammalian Expression. MV10 was constructed from 
pcDNA3.1(+) (Invitrogen) with the following modifications. The CMV promoter was 
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removed via SpeI digestion and T4 ligase recircularization. A dsDNA fragment that 
encodes Kozak (ribosome binding site), XbaI, a nuclear localization sequence, 6x 
histidine, and a stop codon (5’ 
cccgccgccaccatggagtctagacccaagaaaaagcgcaaggtacaccatcaccaccatcacgcgtaaagctgag) with 
SpeI overhangs at both ends (ctag/t) was inserted at XbaI. CMV (SpeI/XbaI fragment) 
was reintroduced upstream of Kozak at SpeI. Proper orientation of inserts was confirmed 
by Sanger sequencing. Constructs PcTF and Pc2TF (Fig. 3.5B) were PCR-amplified 
(Phusion) with primers 9 and 10 (Table 3.S1), double-digested with XbaI and SpeI, and 
column-purified (Qiagen PCR Purification,  28104). Construct PcΔTF (Fig. 3.5B) was 
double-digested with XbaI and SpeI (Thermo Fisher FastDigest) and isolated by 
electrophoresis and gel purification. XbaI/SpeI fragments and 25 ng XbaI-linearized, 
dephosphorylated MV10 vector were ligated at a 2:1 molar ratio in a 10 μL reaction as 
described in the Roche protocol for Rapid DNA Ligation (11635379001 Roche), using 
1.0 μL NEB T4 ligase instead of the supplied enzyme. All 10 μL of each ligation  was 
incubated with 50 μL Turbo competent DH5-alpha E. coli  (New England Biolabs) on ice 
for 5 min, transferred to 45℃ for 45 seconds, then to ice for 5 min. Cells were plated 
directly on pre-warmed LB agar (100 ug/mL ampicillin) without recovery and grown at 
37℃ overnight. Plasmid DNA was prepared (Sigma GeneElute Plasmid Miniprep Kit) 
from 5 mL cultures inoculated with single colonies. Forward orientation of the inserts 
was determined by XbaI and PstI double-digestion of prepped plasmids and Sanger 
sequencing. Annotated sequences for all MV10 constructs are available online at 
Benchling-Hayneslab: Synthetic Chromatin Actuators 2.0 
(https://benchling.com/hayneslab/f_/rmSYkAAU-synthetic-chromatin-actuators-2-0).   
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Cell Culture and Transfection. HEK293 Gal4-EED/luc cells were grown in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% tetracycline-free 
fetal bovine serum and 1% penicillin and streptomycin at 37°C in a humidified CO2 
incubator. Silencing of the reporter gene (Tk-luciferase) was induced by supplementing 
the media with 1 μg/mL of dox for 48 or 96 hours. For wash-out of doxycycline (to allow 
depletion of Gal4-EED), growth medium was removed and replaced with dox-minus 
medium supplemented with 0.5 μg/mL puromycin to select for the transgenic anti-Gal4-
EED shRNA (41), and grown for 5 days. Prior to transfection, dox treated or untreated 
cells were plated in 12-well culture dishes at 40% confluency (~1.0E5 cells per well) in 2 
mL pen/strep-free growth medium. Transient transfections were carried out by adding 
100 μL of DNA/Lipofectamine complexes to each well: 1 μg pDNA or ddH2O for mock 
transfections (10 μL), 3 μL Lipofectamine LTX (Invitrogen), 87 μL Opti-MEM. 48 hours 
after transfection, cellular mCherry (580/610 excitation/emission) was imaged in culture 
dishes on a Nikon Eclipse Ti wide field inverted fluorescent microscope (MEA53100) at 
200x magnification (eyepiece = 10x; objective = CFI S Plan Fluor ELWD 20x, numerical 
aperture = 0.45), 25°C, without oil immersion, and with either phase contrast or an 
mCherry filter set (TE2000 cube, excitation FF01-562/40-25, emission FF01-641/75-25). 
Images from each channel were acquired with a digital monochrome camera (Coolsnap 
ES2 12 bit, 20 MHz) and overlaid using NIS-Elements software. For downstream assays 
(RT-qPCR, Western blots, and flow cytometry), the growth medium was removed, semi-
adherent cells were gently collected with 1x PBS washes, pelleted (200 g, room 
temperature, 5 min) and resuspended in 1x PBS. Six replicate samples (wells) were 
pooled for assays in Figure 3.5B, C, and D. 
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RT-qPCR. Preparation of total RNA, cDNA synthesis, and qPCR were performed as 
previously described (11) using ~1.0E6 HEK293 Gal4-EED/luc cells that were pelleted 
(500 g, room temperature, 5 min) and lysed with 500 μL TRIzol (Thermo Fisher 
#15596026). DNA/LNA oligos for qPCR were: mCherry - forward 5’-
cctgaagggcgagatcaag, reverse 5’-ttgacctcagcgtcgtagtg, LNA probe #41 (Millipore Sigma 
#04688007001); luciferase - forward 5’-caggtcttcccgacgatg, reverse 5’-
gtctttccgtgctccaaaac, LNA probe #70 (Millipore Sigma #04688937001); GAPDH 
(reference) - Roche human G6PD assay (Millipore Sigma #5046246001). Mean Crossing 
point (Cp), the first peak of d2y/dx2 (fluorescence over cycle number), was calculated by 
the Roche LightCycler 480 software for three replicate wells per unique reaction. For 
each biological replicate (one transfection per fusion protein) two replicate cDNA 
synthesis reactions (from one RNA prep) were completed. Expression level was 
calculated as delta Cp = 2[Cpreference – Cp]. “mRNA level log2(FC)” = delta Cp transfected 
cells / delta Cp mock. 
Western blots. Total protein was prepared from roughly 250,000 cells. Sample 
preparation, polyacrylamide gel electrophoresis (PAGE), and membrane blotting are 
described in detail in Supporting Information. Immunostaining was carried out with the 
following: blocking buffer - 5% nonfat dry milk in 1x PBST (1x PBS, 0.1% Tween-20); 
primary 1 - chicken polyclonal anti-mCherry, 1:2000 (Novus Biologicals #NBP2-25158); 
secondary 1 - HRP-conjugated rabbit anti-chicken, 1:2000 (Millipore Sigma #AP162P); 
primary 2 - anti-histone H3, 1:1000 (Abcam #ab1791); secondary 2 - HRP-conjugated 
goat anti-rabbit, 1:2000 (Cell Signalling Technology  #7074). Immunostaining was 
performed at 4°C overnight (primary) or at room temperature for 1 hour (secondary) with 
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nutation in a Parafilm pouch (50). Immunostained blots were washed 4x 10 min in 1x 
PBST, with orbital shaking at room temperature. HRP signal was detected using the 
SuperSignal West Femto substrate kit (Thermo Fisher #34095) and a PXi4 imager 
(Syngene) with GeneSys software. 
Imaging and flow cytometry. Cells were passed through a 35 μm nylon strainer 
(EMS #64750-25). Red fluorescent signal from mCherry was detected on a BD Accuri 
C6 flow cytometer (675 nm LP filter) using CFlow Plus software. Data were further 
analyzed using FlowJo 10.0. One run (~10,000 live cells, gated by forward and side 
scatter) was completed per sample. “RFP median signal/noise (S/N)” = median RFP 
signal from live RFP-positive cells / median RFP noise from live untransfected cells. 
Luciferase Assays. Cell counts (per 100 μL) were determined by flow cytometry 
(BD Accuri C6). 100 μL of cells or 1x PBS (blank) were incubated with 100 μL of 
complete luciferase assay reagent as described in the protocol for the Biotium Firefly 
Luciferase Assay Kit (89138-960) and in previous work (40) in Corning and Costar 96-
well Cell Culture Plates, opaque, white (Corning 3789A). Chemiluminescence was 
detected using a Synergy H1 Multi-Mode Reader (Biotek). Replicates included three 
samples (100 μL each) taken from a single population of transfected cells.  “Luc x cell-
1(a.u.)” = [Sample Luciferase signal] − 1x PBS blank signal / [cell count × (100 μL/20 
μL)]. For fusion protein-expressing cells, normalization was performed by dividing Luc x 
cell-1 by the RFP median signal/noise value (from flow cytometry). 
Associated Content 
Table 3.S1 DNA templates and primers used in experiments 
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Template(s) Primer Name  Primer Sequence (5’-...)  
PcTF_V0120  1. PcTF.pET28.For.2  atgtcaGGATCCATGGAG
CTTTCAGCGGTG  
PcTF_V0120  2. PcTF.pET28.Rev  GCGCTTTTTCTTGGGCT
CGAGCAACATGTCCAA
GTCG  
PcTF_pET28  3. mcVP64.For  aatgcctGGATCCATGGTG
AGCAAGGGCGAGGA  
PcTF_pET28  4. mcVP64.Rev  ATCTCAGTGGTGGTGG
TGG  
Pc2TF_V0120  5. DD.pET28.For  cataacaGGATCCGCGGCC
GCATCTAGAATG  
Pc2TF_V0120  6. DD.pET28.Rev  acttgggCTCGAGGCGGCC
GCTACTAGT  
pET28  7. T7.For  TAATACGACTCACTAT
AGGGGAATTG  
pET28  8. T7.Rev  GCTAGTTATTGCTCAG
CGG  
PcTF_V0120, 
Pc2TF_V0120  
9. Biobrick For  TCACTGACTGACTGAC
TGCGTCTCAA  
PcTF_V0120, 
Pc2TF_V0120  
10. Biobrick Rev  TTCCAGTCAGTCAGTC
AGTCGTCTCTTG  
Primers 1-6 were used for addition of restriction sites to pre-assembled constructs via 
Phusion PCR to build the bacterial/TXTL expression plasmids. Primers 7 and 8 were 
used for verification by Sanger sequencing. Primers 9 and 10 were used to amplify inserts 
for the MV10 vector. Non-binding overhangs are shown in lowercase. Restriction site 
nucleotides are underlined. 
 
113 
 
 
Figure 3.S1 Predicted fluorescence after Pc-fusion binding and subsequent washing. A 
mathematical model was used to predict mCherry (RFP) signal (fluorophore 
concentration) when all H3K27me3 targets were saturated by PCD binding (t = 0 sec) 
and over time during washing with buffer. A mechanistic model of washing of the spot 
assays was created using differential equations and solved using Matlab. Initial 
conditions were written to describe the initial amount of bound PcTF (1 x 10-6 M) and 
bound Pc2TF (0.5 x 10-6 M) to simulate saturated ligands – each Pc2TF is bound to two 
ligands, thus half as many Pc2TF molecules would saturate the surface. In one simulation, 
for washing a spot array with PcTF, an equation was written to describe PcTF association 
and dissociation with a single ligand as: dPb/dt = ka * Pu * Lu – kd * Pb. ka is the 
association rate constant, kd is the dissociation rate constant, Pu is the concentration of 
unbound PcTF or Pc2TF, Lu is the concentration of unbound ligand, and Pb is the 
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complex of PcTF bound to ligand. Algebraic equations also track unbound PcTF (Pu = 
Ptotal – Pb) and unbound ligand (Lu = Ltotal – Pb). In the other simulation, for washing a 
spot array with Pc2TF, two equations were written. The first equation describes Pc2TF 
association with a ligand to form a complex bound by one PCD to one ligand (Pb1) 
which can be lost either by dissociation or association of a second PCD or can be 
regained by one of the two PCDs of a Pb2 dissociating: dPb1/dt = ka * Pu * Lu – kd * 
Pb1 – ka * Vr * Pb1 * Lu + kd * Pb2. These parameters are the same as above but also 
include Vr which is the ratio of overall concentration to effective local concentration (see 
Shewmake et al. 2008) and Pb2 which is a Pc2TF bound to two ligands via a PCD for 
each ligand. The second equation describes the second PCD of Pb1 binding to a ligand 
and dissociation of one PCD from a ligand: dPb2/dt = ka * Vr * Pb1 * Lu – kd * Pb2. 
Algebraic equations also track unbound Pc2TF (Pu = Ptotal – (Pb1 + Pb2)) and unbound 
ligand (Lu = Ltotal – 1* Pb1 – 2* Pb2). Parameters were set to: ka = 2000 M-1 s-1, kd = 
0.01 s-1, Ptotal = initial value of Pb (PcTF) or Pb2 (Pc2TF), Ltotal = 1 x 10-6 M, Vr = 
100. Simulations can be run using most ordinary differential equation (ODE) solvers, but 
we used ode15s with absolute tolerance of 1e-9 and relative tolerance of 1e-6. Pb vs. time 
is plotted for PcTF. (Pb1 + Pb2), Pb1, and Pb2 are plotted vs. time for Pc2TF. Matlab 
codes and equations used to generate these simulations can be found online: 
https://github.com/khaynes5/PcTF_kinetics 
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Figure 3.S2 Additional peptide array binding data. Dot plots show representative results 
from microspot assay trials where varying concentrations of soluble fusion proteins were 
applied to 10, 20, or 20 µM of H3K27me3 (dots = means of 2 replicate spots, error bars = 
SDM). Apparent dissociation constant (Kdapp) values were determined by lines of best fit 
(dashed red line). The table shows calculated Kdapp values, error (SDM), and R2 values 
for all experimental replicates (n/s = no signal, --- = no additional replicate). Bold text 
indicates Kdapp values from curves that are shown in the representative dot plots. 
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Purification of recombinant protein from E. coli. IPTG-induced cells were 
pelleted by centrifugation at 4,000 RCF for 10 min, resuspended in 30 mL of purification 
buffer (10% glycerol, 250 mM NaCl, 50 mM Na2PO4, pH 8.0), and frozen at -80°C 
overnight. Disruption of thawed cells (on ice) was performed by sonication with a 
QSONICA instrument (model Q500) at 50% power: (1 second on, 2 seconds off) x 6000 
cycles. After addition of imidazole (10 mM final concentration), insoluble material was 
pelleted at 16,000 RPM for 30 min at 4°C in a Beckman Coulter Avante J-E Rotor JA-17. 
Purification columns were prepared by washing 2.5 mL of Ni-NTA Agarose (Qiagen 
#30210) with 10 mL of ddH20 on a 50 mL polyprep column, then equilibrated with 15 
mL purification buffer plus 10 mM imidazole. Soluble fractions of cell lysates were 
loaded onto a plugged column, vortexed briefly to homogenize resin and supernatant, and 
incubated with rotation at 4°C for 2 h. The cap and bottom plug were removed to empty 
the unbound fraction, and flow-through was applied back to the column once. Protein-
bound resin was washed with 10 mL binding buffer plus 10 mM imidazole, followed by 5 
mL binding buffer plus 20 mM imidazole and 5 mL binding buffer plus 50 mM 
imidazole. Resin was incubated with 1 mL of binding buffer plus 250 mM imidazole for 
10 min in a plugged column before elution. Elution was repeated with binding buffer plus 
500 mM, and then binding buffer plus 1.0 M imidazole. Proteins were concentrated and 
buffer-exchanged into PBS using a 15 mL 30,000 kDa centrifugal filter and repeated 
washes of PBS followed by centrifugation at 4000 RCF for 10 min, and stored at 4°C in a 
final volume of about 1 mL. Concentration of protein was determined using a denaturing 
polyacrylamide gel with bovine serum albumin (BSA) standards.  
117 
 
Western blot detailed protocol. Roughly 250,000 cells were pelleted at 300 g for 5 
min, lysed by resuspension in 500 μL Mammalian Cell PE LB (G-Biosciences #786-180) 
plus 5 μL 100x ProteaseArrest (G-Biosciences #786-108), and vortexed for 2 min. 
Insoluble debris was pelleted at 16,000 xg, 4°C, 5 min and discarded. Samples for 
denaturing polyacrylamide gel electrophoresis (PAGE) were prepared by heating 15 μL 
lysate plus 4 μL NuPAGE LDS Sample Buffer 4x (Thermo Fisher #NP0007) and 1 μL 1 
M Dithiothreitol (DTT, Millipore Sigma #D0632-1G) at 100°C for 5 min. Samples 
(cooled to room temperature) and a pre-stained protein standard (10 μL, Thermo Fisher 
#10748010) were electrophoresed at 120 V in a 4-12% Bis-Tris gel (Thermo Fisher 
#NP0322BOX) with MOPS-SDS buffer [50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 
mM EDTA, pH 7.7] diluted 1:20 in an XCell SureLock vertical chamber (Invitrogen 
#EI0001). Proteins were transferred onto a nitrocellulose membrane (Bio-Rad #1704158) 
via semi-dry transfer in a Transblot Turbo system (Bio-Rad #1704150). Complete 
transfer was verified by staining the membrane with 1x Ponceau-S (G-Biosciences #786-
576). 
Abbreviations 
BPTF, bromodomain PHD finger transcription factor; ELISA, enzyme-linked 
immunosorbent assay; H3K27me3, histone H3 trimethylated at lysine 27; PCD, 
polycomb chromodomain motif; PCR, polymerase chain reaction; PcTF, monovalent 
polycomb-based transcription factor; Pc2TF, bivalent polycomb- based transcription 
factor; PRC, polycomb repressive complex; PTM, post-translational modification; RFP, 
red fluorescent protein; RT-qPCR, reverse transcription followed by quantitative 
polymerase chain reaction; TXTL, E. coli-based cell-free transcription-translation system 
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CHAPTER 4 
CELL-PENETRATING SYNTHETIC CHROMATIN PROTEINS REGULATE GENES 
IN HUMAN U-2 OS CELLS 
Abstract 
FDA-approved epigenetic drugs are low molecular weight compounds that 
indirectly correct gene expression in cancer cells by inhibiting enzymes that modify 
chromatin. The ease of screening libraries of compounds, high intrinsic membrane 
permeability, and low rates of degradation have made small molecule inhibitors effective 
in treating some epigenetic diseases. However, small molecule inhibitors often target 
cytosolic proteins, and do not directly target nucleosomes. Protein fusion-based 
epigenetic drugs could help mitigate this problem by allowing customizable treatments 
that target one specific histone mark with a tuned gene response, allowing for greater 
efficacy compared to small molecules. Unfortunately, transgene delivery can be generally 
cytotoxic and lead to DNA lesions with unpredictable effects. To address this issue, we 
fused the histone binding domain from CBX8, an mCherry fluorescent reporter, and the 
transcriptional activator VP64 (PcTF) to generate an epigenetic transcription factor 
capable of activating large sets genes independently of DNA sequence. Herein we report 
the delivery of recombinantly expressed and purified polycomb transcription factor 
regulator (PcTF) fused in frame with a nuclear localization signal (NLS) and a cell 
penetrating peptide tag (TAT). We optimized the delivery of purified, cell penetrating 
PcTF-NLS-TAT (CP-PcTF) in vitro with both 2D and 3D spheroids of U-2 OS bone 
cancer cells. We then performed RNAseq on cells treated with CP-PcTF to identify a 
panel of up and downregulated genes. In summary, we have demonstrated that an 
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epigenetic effector fused to a CPP can be delivered to U-2 OS cells and can influence 
gene expression through DNA independent interactions. 
Introduction 
Protein based therapeutics have become more popular since the introduction of 
recombinant insulin decades ago (1). However, a significant hurdle for precision, protein-
based medicine lies in the efficient delivery of treatments (2). While many small 
molecule drugs are able to easily pass through a membrane, many protein therapeutics are 
unable to be efficiently delivered (3). Protein therapeutics offer several advantages over 
small molecule drugs, such as high specificity, potency, and lower likelihood to induce 
immune responses (1, 4). In addition, delivering recombinantly purified proteins offer 
additional benefits over nucleic acid based deliveries such as transfection and viral 
transduction. First, producing protein recombinantly enables precise control of protein 
purity, post translational modifications, and quantity of delivered protein (1). 
Furthermore, recombinant protein delivery avoids nucleic acid induced cytotoxicity and 
off target effects from viral or DNA particles. Third, nucleic acid based delivery can be 
cytotoxic and induce recombination with the endogenous genome. Recombinant protein 
delivery avoids these caveats and has been shown to enhance target binding specificity 
(5). Recently, researchers have used a variety of techniques to deliver recombinant Cas9 
fusions (6-9). Successful delivery and gene editing in plants and animals has 
demonstrated the versatility and utility of recombinant protein delivery for gene therapy. 
Delivery of novel protein therapeutics could provide an alternative treatment for 
defective proteins over gene therapy (10). There is an expansive collection of techniques 
to deliver proteins to cells, ranging from codelivery with small molecules, peptides, 
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polymers, or lipids (reviewed in 1, 11). One technique uses cell penetrating peptides 
(CPPs) to induce endocytosis and deliver cargo through a co-incubation of cargo and 
CPP, or though covalent conjugation of cargo and CPP (12). Covalent fusions of CPPs 
and proteins have been successfully used to deliver enzymes to cells (13), expand stem 
cells (14), and inhibit cancer cell growth (15). For example, protein fusions with an HIV 
protein derived cell penetrating peptide TAT have been used to kill cancer cells and 
induce gene expression in embryonic stem cells (16-17). Understanding design rules to 
efficiently deliver protein-based drugs could lead to new insight in disease, and help lead 
to more precise treatments. 
Designer epigenome effectors can be used to silence genes with high specificity 
(18). However, the majority of epigenetic based drugs are small molecule based and can 
end up in off target locations (19). With the emergence of computational design and new 
high throughput assays, therapeutic protein engineering is becoming more attainable (20). 
Engineering chromatin is a growing field (21), with recent work producing assays for 
determining in vitro function of synthetic histone binding domains (22). However, less 
work has been done to investigate the in cell function of these proteins in 2D and 3D cell 
models. 
We have previously demonstrated the in vitro function of the recombinantly 
purified epigenetic effector PcTF, a fusion of an H3K27me3 binding domain CBX8, an 
mCherry domain fluorescent reporter, and a VP64 transcriptional activator (22). In 
addition, the function of a transiently transfected PcTF and a stably integrated PcTF has 
been characterized in 2D models with several cancer cell lines (23). These results provide 
great insight into the function of PcTF, but do not accurately recapitulate the impact of 
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PcTF on a 3D tumor environment or demonstrate function with a therapeutic protein 
delivery method. In order to elucidate the function of a recombinant PcTF delivered to a 
2D and 3D environment, PcTF would have to be delivered without nucleic acid delivery.  
We explored a variety of CPPs with varying properties to assess which peptide 
would deliver PcTF with minimal toxicity. First, we co-incubated a variety of cell 
penetrating peptides TAT (1), HA2 (24), E5 (25), and L17E (26) with purified PcTF in 
2D U-2 OS cells. We detected mCherry signal inside of U-2 OS cells co-incubated with 
TAT and the L17E peptide after 24 hours (Supplemental Figure 4.S1). In order to 
maximize protein delivery and reduce possible cytotoxicity of exogenous peptides, we 
fused our cell penetrating peptides in-frame with PcTF. We used this PcTF-NLS-TAT 
fusion (CP-PcTF) to investigate the delivery and function of a recombinant epigenetic 
effector on 2D and 3D U-2 OS osteosarcoma cells.  
Here, we demonstrate that CP-PcTF is delivered to cells in a time-dependent 
manner, and that CP-PcTF influence gene expression in 2D U-2 OS. In addition, we 
show that CP-PcTF slows growth in 3D spheroids of U-2 OS cells. Our results have 
important implications for delivering recombinant epigenetic effectors to cells in 2D and 
3D models. 
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Figure 4.1. Delivery and cellular transport of the fusion chromatin protein PcTF. E. Coli 
expressed and purified CP-PcTF is incubated with U-2 OS cells. CP-PcTF enters the cell 
through macropinocytosis, followed by endosomal escape into the cytoplasm. CP-PcTF is 
then imported into the nucleus where it activates H3K27me3-silenced genes. 
Design of a Cell Penetrating PcTF 
In order to determine the optimal delivery vehicle for PcTF, we assayed the 
ability of several CPPs to deliver PcTF to U-2 OS cells (Supplemental Figure 4.S1). We 
synthesized four distinct peptides with varying properties to maximize our likelihood of 
finding a robust delivery partner. First, we synthesised a TAT peptide, a peptide fragment 
from the human immunodeficiency virus 1 (HIV-1) that has robust cell penetrating ability 
(1). However, cargo being delivered by pinocytosis has been known to become stuck in 
endosomes, leading to loss of function (27). Therefore, we synthesized TAT fusion 
peptides such as TAT-HA2, which consists of the N terminal 20 amino acids of the 
influenza virus hemagglutinin protein fused to a TAT peptide. HA2 is hypothesized to 
help with endosomal escape, enabling delivery of functional protein (24). E5-TAT, an 
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enhanced HA2 with increased membrane disruption ability fused with TAT, was also 
synthesized (25). Finally, we synthesized an engineered membrane-lytic peptide L17E, 
which was previously shown to enable robust cellular delivery of protein cargo (26). 
To quickly and efficiently identify peptides that would allow PcTF delivery, we 
incubated each peptide with a high concentration of recombinant PcTF in 2D U-2 OS 
cells. We reasoned that the mCherry domain in PcTF would be a good fluorescent 
reporter for delivery. Each peptide was incubated with PcTF for 24 hours before washing 
and imaging with fluorescent microscopy. After 24 hours of incubation, the cells treated 
with PcTF and TAT or L17E peptides showed detectable mCherry signal inside the cells, 
while the TAT-HA2 and E5-TAT treated cells had no detectable signal (Supplemental 
Figure 4.S1). While the L17E cells showed more overall mCherry signal, we observed a 
localization of signal in the center of each cell with the TAT peptide (Supplemental 
Figure 4.S1). In an attempt to improve cellular delivery and signal for TAT and L17E, we 
constructed PcTF-CPP fusions for recombinant expression and purification. However, 
only the TAT fused PcTF was soluble in E coli. We call this PcTF-NLS-TAT fusion CP-
PcTF (Figure 4.1). CP-PcTF is hypothesized to enter the cell through macropinocytosis, 
where the positively charged TAT residues interact with the negatively charged cell 
membrane, inducing cell entry (Figure 4.1). Once in the cell, CP-PcTF escapes the 
endosome and is imported into the nucleus where it binds to H3K27me3 and upregulates 
proximal genes (Figure 4.1). 
The TAT peptide signal supports delivery of purified PcTF into U-2 OS cells in 2D 
and 3D cultures 
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To obtain purified, CP-PcTF in sufficient quantities for cell delivery, we 
cloned the open reading frame into an isopropyl β-D-1-thiogalactopyranoside (IPTG) 
inducible pET28 vector. We overexpressed CP-PcTF in E coli, with visible mCherry 
signal accumulating after three hours of induction. Cells were harvested, pelleted, and 
lysed before purifying CP-PcTF on a Nickel-NTA column. Purified proteins were 
concentrated into phosphate buffered saline (PBS) and quantified using BSA dilutions on 
a denaturing polyacrylamide gel to obtain delivery ready protein. 
To determine the optimal dose and incubation time for delivery of functional CP-
PcTF, we treated 2-D U-2 OS cells with soluble, purified CP-PcTF fusion proteins and 
observed accumulation of the RFP tag via microscopy and flow cytometry (Figure 4.2). 
Previous reports with TAT-protein fusions as a delivery vehicle used concentrations of 
protein ranging from 2 nM- 5 µM protein (14, 16-17, 28). We treated the cells with CP-
PcTF ranging from 100 nM to 1 uM for 24 hours. We saw an increase of mCherry 
positive cells (RFP+) cells as we increased the concentration of CP-PcTF (Figure 4.2A). 
At 100 nM CP-PcTF, we detected RFP in 85.6% of the live cells, followed by 97.8% for 
200 nM, 99.1% for 300 nM, 99.7% for 500 nM, and 100% for 1 µM. 
To optimize the incubation time of CP-PcTF, we performed a time course by 
varying U-2 OS incubation times with 200 nM CP-PcTF (Figure 4.2B). We observed the 
beginning of cell penetration after an hour of incubation with RFP signal surrounding the 
cell post wash. After 24 hours of incubation, we observed punctate RFP signal appearing 
in the center of the cell. This signal was still detectable 48 hours after washing out 
unpenetrated protein, indicating that CP-PcTF is able to endogenous survive protease 
activity for at least 72 hours (Figure 4.2B). To ensure localization of RFP signal 
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correlated to our expected nuclear target of H3K27me3, we treated U-2 OS cells with 
CP-PcTF (Figure 4.2C). We treated U-2 OS cells with CP-PcTF and PcTF for 24 hours, 
followed by 48 hours of growth. We stained the cells for nuclear signal (Hoescht) and 
imaged the cells using fluorescent microscopy (Figure 4.2C). We observed colocalization 
of RFP signal and Hoescht (nuclear stain) signal, indicating that CP-PcTF is being 
imported into the nucleus. 
 
Figure 4.2. Uptake of soluble CP-PcTF by 2D U-2 OS cells (A) Flow cytometry of 2D 
U-2 OS cells treated with varying concentrations of CP-PcTF for 24 hours. (B) CP-PcTF 
shows time dependent delivery into U-2 OS cells. Cells were treated with 200 nM of CP-
PcTF for 15 minutes, 1 hour, 5 hours, or 24 hours before washing 3 times with PBS and 
imaging with fluorescent microscopy. The 72-hour time point is from cells treated with 
CP-PcTF for 24 hours. (C) C-terminal TAT peptide supports dose-dependent 
accumulation of PcTF in 2-D cultured U-2 OS cells. 
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Genes become upregulated by CP-PcTF 
To determine if CP-PcTF induced a transcriptional response upon delivery, we 
treated 2D U-2 OS cells with CP-PcTF for 24 hours and harvested the genomic RNA for 
next generation RNA sequencing (RNAseq). We also treated U-2 OS cells with CP-
PcΔTF as a control.  
RNAseq revealed a set of genes significantly (p<0.05) upregulated compared to 
untreated cells. Compared to an untransfected control, we observed 103 and 82 
significantly upregulated (2 fold) genes in the CP-PcTF and the CP-Pc∆TF respectively. 
Of these genes, 69 of them were unique to CP-PcTF, while 48 were unique to CP-Pc∆TF. 
Many of these genes code for hypothetical proteins, are untranslated, or have unknown 
function. Regulation of these transcripts could be explained by H3K27me3-mediated 
silencing at these loci, but further investigation such as ChIP and qPCR is required to 
validate these targets. 
We removed genes that code for uncharacterized predicted proteins, or have no 
known function, resulting in 58 annotated genes for CP-PcTF and 38 for CP-PcΔTF. We 
compared the filtered lists to each other, resulting in 16 shared genes and 42 uniquely 
upregulated genes for CP-PcTF (Figure 4.3A). In order to compare the upregulated genes 
to previous work with PcTF, we mapped the fold change from the significantly 
upregulated CP-PcTF genes to the fold change of the same genes from the previous 
transgenic PcTF (TG-PcTF) work (23) (Figure 4.3B). Interestingly, only 12 of the genes 
uniquely upregulated by CP-PcTF were also upregulated by TG-PcTF at the same time 
point. These genes mainly fall into the chemokine category of genes and suggest that 
PcTF might induce transcription of immune response genes in U-2 OS cells. The large 
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difference in significantly upregulated genes between CP-PcTF and TG-PcTF could be 
do to differing time scales for PcTF effectiveness, or different modes of action due to 
delivery. Of the 16 genes commonly upregulated by both CP-PcTF and CP-PcΔTF, only 
two were shared with TG-PcTF, suggesting that these genes might be upregulated in 
response to protein delivery and not PcTF itself (Figure 4.3B). 
In order to investigate common gene functions between the genes upregulated by 
CP-PcTF, we performed an overrepresentation test using Protein ANalysis THrough 
Evolutionary Relationships (PANTHER) (29). This analysis can help reveal 
evolutionarily related proteins and families based on omics data. The output of the 
analysis produces three classes: molecular function, biological process, and pathway. Our 
data revealed significant enrichment (p <0.05, FDR < 0.05) of gene families for each 
analysis. There were four clusters for biological processes, three for molecular functions, 
and one for cellular components (Figure 4.3C). The number of upregulated genes 
involved in the immune response suggests that these genes might be epigenetically 
silenced by H3K27me3. 
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Figure 4.3. Regulation of genes by CP-PcTF. (A) The Venn diagram shows shared and 
distinct genes with significant upregulation (FC ≥ 2, p < 0.05) for cells treated with CP-
PcTF or the truncation control CP-PcΔTF. Out of 103 CP-PcTF upregulated genes, a set 
of genes (box) showed statistically significant gene ontology term enrichment (bar chart). 
(B) Heatmap of regulated genes. * = Cytokines, white boxes indicate a p value >0.05 or 
no signal. 
3D cells treated with CP-PcTF show delayed growth 
In order to investigate the ability of CP-PcTF to penetrate cells in a 3D tumor 
environment, we delivered protein to U-2 OS spheroids. We generated spheroids by 
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culturing cells in low attachment plates with constant rotation for several days. We 
treated the spheroids with CP-PcTF for 24 hours and used fluorescent microscopy and 
flow cytometry to visualize and quantify cell penetration (Figure 4.4A). We observed 
punctate RFP signal in the 3D spheroids (Figure 4.4A) similar to the 2D delivery (Figure 
4.4B). However, we were unable to image the center of the spheroid where CP-PcTF 
might be excluded. Therefore, we dissociated the tumoroids into a single cell suspension 
and determined the fraction of RFP positive (RFP+) cells using a flow cytometer (Figure 
4.4B). Compared to the 2D delivery assay, the 3D cells contained fewer RFP+ cells at the 
same concentrations. 100 nM CP-PcTF was only 8.2% RFP+, followed by 200 nM with 
20.6%, 300 nM with 21.2%, 500 nM with 30.1%, and 1 µM at 45.4% RFP+ (Figure 
4.4B). This lower efficiency suggests CP-PcTF is unable to penetrate all cells in 
spheroids.  
 
Figure 4.4. Incomplete uptake of CP-PcTF in U-2 OS spheroids. (A) Treatment with 200 
nM CP-PcTF shows cell penetration into spheroids (B) Flow cytometry analysis indicates 
an incomplete delivery of CP-PcTF to cells in spheroid. 
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To determine how CP-PcTF might affect the growth of tumor tissue, we treated 
U-2 OS spheroids with CP-PcTF and performed a time course monitoring spheroid 
growth. Since an immune response can be caused by cellular senescence, and CP-PcTF 
showed activation of immune response genes (30), we hypothesized that CP-PcTF might 
be able to influence the growth of the cells by inducing a senescence like state. This was 
previously demonstrated in a 2D environment with transgenic U-2 OS epressing PcTF 
(31). Therefore, we treated the tumoroids with protein for 24 hours followed by CP-PcTF 
washout and incubation in normal growth media. Each day, phase microscopy images 
were taken for spheroid size analysis. We measured cell size in Adobe Illustrator by 
measuring the diameter of spheroids (Figure 4.5A). 
We observed a significant difference in tumoroid size (p <0.001) by the fourth 
day between the CP-PcTF treated and untreated cells (Figure 4.5A). As a control, we also 
treated spheroids with CP-PcΔTF, but saw no significant reduction (p =0.33) in size 
between untreated and cpΔPcTF treated cells after 4 days (Figure 4.5A). As expected, we 
observed a loss of mCherry signal over time in the cells treated with protein as seen by 
RFP negative cells on the outside of spheroids (Figure 4.5B). These results suggest that 
CP-PcTF is able to induce senescence in a U2-OS cancer line. This is consistent with 
previous work that demonstrated PcTF induces a senescence like state in 2D U-2 OS 
models (31). 
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Figure 4.5. Comparisons of spheroid growth over time in CP-PcTF-treated samples 
versus controls. (A) Spheroid diameter (points) of 3D spheroid U-2 OS over time. Sizes 
measured in illustrator. (B) Representative images of U-2 OS tumoroid during each day 
of treatment. * denotes a p value <0.001. Significance was determined using a student's 
two tailed t test. 
 
Discussion 
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This work presents the first characterization of a synthetic, cell penetrating 
epigenetic effector. Our previous work demonstrated the in vitro function of an 
H3K27me3 binding activator fusion PcTF using inducible systems and transient 
expression. In this study, we fuse a cell penetrating peptide tag to PcTF to generate CP-
PcTF. We express and purify CP-PcTF, and characterize its effect on 2D and 3D cells. 
Here, we demonstrated that CP-PcTF is delivered to 2D U-2 OS cells in a time 
and concentration dependent manner. At just 200 nM CP-PcTF, we detected mCherry in 
over 95% of the cells after 24 hours of incubation, indicating that relatively low 
concentrations of TAT-fused epigenetic regulators can be robustly delivered to U-2 OS 
cells. However, 24 hours of incubation is not a likely possibility for protein based 
therapies, so future work optimizing minimal delivery time and possible microinjections 
into tumoroids should be explored. For example, fusing a receptor ligand to a protein has 
enabled cell specific delivery (32).  
Whole transcriptome analysis of CP-PcTF treated U-2 OS cells revealed a set of 
genes specifically upregulated compared to a nonbinding control (CP-PcΔTF) treated line. 
Very few of these genes matched the results of a transgenic PcTF expressing line (23), 
but the differences could be attributed to timing or differing modes of delivery. qPCR 
should be used to validate this set of genes. 
Additional protein incubation time points followed by RNAseq will help elucidate 
the function of CP-PcTF. This work used a 24 hour time point based on previous work 
(23), however, there might be a different result based on transient transfection versus 
transient protein delivery in terms of gene response.     
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In the context of a 3D tumor environment, CP-PcTF is inefficiently delivered. 
When treated with 1 uM CP-PcTF, RFP signal was detected in less than 50% of cells. 
This is consistent with previous reports that show better delivery efficiency in 2D 
monolayers compared to 3D cultures (33).  
Future work will confirm RNAseq and cell growth assay results. Quantitative 
PCR (qPCR) assaying genes identified from the RNAseq results will validate CP-PcTF-
dependent responses. WST1 and B-galactosidase assays will confirm CP-PcTF induced 
cellular senescence. To further improve function, engineering of the PcTF binding 
domain can lead to a more robust gene response. For example, a multivalent CP-Pc2TF 
might have enhanced function compared to CP-PcTF, as seen previously in transiently 
transfected cells (34).  
Protein therapeutics have become increasingly popular. The ability to robustly 
deliver proteins to cell targets will advance precision medicine and enable more advanced 
disease research. Understanding design rules for recombinant delivery of therapeutic 
synthetic gene regulators can help engineers design optimal fusions that overcome the 
problems associated with small molecule epigenetic inhibitors. In conclusion, this work 
demonstrates that the synthetic epigenetic effector PcTF can be delivered to 2D and 3D 
cells, and provides a possible solution for delivery of engineered chromatin proteins. 
Methods 
Peptide synthesis: 
The peptide sequences were synthesized on a resin using standard Fmoc 
chemistries. Analysis of the peptides by analytical HPLC and MALDI-TOF confirmed 
that the peptides had the correct expected masses. 
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Plasmid constructs: 
Plasmids were assembled by consecutive PCRs using pET28(PcΔTF) and 
pET28(PcTF) ((https:// benchling.com/hayneslab/f_/rmSYkAAU-synthetic-
chromatinactuators- 
2-0). A 3’ NLS was added to PcTF PCR using FP 5’ 
ATACAGGATCCATGGAGCTTTCAGCGG and RP 5’ 
ACAATAAAGCTTTCATACCTTGCGCTTTTTCTTGGG. A 3’ TAT was assembled 
onto PcTF-NLS by PCR using FP: 5’ ATCAGGATCCATGGAGCTTTCAGCGG and 
RP 5’ CGTTTTTTACGACCATATACCTTGCGCTTTTTC, followed by another PCR 
with the same forward primer and the RP 5’ 
ATGCTAAGCTTCTAACGACGACGCTGACGACGTTTTTTACGACCA.  PCR 
products were digested with BamHI and HindIII, followed by ligation into a pET28 
previously digested with BamHI and HindIII, followed by gel purification. cpPcΔTF was 
assembled by PCR amplifying CP-PcTF with 
5’GGTCGCGGATCCGTGAGCAAGGGCGAGGAG and 3’ 
ATGCTAAGCTTCTAACGACGACGCTGACGACGTTTTTTACGACCA and cloning 
into pET28 as described above. 
Expression and purification of recombinant proteins: 
Proteins were expressed, purified, and quantified as described in Tekel et al 2018 
(34). 
Cell culture:  
U-2 OS cells (ATCC HTB-96) were maintained in McCoy's 5A (Modified) 
Medium supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin-
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streptomycin (all from ThermoFisher). Cells were maintained in a 37°C incubator with 
5% CO2 and passaged once ~80% confluent. 3-D spheroids were generated by seeding 
2.0 E6 cells per well of a 6-well cell repellent plate (VWR) in a final volume of 4 mL 
complete media and placed on an orbital shaker at 95 RPM for 24 hours. Half media 
change was performed every 24 hours. Spheroids were cultured for a minimum of 48 
hours before treatment. BJ fibroblasts (ATCC CRL-2522) were maintained in Dulbecco’s 
modified eagle medium supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% 
(v/v) penicillin-streptomycin (ThermoFisher). Cells were maintained in a 37°C incubator 
with 5% CO2 and passaged once ~80% confluent. 
Microscopy and flow cytometry: 
Fluorescent images of each well at 10x and 20x were obtained using an EVOS 
Cell Imaging System using the RFP channel (ex/em: 470/510 nm) at 500 ms exposure 
time. Flow cytometry was performed to determine protein uptake. Briefly, cells were 
dissociated using Accutase (ThermoFisher), resuspended in PBS, and analyzed using a 
BD Accuri C6 cytometer (BD Biosciences). RFP-positive cells were measured using the 
FL-3 (ex/em: 488/670 nm) channel and gated based on negative control. Data was 
analyzed using Flowjo.  
3D cell growth analysis: 
5 unique 10x phase contrast images were taken for each condition on each day 
using an EVOS. Cell diameter was measured in Adobe Illustrator for 100 
cells/image/day.  
RNA-seq: 
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RNAseq was performed by the Bioinformatics core at ASU. Using KAPA’s Ribo-
Zero RNA HyperPrep Kit with RiboErase (HMR) (Roche #KK8560), total RNA was ribo 
depleted, sheared to roughly 250 bp, and then converted to cDNA. Illumina-compatible 
adapters with unique indexes (IDT #00989130v2) was then ligated onto each sample 
individually.  The adapter ligated molecules were then cleaned using AMPure beads 
(Agencourt Bioscience/Beckman Coulter, A63883), and amplified with Kapa’s HIFI 
enzyme (KK2502). Each library was then analyzed for fragment size on an Agilent 
Tapestation, and quantified by qPCR (KAPA KK4835) on Thermo Fisher Scientific’s 
Quantstudio 5 before multiplex pooling and sequencing on a 1x75 flow cell on the 
NextSeq500 platform (Illumina) at the ASU Genomics Core facility. 
RNAseq data analysis: 
Genes fitting both p <0.05 and log2 fold change >2 from CP-PcTF vs untreated 
and CP-PcΔTF vs untreated were identified by cross referencing gene symbols with the 
NCBI database. Genes with no known function were removed. Venn diagrams were 
generated between CP-PcTF and CP-PcΔTF with Venny 2.1 
(http://bioinfogp.cnb.csic.es/tools/venny/) (35). GOterm analysis was performed by 
analyzing the genes regulated specifically by CP-PcTF using the following parameters: 
Analysis Type: PANTHER Statistical Overrepresentation Test (Released 20181113) 
Annotation Version and Release Date: PANTHER version 14.0 Released 2018-12-03. 
Analyzed List: Client Text Box Input (Homo sapiens) Reference List: Homo sapiens (all 
genes in database). 
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Supplemental Figure 4.S1. Comparisons of cell penetrating peptides co-incubated with 
PcTF. (A) 1. 2D U-2 OS cells are co-incubated with PcTF and cell penetrating peptides 
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(CPP), followed by 2. 24-hour incubation. 3. Imaging using fluorescent microscopy. (B) 
Control wells of cells only and PcTF with no CPP show no detectable mCherry signal. 
(C) Cells treated with PcTF and CPPs show varying levels of cell penetration. 
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CHAPTER 5 
A NEXTGEN HISTONE POSTTRANSLATION MODIFICATION BINDING ASSAY, 
CONCLUSIONS, AND FUTURE WORK 
Nextgen PTM Binding Analysis: Peptide Arrays 
 Classic in vitro characterization of histone binding domains (HBDs) generally 
includes protein purification followed by radioactive labeling, low dynamic range dot 
blots, fluorescent polarization, isothermal calorimetry, or other in vitro methods (1-3). 
Our previous work has described the development and validation of an assay to detect 
histone posttranslational modification (PTM) binding at a small scale (a few binding 
variants and a few target peptides) using an enzyme linked immunosorbent-based assay 
(ELISA), followed by in cell functional validation. While our ELISAs have successfully 
demonstrated a proof of concept approach to validating binding of novel histone binding 
fusions, the methods suffer from a few limitations. First, 96 well plate based ELISAs can 
only contain a few immobilized histone peptide tails per plate, resuling in low specificity 
throughput. Second, expression and purification of large fusion proteins is time 
consuming and can be difficult due to solublity of fusions. For example, the bivalent 
version of PcTF, Pc2TF, requires overnight, room temperature induction to produce 
soluble protein (4). This suggests that other large fusion proteins might experience 
similar solubility problems when recombinantly expressed in E. coli. To address these 
limitations, we set out to develop a next generation (nextgen) protocol to screen novel 
PTM binding proteins for function and specificity. 
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 In order to address assay length and to develop a screening technique better 
capable of testing specificity, we approached our assay optimization from two directions. 
First, to decrease variant protein production time, we utilized TXTL, an E. coli based cell 
free in vitro transcription and translation (IVTT) system (5). Hard to express proteins 
such as bivalent PcTFs benefit from the lower incubation temperature (30°C) of TXTL 
by enabling proper protein folding. In addition, we can quickly express up to 96 assay 
ready protein variants within 16 hours. This system should be expandable to 384 well 
plates to further increase variant expression throughput. Second, to increase the number 
of histone PTM peptide variants assayed to reduce assay run time, we used a 
prefabricated MODified™ Histone Peptide Array (Active Motif) that contains 384 
unique modifications immobilized on a microscope slide. Herein, we validate an 
improved assay for determining function and specificity of the engineered histone 
binding protein Pc2TF (Figure 5.1). 
 
Figure 5.1 General peptide array protocol. (A) An array of pre-immobilized histone 
peptides containing PTMs on a glass slide. (B) IVTT expressed protein is incubated with 
slide to allow binding to histone tails. (C) Binding is detected through a primary anti-tag 
antibody followed by a fluorophore-conjugated secondary antibody. (D) Slide is scanned 
and analyzed for PTM binding. 
Results and Discussion 
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 To demonstrate feasibility of this nextgen histone PTM binding assay, we first 
expressed a large quantity of Pc2TF using TXTL. We used 15 wells of a 96 well plate to 
produce protein, allowing at least six variants to be produced in one plate for nextgen 
binding anaylsis. For this work, we decided to use a single slide for one variant to allow 
measurement of technical replicates for each histone modification (Figure 5.1A). The 
slides are capable of being partitioned to enable two variants per slide, increasing 
throughput. However, a single technical replicate for variant binding makes the data less 
reliable. The histone peptide array was blocked overnight to reduce background binding 
before being incubated with the protein-lysate mix. Blocking the night before removed 
the need for blocking the morning of the assay, decreasing assay time. We incubated the 
slides with unpurified, TXTL expressed Pc2TF to allow binding (Figure 5.1B). Avoiding 
protein purification saves a significant amount of time by enabling immediate assaying of 
expressed protein. Next, we detected Pc2TF binding through a polyclonal anti-RFP 
primary antibody followed by signal amplification with a polyclonal anti-primary Cy5-
conjugated antibody (Figure 5.1C). Since we were using such a small quantity of 
unpurified protein, we reasoned that using two antibodies for signal amplification would 
enable us to maximize our signal: noise. To detect binding, we used a general microscope 
slide array scanner (Figure 5.1D). A quick, two-step protocol using free software 
analyzed the data. 
 The scanned peptide microarray contains two identical subarrays, each containing 
384 unique histone peptide modifications (Figure 5.1A). The top subarray incubated with 
Pc2TF (Figure 5.2) shows signal at multiple spots, indicating that Pc2TF binds to more 
than one PTM. We observe little signal around each spot, indicating that there is low 
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background signal on the slide (Figure 5.2). This suggests that the TXTL lysate mix does 
not interfere with fusion protein binding, or fusion binding detection in this assay.  
  
 
Figure 5.2 Pc2TF peptide subarray (Top array). IVTT expressed Pc2TF is incubated with 
a peptide array and is detected with an anti-mCherry primary followed by a Cy5 
conjugated secondary. Image scanned at 5 µm resolution, 635 nm excitation (Cy5), and 
saved as a .TIFF. Top array cropped in Adobe Fireworks. Each spot represents a unique 
histone tail PTM.  
Precision and accuracy are important aspects of a high throughput assay. Since 
each array contains two identical subarrays, we are able to assess precision by comparing 
signal intensities of the same PTM on each array. Therefore, we plotted the intenisites of 
each spot from each array against the other, expecting to see good correlation from a 
precise array (Figure 5.3A). The Pc2TF subarrays showed some spots clustering at at the 
dashed line, however, the R squared value comparing the signal of each array to each 
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other was only R2=0.41, indicating that there are some major variances in signal between 
the two subarrays. This could be due to poor washing, incubation, or detection. Further 
optimization of these conditions will help reduce the variance. However, the error for 
each PTM can be independently compared using the raw data, allowing extraction of 
reliable data from a set with unusable spots. For each individual PTM, a spot error can be 
calculated by averaging intensities across the single spot. We calculated the spot error 
range for the Pc2TF array, with lesss than 5% error for over 250 of the peptides (Figure 
5.3B). This suggests that overall; there is low error within a single spot. This error could 
be reduced by ensuring equal distribution of protein lysate mix across the slide 
throughout the incubation step. 
 
Figure 5.3 Peptide array variance and error. (A) Signal intensity of Array 1 plotted 
against signal intensity of Array 2. (B) Spot error range for each modified peptide. Error 
range calculated measuring differences in subarray spot intensities.  
R2= 0.41 
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 We cannot determine the binding affinity of Pc2TF using this type of microarray-
based assay because the post incubation washing steps disrupt the binding equilibrium. 
However, we are able to determine relative binding and specificity, which provides good 
information on engineered binding domains. To enable easier interpretation of the 
relative binding, we set the histone PTM with the highest binding signal equal to one. We 
then compared the other PTM binding spots with values over the background signal (auto 
set by software) (Figure 5.4). Not surprisingly, the strongest binding event occured 
between Pc2TF and a spot was with our expected target ligand, H3K27me3 (Figure 5.4). 
We observed additional binding by single or doubly methylated H3K27 (me2/me3), as 
well as H3K36me1, 2, and 3. The binding to H3K36 is unexpected because it does not 
share the ARKS sequence motif from H3K27 (1). Surprisingly, we also detected binding 
to some acetylated histones (Figure 5.4), which are not known to interact with 
chromodomains at all. In addition, Pc2TF showed modest binding to H3K14Ac and 
H2AK13Ac (Figure 5.4). Since there have been no previous report on the interactions of 
CBX8 fusions on this number of histone tail PTM variants, our binding results might 
indicate additional uncharacterized protein-histone tail PTM interactions. In order to 
draw conclusions, additional biological replicates will be needed to ensure accuracy of 
these binding results. Furthermore, to determine if there are any non-CBX8 related 
interactions with the histone array, this assay should be performed with the nonbinding 
domain (Pc∆TF) control. Lack of signal on a Pc∆TF array would indicate no off target 
interactions, and further reinforce the binding results of the Pc2TF array. 
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Figure 5.4 Relative binding of Pc2TF to singly modified peptides. Binding is scaled to 
the highest binding PTM H3K27me3 (max is 1). 
The protocols and results described in this chapter are preliminary and can be 
improved with a few optimizations. First, optimizing the quantity of TXTL lysate needed 
for good signal to noise will enable a minimum input of material, saving money and 
allowing more variants to be expressed at once. Second, optimizing washes, blocking, 
and incubation time, will maximize throughput by reducing time for each step while 
simultaneously enabling the highest signal to noise for this assay.  
 Overall, we are the first to describe a high throughput screening method that 
combines that ease, speed, and versatility of IVTT expressed protein, coupled with the 
diversity of prefabricated histone tail microarrays for determining function and specificity 
of novel histone binding proteins. This assay will enable synthetic biologists to quickly 
screen novel histone binding domains for in vitro function and specicity. 
Methods 
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 In vitro transcription and translation (IVTT) was performed as described in 
chapter 2: Real Time Detection of Cell-Free Transcription-Translation (TXTL). In brief, 
9 μL of Sigma 70 Master Mix (myTXTL, Arbor Biosciences), 1 μL of 5 nM P70a-T7 
RNA pol vector (Arbor Biosciences), and 2 μL of 50 ng/μL pET28-Pc2TF in a total 
volume of 12 μL in one well of a white, 96-well plate. A total of 15 reactions were 
assembled. The reaction was incubated for 16 hours at 30 °C to allow for transcription 
and translation of Pc2TF. After incubation, the samples were pooled to obtain 
approximately 150 μL of Pc2TF –TXTL lysate mix. 
The peptide array was blocked the day before the assay by incubating the slide in 
5% BSA in 0.2% PBST at 4°C overnight with shaking. On the day of the experiment, the 
slide was washed three times with 3 mL of 0.2% PBST with agitation, 5 minutes each. 
150 μL of Pc2TF –TXTL lysate mix was diluted into 1 mL 5% skim milk in 0.2% PBST 
and incubated on the slide at 4°C with agitation for 1 hour, ensuring the liquid evenly 
covered and was flowing across slide. The slide was washed three times in 3 mL of 5% 
skim milk in 0.2% PBST with agitation, 5 minutes each. Binding was detected by 
diluting rabbit anti-mCherry (ab167453) 1:3000 in 5% skim milk in 0.2% PBST and 
incubating the slide for 1 hour at 4°C with agitation. The slide was washed three times 
with 3 mL of 5% skim milk in 0.2% PBST with agitation, 5 minutes each. Signal was 
amplified by incubating the slide with polyclonal goat anti-rabbit Cy5 (ab6564) 1:3000 in 
5% skim milk in 0.2% PBST and incubating the slide for 1 hour at 4°C with agitation, 
followed by 5 final washes with 3 mL of 0.2% PBST for 3 minutes each. 
The slide was scanned on a GenePix 4000B (Molecular Devices) using standard 
settings (5µM resolution, dual excitation channels). The output was saved as a .TIFF file. 
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Analysis was performed in the Array Analyze Software (Active Motif). In brief, a 
.TIFF was imported into the software and cropped to only display the two subarrays. A 
left and right bound were set to allow for optimal automatic spot positioning. The 
software performed automatic background calculation, error, and binding intensity 
analysis. Data was exported as a .csv for additional analyses. 
Rational Design of High Specificity PTM Binding Proteins 
 In our previous work, we used mutlivalency as a solution to increase binding and 
function of synthetic HBPs. We took endogenous binding domains and generated the first 
reported double chromodomain that functions in cells. However, this fusion consists of a 
CBX8 peptide fragment sourced from nature without any binding optimization (i.e. 
affinity or specificity). Evolution has selected HBPs to perform a specific task, such as 
binding to multiple histone marks to maintain differentiations (3), which is not always a 
desired function in synthetic systems. One might envision a histone binding protein that 
can bind specifically and with high affinity to only one PTM for a highly specific 
response. A HBD that could bind to an unnaturally deposited PTM could enable 
orthogonal epigenetic regulation without interference from natural HBPs. Since many 
histone-binding domains are promiscuous in binding (6-7) or are part of a complex that 
can bind to several different modified histone tails (8), finding protein domains directly 
from nature that can meet our stringent functional expectations can be challenging. 
Luckily, synthetic biology tools allow us to engineer novel and improved function in 
proteins (9). Rational design and directed evolution (or a combination of both) are 
strategies that can lead to histone binding proteins with higher affinity and specificty. 
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Here, I briefly describe how rational design and directed evolution can be used to 
generate a modified CBX8 for higher affinity and specificity for H3K27me3 (Figure 5.5). 
 
Figure 5.5 Methods to optimize CBX8 binding. (A) Engineering CBX8 for improved 
binding to H3K27me3. (B) Directed evolution using a random or semi rational library 
can enrich a library of variants for better binding and specificity. (C) Structure guided 
rational design can lead to mutations that increase affinity and/or specificity for 
H3K27me3. 
Understanding which mutations in HBDs influence PTM binding can lead to 
design principles for engineering synthetic chromatin systems. Directed evolution is an 
approach to optimizing protein binding that works by applying a selective pressure to a 
library of rationally designed, semirationally designed, or random protein variants (Figure 
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5.5B). Through iterative rounds of selective pressure, directed evolution enriches a pool 
of variants for improved function (10-11). One method of directed evolution, mRNA 
display (Figure 5.6), is a good candidate for evolving CBX8 into a higher affinity binder 
because the process has a higher chance of success with smaller proteins (less than 110 
amino acids) (12). In addition, starting with innate binding or activity for a target ligand 
greatly improves the chance of successful optimization (13). A round of selection using 
mRNA display would start with a random or semi rational library of DNA encoding 
CBX8 variants and associated regulatory units (Figure 5.6). First, the library is 
transcribed into RNA (Figure 5.61), followed by photo crosslinking of the mRNA (Figure 
5.62) to a puromycin moiety. The crosslinked RNA is translated in a cell free system 
(Figure 5.63), followed by purification of RNA-protein fusions on an oligo-dT column 
(Figure 5.64). Reverse transcription (Figure 5.65) increases stability of the protein-
nucleic acid complex and enables downstream PCR, which is followed by binding 
fusions on an H3K27me3 immobilized column (Figure 5.66) in the presence of free 
H3K27me3 competitor. This step selects for better binders by enabling the lower affinity 
binders to dissociate and bind to free competitor. Including a negative selection by 
flowing the RNA-peptide fusions over a column immobilized with a similar PTM before 
this step would help enrich for specificity as well as affinity, since off target binders 
would be left immobilized on the negative selection column. Finally, the remaining 
fusions are competitively eluted off the column with high concentrations of H3K27me3 
and PCR amplified to enrich the population for better binders before repeating the 
process. After a number of cycles, the library is sequenced to look for consensus 
sequences and mutations. Using a strategy such as mRNA display has been successful in 
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evolving de novo binding proteins, as well as increasing affinity of proteins (14-15), 
suggesting its plausibility in selecting a CBX8 variants for enhanced H3K27me3 binding. 
Unfortunately, mRNA display requires expensive and specialized equipment (16) and is 
very dependent on the quality of the selection strategy for enrichment. Due to these 
restrictions, we investigated additional approaches to engineer CBX8 for higher affinity. 
 
Figure 5.6 Directed evolution of PTM-binding proteins. A DNA variant library (top) is 
(1) transcribed into RNA followed by (2) RNA photo crosslinking to a puromycin 
moiety. (3) The cross-linked RNA is translated into protein using a cell free system, 
followed by purification of protein-RNA fusions on an oligo-dT column. The fusions are 
eluted from the oligo-dT column and (5) reverse transcribed to form RNA-DNA hybrids 
159 
 
covalently fused to their corresponding protein. (6) A selection (positive, negative, or 
both) is performed to enrich for binding, followed by (7) competitive elution with free 
target molecule. The eluted fusions are then (8) PCR amplified to generate templates for 
the next round of selection. 
Coupling structures of protein-ligand interactions with computer modeling can 
help predict point mutations that can lead to a desired function (Figure 5.5C) (17). Due to 
the extensive in vitro characterization of the CBX histone binding proteins, we set out to 
use rational design to predict point mutations that might enhance the binding affinity of 
CBX8 for H3K27me3. We envision a standard workflow to optimize histone-binding 
proteins in silico (Figure 5.7) starting with a HBD that has a solved structure. For 
example, the structure of CBX8 has been elucidated and is a good proof of concept 
domain for binding optimization (Figure 5.7A). Alignments of CBX8 with the other CBX 
orthologs might elucidate mutations that could increase affinity (Figure 5.7B). A more 
software-based approach couples the structure of a CBX8-H3K27me3 complex with a 
minimal free energy analysis using Rosetta (18) (Figure 5.7B) to predict single mutations 
within the protein that might increase binding affinity. The output of either approach 
(Figure 5.7C) can either be used as an input for further in silico characterization or be 
tested for function in an in vitro assay (Figure 5.7D). Any proteins that demonstrate 
improved function in vitro can be further tested as fusions with effector domains for in 
cell activity (Figure 5.7E). The main caveat of computer-based approaches is the need for 
programming knowledge and familiarity with modeling software, as well as computers 
with strong processors, which can be cost prohibitive.  
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Figure 5.7 Standard workflow to optimize protein binding using structure/function 
knowledge. (A) Native proteins or homologous sequences that have solved structures act 
as a starting point for optimization. (B) Structures are fed into a software such as Rosetta 
(https://www.rosettacommons.org/) to optimize protein-ligand interaction or are aligned 
to determine possible residues responsible for affinity. (C) A library of sequences is 
returned with predicted binding to target and can be reused as input for in silico 
modeling. (D) An in vitro assay finds higher binding variants. (E) New variants are tested 
as fusions to effector domains for enhanced function in cells. 
Since CBX8 is a relatively small protein (~80 amino acids), we hypothesized that 
we could rationally design single base mutations using the available in vitro binding data 
of CBX orthologs along with primary structure alignments. The human CBX orthologs 
that can bind to H3K27me3 have been extensively characterized in vitro, with available 
data on both three dimensional structure and target binding affinity (1-2). 
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We aligned the amino acid primary structures of the human CBX orthologs CBX 
2, 4, 6, 7, and 8, sorting them high to low by their in vitro binding affinity to H3K27me3 
(Figure 5.8). Interestingly, there is a large variance in reported binding affinities for the 
CBX orthologs using the same technique (fluorescence polarization), which might be due 
to the different buffers used in the experiment or other experiment specific parameters. 
Regardless, the order of the orthologs based on binding affinity remains the same. The 
similarity of the consensus sequence to each ortholog reinforces the structural similarity 
of each CBX homolog, and how just a few amino acid changes must be responsible for 
the large variance in binding affinity (Figure 5.8). For example, the primary structure of 
CBX7 varies by about 15% when compared to other orthologs, but has an affinity for 
H3K27me3 up to 15 times greater (1). We hypothesized that one or several of the amino 
acid differences in the orthologs that are responsible for high affinity binding in CBX7 
might be portable into the CBX8 chassis, increasing the binding affinity for H3K27me3. 
However, several of these higher affinity orthologs (i.e. CBX7 and CBX2) have 
increased affinities for off target PTMs, such as H3K9me3 (1-2). Therefore, the 
beneficial mutations that might increase affinity for H3K27me3 have to be weighed 
against the possibility of acquiring off target binding that was previously absent in CBX8 
(1-2). 
 
Figure 5.8 CBX sequence alignment based on H3K27me3 affinity. Human CBX 
homologs are aligned and assembled from highest binding affinity (low Kd) to lowest 
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binding affinity (high Kd). Sequences obtained from NCBI. Alignments assembled using 
CLC Main. a(1), b(2). 
 To focus on the orthologs with a higher affinity for H3K27me3 compared to 
CBX8, we aligned the primary structure of the two orthologs with the highest affinity for 
H3K27me3, CBX7 and 2, to CBX8. This resulted in a consensus sequence being 78% 
similar (64/82 amino acids) to wild type CBX8 (Figure 5.9). Of the 18 varying positions, 
7 of these residues are in an unconserved region starting after amino acid 61 (Figure 5.9). 
Of the remaining 11 residues, several are conserved between CBX7 and CBX2 and are 
not found in CBX8. For example, residues 9 (glutamine), 16 (isoleucine), 25 (lysine), 51 
(proline), 60 (lysine), and 70 (arginine) are shared between CBX7 and CBX2, but not 
CBX8. This suggests that one or a combination of these residues could be responsible for 
the increased affinity for H3K27me3. In fact, it was previously suggested that CBX8 has 
a lower affinity for H3K27me3 because of its overall electropositive charge (2). 
Therefore, removing some of the positive charges by mutating them to an uncharged 
residue or a less basic residue could improve affinity. A library of CBX8 mutants 
containing a distribution of the mutations R10Q, L17I, R26K, A52P, R61K, and K71R 
would be a good starting point for screening (Figure 5.9). To reduce the number of 
variants to be constructed and assayed, we sought to use structural data to help us 
rationally elucidate the impact of each mutation on the binding to H3K27me3.  
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Figure 5.9 Primary structure of CBX8 vs CBX7 and CBX2. Rational mutations for 
CBX8 are based on the consensus amino acids from CBX orthologs that have a higher 
affinity for H3K27me3. 
 There is no available solved structure of a CBX8-H3K27me3 complex, but there 
is structural data for the ortholog CBX7 complexed with H3K27me3, and CBX8 
complexed with H3K9me3. Using these structures, we used Pymol (19) to align the 
CBX8 crystal structure and the NMR state of CBX7 that most closely resembles the 
CBX8 structure. We then removed the H3K9me3 and the CBX7, leaving an approximate 
CBX8-H3K27me3 complex (Figure 5.10). The red residues comprise the conserved 
hydrophobic core consisting of Phenylalanine 11 (F11), Tryptophan 32 (W32), and 
Tryptophan 35 (W35) that encapsulates the trimethyl moiety (me3) (Figure 5.10A). The 
gray peptide represents histone 3 peptides 19-33. This peptide containing H3K27me3 
traverses the side of the CBX8, highlighting the protein-ligand interactions (Figure 
5.10B). We highlighted the proposed residues for mutation from Figure 5.9 on the 
structure CBX8 to elucidate how they might interact with H3K27me3. We reasoned that 
we might be able to determine the contribution of each mutation to binding of 
H3K27me3. 
 Two highlighted residues appear to have direct interactions with the H3K27me3 
peptide, arginine 25 (R25) and arginine 9 (R9) (Figure 5.10). Kaustov et al previously 
noted that the positive charge from arginine 9 might associate less efficiently with a basic 
histone peptide, lowering the overall binding affinity (2). Introducing the R25Q mutation 
would eliminate the basic charge at that interaction and might allow for higher binding 
affinity. Introducing R25K in CBX8 would not remove the positive charge, but it does 
164 
 
replace arginine with a slightly less basic residue (pKa of 12.48 vs 10.79), which might 
allow for a stronger protein-ligand interaction.  
 The other predicted mutations (L16I, A51P, and R60K) have a much less obvious 
impact on binding. Alanine 51 (A51) and arginine 60 (R60) reside in the alpha helix of 
CBX8 that does not look like it directly interacts with H3K27me3 (Figure 5.10). Perhaps, 
in addition to arginine 9, mutating this arginine residue to a less basic lysine would help 
the overall association and binding to histone tails. In addition, leucine 16 (L16) resides 
in a linker region between a beta sheet and turn (Figure 5.10A). A proline might 
introduce a more rigid turn that stabilize the protein-ligand interaction.  
These less obvious residues could also carry an unknown significance that 
contributes to binding through overall protein stabilization. For example, Hatley et al 
demonstrated that a network of amino acids could allosterically mediate binding to GTP 
(20). Perhaps one of these residues has a more subtle impact on binding that cannot be 
elucidated in silico. Ultimately, these mutations will have to be introduced as a library of 
CBX8 mutants and screened to determine the impact of each mutation. Cycles of design, 
build, and test, could result in a set of improved binders that could be further optimized 
through additional in silico or in vitro testing (Figure 5.11). 
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Figure 5.10 3D structure of CBX8 highlighting residues hypothesized to impact binding 
affinity based on primary structure alignment of higher affinity orthologs. CBX8 (PDB 
3I91) complexed with H3K9me3 is aligned with CBX7 (PDB 2L1B) complexed with 
H3K27me3. CBX7 and H3K9me3 are removed to approximate a CBX8-H3K27me3 
interaction (A) View of complex showing hydrophobic core interaction with trimethyl 
lysine (Kme3). (B) View of complex highlighting H3K27me3 interaction along CBX8 
backbone. Yellow residues indicate CBX8 backbone. Purple sticks highlight human wild 
type CBX8 residues that would be mutated as shown. Gray chain shows H3K27me3 
peptide residues 19-33. Red residues indicate hydrophobic cage for trimethyl (me3) 
moiety. Figure generated with PyMol (19). 
 Expanding H3K27me3 binding protein variant library size by including orthologs 
from other species can increase the likelihood of finding a better binder. Both fruit fly 
(drosophila melanogaster) and zebrafish (danio rerio) have polycomb proteins with 
differing primary structure (21), which could mean they have differing affinities for their 
target ligands. However, many polycomb proteins are expressed during development (22-
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23), and each species has a different optimal developmental temperature (24-25) which 
might be required for optimal binding and function of the endogenous polycomb proteins. 
This study focused on human polycomb proteins because it allowed us to minimize the 
potential for misfolding or functional differences due to native expression temperature 
and conditions when used in human cells. In addition, structural data is not available for 
every ortholog from every species, but modeling software such as Rosetta 
(https://www.rosettacommons.org/), or additional in vitro structural studies can help fill 
in those gaps. Iterative processes of design, build, and test (Figure 5.11) can be applied to 
other histone binding proteins such as bromodomains or PHD domains that target 
different PTMs, resulting in an expanded synthetic histone binding protein toolbox for 
engineering biological systems.  
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Figure 5.11 Design, build, test. Structural and biochemical data guides design of protein 
variants. High throughput DNA synthesis enables facile library assembly. A series of in 
vitro and in cell assays determines the function and specificity of the variants. The 
variants with desired functions are used as input for further optimization.  
Future Work 
 Significant work is still required to elucidate all of the rules for designing 
synthetic histone-binding proteins. Since new technology has enabled fast DNA library 
synthesis, building constructs is no longer a bottleneck in the design, build, and test cycle. 
Histone PTM binding assays developed in this thesis will suffice for testing novel fusion 
protein functionality, but need to be further optimized to test as many variants in parallel 
as possible. In addition to computer modeling, a directed evolution approach should be 
taken to test a larger library of variants for function. This process could enrich for 
expected active site mutations, or allosteric mutations that contribute to affinity that 
rational design might miss. Additional ration design rules that arise from these 
experiments can help synthetic biologists engineer other histone binding domains. The 
best mutants from these screens should be tested in live cells as fusions with effector 
domains to assay for in cell function. Cycles of design, test, and build can be expanded to 
other PTM binding proteins that have characterization data available to engineer 
additional synthetic histone binding effectors. 
Further optimization of protein delivery to live cells can result in a set of 
principles for designing proteins for recombinant delivery. This optimization can occur 
through a two-step process. First, by expanding the variety of different cell penetration 
tags tested, we can determine the best delivery method using the least amount of protein, 
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enabling a lower overall dose of protein while maximizing function. Second, delivering 
recombinant bivalent proteins might reinforce the in vitro data that demonstrates 
enhanced in vitro binding and in cell function compared to monovalent versions. This 
knowledge will expand our understanding of mutlivalency in epigenetics, enabling 
scientists to harness engineered histone binding proteins for other applications such as 
personalized medicine, agriculture, and the biotechnology industry. 
Thesis Summary and Conclusions 
 In chapter 1, we introduced the concept of engineering chromatin proteins. We 
outlined the composition of chromatin and how each component has previously been 
engineered. We described how structural and biochemical information could be used to 
help rationally design new chromatin binding proteins. We then concluded with a 
proposed pipeline for in vitro screening of novel histone PTM binding proteins.  
 In chapter 2, we described and outlined our pipeline for in vitro screening of 
novel histone PTM binding proteins. As proof of concept for our pipeline, we assayed a 
small library of bivalent CBX8 fusions varying by species of CBX8 binding domain. We 
demonstrated an easy cloning strategy to assemble the constructs, followed by a cell free 
in vitro transcription and translation system that produced enough functional protein for 
assaying without need for further purification. Next, we performed ELISAs to determine 
relative binding to on (H3K27me3) and off (other me3 peptides) target histone peptides. 
We ported the highest relative binding variants into a mammalian expression vectors and 
transfected them into a cell line containing a silenced reporter gene under the control of 
H3K27me3. A three in one microplate assay determined the fusion protein expression 
and function in cells. In addition to demonstrating the feasibility of our pipeline, we 
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outlined recommended human cell lines for testing other PTM binding proteins using 
endogenous genes as output and described our best practices for chromatin 
immunoprecipitation (ChIP) to validate that the protein is binding to the expected PTM. 
Overall, we successfully demonstrated the functionality of our pipeline to test synthetic 
chromatin proteins for binding. 
 Chapter 3 investigated the impact of bivalency on PTM binding in vitro and in 
cells, expanding the available functional tests for engineered histone binding proteins. 
We characterized Pc2TF, a bivalent version of PcTF that contains two CBX8 domains 
linked by a short, flexible (GGGGS)4 linker. We started by screening a small set of Pc2TF 
fusions varying in linker characteristics for binding to H3K27me3, resulting in Pc2TF. 
We then recombinantly expressed and purified Pc∆TF, PcTF, and Pc2TF in order to 
determine their apparent binding affinity (Kdapp). We concluded that Pc2TF shows 
enhanced avidity for H3K27me3 over PcTF. We then ported these constructs into 
mammalian constructs, and tested their ability to reactivate a synthetically silenced 
reporter locus. Compared to PcTF, Pc2TF was able to reactivate transcription of an 
H3K27me3 silenced luciferase by a factor of two. This chapter presented the first in vitro 
and in cell characterization of a synthetic, multivalent chromatin-derived histone-binding 
protein. 
 In Chapter 4, we investigated cell delivery mechanisms for the recombinant, 
synthetic histone binding effector PcTF. We screened a variety of cell penetrating 
peptides co incubated and fused to PcTF. Our most promising candidate contained a 
short, cell penetrating peptide fused to the C terminus of PcTF (CP-PcTF). To determine 
characteristics of CP-PcTF delivery to cells, we compared varying concentrations of CP-
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PcTF over varying time points to optimize nuclear delivery. We then demonstrated how 
incubating CP-PcTF enabled time dependent uptake into 2D and 3D U-2 OS cells. In 
order to determine the gene response to CP-PcTF, we performed RNA sequencing on 
both U-2 OS and foreskin fibroblasts treated with either CP-PcTF or CP-Pc∆TF. We 
outlined the genes significantly up and downregulated by CP-PcTF, and explored 
plausible reasons for the specific responses. Finally, we demonstrated that U-2 OS cells 
treated with CP-PcTF experience a delayed growth compared to an untreated control or 
CP-Pc∆TF. This work ourlines a foundation for testing newly designed histone binding 
protein fusions for function in cells without the complications associated with DNA or 
viral transfection. 
 Chapter 5 explored steps toward optimizing a PTM binding specificity assay, and 
outlined how structural data enables rational design of proteins. We started our assay 
optimization by expressing a large quantity of Pc2TF using TXTL as a proof of concept. 
We directly incubated the protein-lysate mix with a peptide array consisting of 384 
unique histone PTMs. Instead of the classic HRP detection, we detected the array with a 
fluorophore-conjugated antibody, followed by imaging on a generic array scanner. The 
preliminary results indicated that TXTL can express enough protein to detect binding on 
this array with our new detection method, and that Pc2TF has the strongest binding 
interaction with H3K27me3. This protocol has improved the throughput of screening 
histone-binding proteins by enabling assay ready protein production in vitro and 
screening hundreds of peptides for binding at once. 
 Next, we hypothesized that we could leverage structural and biochemical data to 
design synthetic histone proteins as another approach to engineering higher affinity 
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binders. Since our work focused on engineering CBX8 fusions, we used the CBX8-
H3K27me3 interaction as an example. We proposed a generic outline for optimizing 
binding using computer software, as well as using structural data coupled with 
biochemical binding affinity data. We discussed using directed evolution to increase 
affinity and specificity, along with an overview of mRNA display as a possible approach. 
Based on primary structure alignments, we rationally proposed several residues of 
interest for mutating in CBX8, and explored their possible contribution to overall binding 
affinity. Overall, this chapter explored steps to improve histone PTM binding assays, and 
two additional approaches to engineer synthetic chromatin effectors. 
 The work outlined in this thesis only begins to unravel the potential of synthetic 
epigenetics. We elucidate design rules for engineering histone binding proteins by 
characterizing novel HBDs and their functional delivery to cells. The work in this thesis 
will enable synthetic biologists to be able to engineer novel histone binding proteins and 
effectors using cycles of design, build, and test.  
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